UNIVERSITY of York

This is a repository copy of Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis : a multicentre, randomised controlled trial of the ProLife programme in South Africa.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/182113/

Version: Accepted Version

Article:

Louwagie, Goedele M, Kanaan, Mona orcid.org/0000-0001-7956-7576, Morojele, Neo et al. (11 more authors) (Accepted: 2022) Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis : a multicentre, randomised controlled trial of the ProLife programme in South Africa. BMJ Open. ISSN 2044-6055 (In Press)

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

BMJ Open

Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-056496.R2
Article Type:	Original research
Date Submitted by the Author:	17-Dec-2021
Complete List of Authors:	Louwagie, Goedele; Sefako Makgatho Health Sciences University, Research, Postgraduate Studies and Innovation; University of Pretoria, School of Health Systems and Public Health Kanaan, Mona; University of York, Department of Health Sciences Morojele, Neo; University of Johannesburg, Department of Psychology; Medical Research Council of South Africa, Alcohol, Tobacco and Other Drug Research Unit Van Zyl, Andre; Sefako Makgatho Health Sciences University Moriarty, Andrew; University of York, Hull York Medical School Li, Jinshuo; University of York, Department of Health Sciences Siddiqi, Kamran; University of York, Department of Health Sciences and the Hull York Medical School Turner, Astrid; University of Pretoria, School of Health Systems and Public Health Mdege, Noreen; University of York, Department of Health Sciences Omole, Olufemi; University of York, Department of Health Sciences Omole, Noreen; University of the Witwatersrand, Department of Family Medicine Tumbo, John; Sefako Makgatho Health Sciences University, Department of Family Medicine Bachmann, Max; University of York, Department of Health Sciences Ayo-Yusuf, Olalekan; Sefako Makgatho Health Sciences University, Africa Centre for Tobacco Industry Monitoring & Policy Research; University of Pretoria, School of Health Systems and Public Health
Primary Subject Heading :	Public health
Secondary Subject Heading:	Health economics, Infectious diseases, HIV/AIDS, Smoking and tobacco, Health services research
Keywords:	Tuberculosis < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, Substance misuse < PSYCHIATRY, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2 3	
4	
5 6 7 8 9	SCHOLARONE [™] Manuscripts
10	
11 12	
13	
14 15	
16 17	
18	
19 20	
21	
22 23	
24	
25 26	
27	
28 29	
30 31	
32	
33 34	
35	
36 37	
38	
39 40	
41 42	
43	
44 45	
46	
47 48	
49	
50 51	
52	
53 54	
55 56	
57	
58 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

1		
2 3	1	Effect of a brief motivational interview and text message intervention targeting tobacco smoking,
4 5	2	alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult
6 7	3	patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in
8 9	4	South Africa
10	5	Goedele Maria Louwagie ^{1, 2} , Mona Kanaan ³ , Neo Keitumetse Morojele ^{4, 5} , André van Zyl ¹ , Andrew
11 12	6	Stephen Moriarty ³ , Jinshuo Li ³ , Kamran Siddiqi ³ , Astrid Turner ² , Noreen Dadirai Mdege ³ , Olufemi
13	7	Babatunde Omole ⁶ , John Tumbo ¹ , Max Oscar Bachmann ⁷ , Steve Parrott ³ , Olalekan Ayo-Yusuf ^{1, 2}
14 15	8	Correspondence to Goedele Maria Louwagie; goedele.louwagie@up.ac.za
16	9	
17	10	¹ Goedele Maria Louwagie, Sefako Makgatho Health Sciences University and ² School of Health
18 19	11	Systems and Public Health, University of Pretoria , RSA; goedele.louwagie@up.ac.za
20	12	
21	13	³ Mona Kanaan, Department of Health Sciences, University of York, UK; mona.kanaan@york.ac.uk
22	14	
23 24	15	⁴ Neo Keitumetse Morojele, Department of Psychology, University of Johannesburg and ⁵ Alcohol,
25	16	Tobacco and Other Drug Research Unit, South African Medical Research Council, RSA;
26	17	nmorojele@uj.ac.za
27	18	
28 29	19	¹ André van Zyl, Sefako Makgatho Health Sciences University, RSA; drevanzyl@gmail.com
30	20	Andre van zyl, serako Makgarno nearri sciences oniversity, koz, arevanzyle ginancom
31	20	³ Andrew Stephen Moriarty, Department of Health Sciences and the Hull York Medical School,
32	22	University of York, UK; <u>andrew.moriarty@york.ac.uk</u>
33 34	22	University of Tork, OK, and ew.monarty@york.ac.uk
35	23 24	³ Jinshuo Li, Department of Health Sciences, University of York, UK; jinshuo.li@york.ac.uk
36		Sinsindo El, Department of Health Sciences, Oniversity of York, OK, <u>Jinsindo.ir@york.ac.uk</u>
37	25 26	We man Ciddini Department of Health Criences and the Hull York Medical Cabeel, University of York
38 39	26	³ Kamran Siddiqi, Department of Health Sciences and the Hull York Medical School, University of York,
40	27	UK; <u>kamran.siddiqi@york.ac.uk</u>
41	28	
42	29	² Astrid Turner, School of Health Systems and Public Health, University of Pretoria, RSA;
43 44	30	astrid.turner@up.ac.za
45	31	
46	32	³ Noreen Dadirai Mdege, Department of Health Sciences, University of York, UK;
47	33	noreen.mdege@york.ac.uk
48 49	34	
50	35	⁶ Olufemi Babatunde Omole, Department of Family Medicine, University of Witwatersrand, RSA;
51	36	<u>Olufemi.Omole@wits.ac.za</u>
52	37	
53 54	38	¹ John Tumbo, Department of Family Medicine, Sefako Makgatho Health Sciences University, RSA;
55	39	tumbo@lantic.net
56	40	
57	41	⁷ Max Oscar Bachmann, Norwich Medical School, University of East Anglia, UK;
58 59	42	m.bachmann@uea.ac.uk
60	43	
		1

Page 4 of 155

BMJ Open

1

 ³ 44 ³Steve Parrott, Department of Health Sciences, University of York, UK; <u>steve.parrott@york.ac</u> ⁴⁵ ⁴⁵ ⁴⁶ ¹Olalekan Ayo-Yusuf, Africa Centre for Tobacco Industry Monitoring & Policy Research, Sefako ⁷ 47 Makgatho Health Sciences University, and ²School of Health Systems and Public Health, University ⁸ 48 Pretoria, RSAⁱ lekan.ayo-yusuf@smu.ac.za ⁹ 49 ¹⁰ 50 ABSTRACT ¹³ 51 Objectives: To investigate the effectiveness of a complex behavioural intervention, Pro ¹⁵ 52 tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking 	ersity of Life, on
 ¹Olalekan Ayo-Yusuf, Africa Centre for Tobacco Industry Monitoring & Policy Research, Sefako Makgatho Health Sciences University, and ²School of Health Systems and Public Health, University Pretoria, RSAⁱ lekan.ayo-yusuf@smu.ac.za ABSTRACT Objectives: To investigate the effectiveness of a complex behavioural intervention, Pro tubargulasis (TD) treatment suggests mediantian adherence, algebal use and tabases smaking 	ersity of Life, on g.
 7 47 Makgatho Health Sciences University, and ²School of Health Systems and Public Health, University, and ²School of Health Systems, and ²School of Health Systems, and ²School of Health Systems, and ³School of Health Systems, and ³Sc	Life, on g.
 9 48 Pretona, RSA/<u>lekan.ayo-yusur@smu.ac.za</u> 9 49 11 50 ABSTRACT 13 14 51 Objectives: To investigate the effectiveness of a complex behavioural intervention, Pro 15 52 tubercularis (TB) treatment success mediantion adherence alreaded use and tobacce smalling 	<u>.</u>
11 50 ABSTRACT 12 13 13 51 Objectives: To investigate the effectiveness of a complex behavioural intervention, Pro 15 52 tubergulasis (TB) treatment suggests mediantion adherence, alreaded use and tobacco smalling	<u>.</u>
 Abstract Abstract Abstract Abstract Body and the second second	<u>.</u>
14 51 Objectives: To investigate the effectiveness of a complex behavioural intervention, Pro	<u>.</u>
E2 tuberculosis (TD) treatment success medication adherance alcohol use and tebacce smalling	
	(1:1)
¹⁷ 53 Design: Multicentre, individual, randomised controlled trial where participants were assigned	
18 19 54 to the ProLife intervention or usual care.	
 Setting: 27 primary care clinics in South Africa. 	
 Participants: 574 adults starting treatment for drug-sensitive pulmonary TB who smoked toba 	acco or
24 57 reported harmful/hazardous alcohol use.	
 Interventions: The intervention, delivered by lay health workers (LHWs), consisted of 3 brief 	
 27 28 59 motivational interviewing (MI) sessions, augmented with Short Message Service (SMS) message 	ges,
29 60 targeting medication adherence, alcohol use and tobacco smoking.	
 30 31 61 Outcome measures: The primary outcome was successful versus unsuccessful TB treatment a 	nt 6 to 9
 62 months, from TB records. Secondary outcomes were biochemically confirmed sustained smol 63 months, from TB records. Secondary outcomes were biochemically confirmed sustained smol 	king
34 63 cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved 1	B and
 antiretroviral treatment (ART) adherence and ART initiation, each measured at 3 and 6 month 	is by
$\frac{37}{38}$ 65 questionnaires; and cure rates in patients who had bacteriology-confirmed TB at baseline, from	m TB
39 66 records.	
40 41 67 Results: Between 15 November 2018 and 31 August 2019, 574 participants were random	nised to
$\frac{42}{43}$ 68 receive either the intervention (n=283) or usual care (n=291). TB treatment success rates	did not
44 69 differ significantly between intervention (67.8%) and control (70.1%; OR=0.9 (95% CI: 0.64	4,1.27)).
46 70 There was no evidence of an effect at 3- and 6-months respectively on continuous s	moking
47 48 71 abstinence (OR=0.65 (95% CI: 0.37,1.14); OR=0.76 (95% CI: 0.35,1.63)), TB medication ad	herence
49 72 (OR=1.22 (95%CI: 0.52,2.87); OR=0.89 (95%CI: 0.26,3.07)), taking ART (OR=0.79 (0.38,1.65), 0 50	OR=2.05
51 73 (0.80,5.27)) or AUDIT scores (mean score difference 0.55 (95% CI: -1.01,2.11); -0.04 (95% CI: -	2,1.91);
 and adjusting for baseline values. Cure rates were not significantly higher (OR=1.16 (0.83,1.63)) 	3)).
54 75 Conclusions: Simultaneous targeting of multiple health risk behaviours with MI and SMS usir 55	ig LHWs
56 76 may not be an effective approach to improve TB outcomes.	
57 58 77	
59 60	

2 3 4	78	Trial registration: ISRCTN62728852, Registered on 13th April 2018.						
5 6	79	Key words: Tuberculosis, smoking, alcohol, motivational interviewing, mHealth, anti-retroviral						
7 8	80	therapy, adherence						
9 10 11	81							
12 13 14	82	STRENGTHS AND LIMITATIONS OF THIS STUDY						
15 16	83	• The use of motivational interviewing combined with Short Text Messaging to address the						
17	84	effect of multiple risk behaviours (smoking, drinking and poor adherence) on tuberculosis						
18 19	85	treatment outcomes is a novel and much needed intervention.						
20 21	86	• Our study design was strong: this was a multi-site individually randomised controlled trial						
22	87	with a large sample size and a high follow up rate for the primary outcome.						
23 24	88	• We used validated measurement tools; furthermore, data analysis and primary outcome						
25 26	89	assessment were blinded, thereby limiting measurement bias.						
27	90	 However, the study was underpowered for secondary outcomes, and low intervention 						
28 29	91	uptake may have diluted any potential intervention effects.						
30 31	92							
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 7 58 59 60								

93 INTRODUCTION

Tuberculosis (TB) is among the most common chronic infectious diseases in the world today. In 2019, 1.4 million deaths worldwide were attributed to TB, and the majority of these occurred in low-income and middle-income countries (LMICs).(1) South Africa not only has one of the highest TB burdens in the world; it is faced with high TB treatment interruption and loss to follow-up rates. It also has a high prevalence of human immunodeficiency virus (HIV) co-infection in patients with TB and a relatively high mortality in these co-infected patients.(1) Studies of interventions to advance the goal of ending the TB epidemic and improving treatment outcomes are therefore research priorities in South Africa and other LMICs.(2)

Mortality and morbidity from TB is strongly associated with health risk behaviours, particularly smoking and hazardous or harmful alcohol use, both of which are prevalent and often co-occur in patients with TB.(3–10) Strategies are also required to improve TB medication adherence in patients with TB and adherence to TB medication and anti-retroviral therapy (ART) in patients co-infected with TB and HIV, both of which may be negatively influenced by excessive alcohol use.(1) There is very limited research on how to concurrently tackle these three risk behaviours - namely smoking, harmful alcohol use and poor medication adherence - in patients with TB, particularly in LMICs.

Motivational Interviewing (MI) has been shown to support reduced drinking, smoking cessation in TB patients and TB treatment and/or antiretroviral therapy (ART) medication adherence.(11-13) MI interventions can be effectively delivered by lay health workers (LHWs).(14) The more widespread use of LHWs and the increased use of mobile health (mHealth) digital technologies represent promising ways to increase the scalability of MI interventions. Indeed, the World Health Organisation (WHO) has called for researchers to capitalise on advances in mobile phone technology, network coverage and the increased use of common and widely available digital technologies (including the mobile phone short message service (SMS)) to improve TB care.(15) There is evidence that mHealth technologies can have modest beneficial effects on a range of health outcomes, including medication adherence. (16,17) Mobile phone messaging also shows a modest effect in improving TB treatment success rates.(18,19) The evidence is however stronger for two-way messaging and interactive systems for which smart phones are required.(18) These are often not available to patients with TB in Africa.(20)

A limitation of existing MI and mHealth interventions is that they have been studied in the context of
 modifying a single lifestyle factor. Integrated interventions are likely to be better accepted and more
 effective than multiple interventions targeting different health risk factors.(21,22) In the case of TB,

Page 7 of 155

1 2 3 **BMJ** Open

4	
5	127
6 7	128
8 9	129
9 10	130
11 12	131
13	132
14 15	133
16 17	134
18	135
19 20	136
21	137
22 23	138
24 25	139
26	
27 28	140
29	141
30 31	142
32 33	143
34	144
35 36	145
37	146
38 39	147
40 41	148
41	149
43 44	150
45	151
46 47	152
48 49	153
50	154
51 52	155
53	155
54 55	150
56	
57 58	158
59	159

60

there is a need for an intervention that has the flexibility to target multiple lifestyle factors as appropriate and in line with patient preferences. This could be achieved through increased integration of TB and non-communicable disease services.(23)

130 Recent re-engineering of primary health care in South Africa has seen the introduction of municipal 131 ward-based primary healthcare outreach teams of community health workers (CHWS). CHWS work 32 in an integrated, team-based manner, supported by nurses, and take responsibility for health 33 education and promotion, counselling and support for a range of health conditions.(24,25) Task 34 shifting in this context has been shown to improve population health in LMICs (26) and these teams can be trained and supported to take responsibility for TB/HIV care.(27) Integrated interventions 135 136 could be implemented within this framework in a feasible and scalable way to improve outcomes for 137 patients with TB across South Africa and beyond.

139 Building on previous successes with MI and mHealth interventions, we developed a complex 40 behavioural intervention (ProLife) comprising MI-based counselling and SMS, targeting three lifestyle risk behaviours for poor TB outcomes (smoking, hazardous/harmful alcohol consumption 41 42 and poor medication adherence), and delivered by LHWs. We then conducted a randomised controlled trial (RCT) to assess the effectiveness of the ProLife intervention on improving TB 43 44 treatment outcomes, smoking abstinence, reducing alcohol consumption and improving adherence .45 to TB and ART medication compared to usual care. The cost-effectiveness of the intervention was also assessed but only the costing results will be presented in this paper. .46

148 METHODS

150 Study design and participants

151 This was a prospective, two-arm, multicentre, individual RCT, which took place across 27 primary 152 care clinics in 3 districts in South Africa (Lejweleputswa in the Free State province; Bojanala in the 153 North West province; and Sedibeng in Gauteng province). Adult patients (18 years or older) were 154 eligible for the study if they had drug-sensitive Pulmonary TB (PTB), and were initiating TB treatment 155 or had been on TB treatment for less than a month for this treatment episode (both "new" and 156 "retreatment patients"). They had to be tobacco smokers (defined as smoking daily or non-daily in 157 the last four weeks on the Global Adult Tobacco Survey questionnaire)(28) and/or .58 hazardous/harmful drinkers who were not alcohol dependent (Alcohol Use Disorders Identification .59 Test (AUDIT) score \geq 8 for men or \geq 7 for women but <20).(29) They also had to have access to a

mobile phone and understand one of the 4 languages used for the trial (English, IsiZulu, SeSotho and Setswana). Potential participants were recruited consecutively at the participating clinics between 15 November 2018 and 31 August 2019. Trained field workers identified those interested in the study and screened them for eligibility. If eligible and willing to be enrolled into the trial, written informed consent was obtained. The RCT received ethics approval from the Research Ethics Committees of the five participating research institutions and the trial protocol was previously published.(30)

Randomisation and blinding

Patients were centrally randomised (1:1) to the ProLife intervention or control group using a randomised sequence generator by the trial statistician (MK) who was blind to the arm allocation. We used block randomisation with varying block sizes stratified by clinic so as to achieve equal numbers in intervention and control groups within each clinic. Fieldworkers used sequentially numbered, sealed, opaque envelopes to allocate participants to intervention or control. ProLife involved a complex behavioural intervention therefore LHWs and participants could not be blinded to the intervention. However, the determination of the primary outcome was done by the TB nurses who were blinded to the intervention status of the participants, based on routinely collected data. The statistician (MK) was blinded to the intervention or control arm allocation of participants during the analysis.

Intervention and procedures

The ProLife intervention was developed based on a conceptual framework, following a review of pre-existing evidence.(31) This framework assumed that smoking cessation, reducing harmful alcohol use and improved adherence to TB and HIV treatment would result in improved TB treatment outcomes.(30) The intervention consisted of 3 brief MI counselling sessions, lasting 15-20 minutes, one month apart, delivered by trained LHWs at their TB clinic. The first MI session took place immediately or shortly after the randomisation and involved prioritisation and agenda setting, wherein the participant determined which factor should be prioritised (either a plan to quit tobacco smoking, or reduce or quit drinking, or deal with barriers relating to ART or TB medication adherence). The second and third sessions built on the previous one until all relevant behavioural problems had been addressed. These sessions were reinforced with follow-up SMS text messages, twice a week over 12 weeks.(30) Study patients received 10 TB-related messages followed by seven alcohol reduction- and/or seven smoking cessation-related messages, as appropriate. Messages were aimed at giving information, and augmenting motivation or behavioural skills (we refer to the

BMJ Open

3 4	194	feasibility paper for more details).(31) Applicable SMS-messages were automatically activated after
5 6 7 8 9 10 11 12 13 14 15	195	the first MI had taken place. Thereafter remaining messages were delivered even if the participant
	196	did not attend the second or third MI session.
	197	
	198	
	199	Participants randomised to the ProLife intervention also received the same "usual care" as those in
	200	the control group. The control group received the usual care and routine treatment and support
	201	offered to patients with TB in South Africa, which varies by district but includes: health education;
16 17	202	dietetic input; social support; point of care biochemical testing; and HIV testing with pre- and post-
18 19	203	test HIV test counselling.
20	204	
21 22	205	Data were collected at baseline, 3- and 6-months and recorded by fieldworkers equipped with
23 24	206	mobile phones with the ProLife mobile data collection application (built with CommCare)(32)
25 26	207	installed. They used a standardised electronic case report form (CRF) and followed standard
27	208	operating procedures (SOPs) to ensure quality. Details of data collection, protection and storage
28 29	209	procedures have been reported elsewhere.(30)
30 31	210	
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 	211	Patient and public involvement
	212	Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
	213	plans of our research.
	214	
	215	Outcomes
	216	Primary Outcome
	217	The primary outcome of TB treatment success at 6 to 9 months follow-up (depending on when it was
	218	recorded) was as per the WHO definitions adopted in South Africa,(10) that is, either successful
45 46	219	treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss
47 48 49 50 51 52 53 54 55 56	220	to follow-up (defined as treatment interruption of more than 2 months), or outcome not evaluated.
	221	It was measured using the routinely collected TB treatment outcomes in patients' individual files.
	222	
	223	Secondary Outcomes
	224	For those participants with bacteriologically confirmed PTB at baseline (either sputum acid fast
	225	bacilli (AFB) positive, culture positive or GeneXpert positive PTB), sputum conversion at the end of
57	226	treatment ("cure rate") was measured as a secondary outcome.(10) Continuous smoking abstinence
58 59 60	227	was assessed at 3- and 6-months follow-up in those participants who were current cigarette smokers
		7

at baseline. It was defined as having quit smoking completely and a self-report of not smoking more than 5 cigarettes from the start of the study, in addition to a negative biochemical test (exhaled Carbon Monoxide (CO) < 7 ppm).(33,34) Changes in alcohol consumption were computed using the AUDIT questionnaire scores measured at 3- and 6-months follow-up in those participants who were hazardous/harmful drinkers at baseline.

HIV positive participants were asked about ART status at baseline, 3- and 6-months using standardised questions on the CRF and change in ART status as measured at the 2 follow-up times.

TB and ART medication adherence was measured using modified versions of the AIDS Clinical Trials Group Adherence Questionnaire, a validated tool for measuring adherence specifically to ART.(35) Adherence was measured using an adherence index calculated by the formula (using the 4-day recall): [Total number of doses taken/Total number of doses prescribed] x 100. Patients with at least 95% adherence were classed as having optimal adherence and those with less than 95% were classed as having low (or suboptimal) adherence. This was assessed at 3- and 6-months.

During COVID-19 lockdown (in the second term of 2020) we switched to telephonic follow-up of participants using a shortened questionnaire whereby only strictly needed information for the measurement of outcomes was inquired about.

Training and Intervention Fidelity Monitoring

The training and intervention fidelity monitoring is described in more detail in previous papers.(30,31) In brief, 18 LHWs, 3 district coordinators and 1 research assistant who focused on counselling supervision underwent MI training over 5 days. LHWs completed a post-session semi-structured form onto which they indicated the extent to which they implemented each element of MI, as well as their general qualitative impressions of that particular session. In addition, we assessed MI intervention fidelity based on ratings of the counsellors' recorded MI sessions, as described below and in footnotes to the relevant supplementary table. SMS-message delivery was also assessed.

Economic evaluation

The ProLife intervention costs consisted of the costs of training and the delivery of the ProLife intervention, including relevant personnel involvement (trainers and LHWs), materials used, travel, accommodation and refreshments, and digital infrastructure for the intervention. These were estimated based on research team records. Usual care costs consisted of TB medication costs, biochemical investigations, and ART costs if applicable. These were estimated based on information

260	obtained through routine records. The country specific version of Euroqol with 5 dimensions and 3
261	levels of response categories (EQ-5D-3L) for South Africa was administered to participants at
262	baseline, 3- and 6-months follow-up to measure health-related quality of life.(36,37)

11 264 Statistical analysis

The sample size was estimated at 696 in total (348 participants per arm), to detect a 10% difference in TB treatment success rates (0.86 vs. 0.76) in the ProLife arm (intervention) vs. the control arm with 80% power, a significance level of 0.05 and 25% attrition rate. The assumed success rates in the control group were based on actual success rates in patients with TB in the studied provinces obtained from TB managers at the time of the grant application for this study.

We summarised baseline data descriptively by trial arm. For the primary outcome, we conducted statistical analysis on an intention-to-treat basis. We used binary logistic regression to compare the main outcome (TB treatment success rate) between the intervention and the usual care arm. Where treatment outcome data were missing, the outcome was coded as unsuccessful. TB treatment outcomes recorded by the TB nurse were taken on face value as inconsistencies in the dates of bacteriological results did not permit us to verify the correctness of the nurse assessment. We carried out similar statistical analyses for the secondary outcomes with appropriate regression techniques. For the reduction in harmful or hazardous drinking, we used linear regression to estimate the difference in total AUDIT score between control and intervention groups accounting for the baseline AUDIT score as covariate. Separate analyses at 3- and 6-months were performed.

For our main analyses we adjusted for baseline characteristics if these differed between trial arms at baseline. The covariates that we controlled for in each model are specified when a model is presented. The statistical packages STATA (38) and R (39) were used to carry out the analyses, with a P-value < 0.05 considered statistically significant.

The validated Motivational Interviewing Treatment Integrity (MITI) coding tool (version 4.2.1) was used to assess MI intervention fidelity.(40) The coding entailed making 'Global Ratings' (on 4 dimensions: Cultivating change talk, Softening sustain talk, Partnership and Empathy) and 'Behaviour' counts (with respect to the items: giving information, persuade, persuade with permission, question, simple reflection, complex reflection, affirm, seeking collaboration, emphasising autonomy and confront). A score was assigned to each of these items and the scores compared against the competency and proficiency thresholds that are specified in the MITI manual.

2		
3 4	291	
5	292	For the analysis of the costs, all costs were collected in South Africa Rand (ZAR) except for the data
6 7	293	management system subscription. Results are presented in both ZAR and US dollar (\$) using the
8 9	294	2019 OECD exchange rate (1 USD = 14.448 Rand).(36) No South African specific valuation set was
10	295	available for EQ-5D-3L. The valuation set of Argentina, based on a Visual Analogue Scale, was used to
11 12	296	derive utility values, because the GDP per capita in international dollars was the closest between the
13 14	297	two countries at the time of analysis.(37,41) Quality-adjusted life years (QALYs) were derived from
15	298	the utility values at the time points by calculating the area under the curve.(42) No missing data
16 17	299	imputation was performed.
18 19	300	
20	301	
21 22	302	RESULTS
23 24	303	
25	304	Participant enrolment and follow-up
26 27 28 29 30 31	305	A total of 2099 patients with TB were screened for eligibility out of which 574 consenting and eligible
	306	participants were randomised: 291 to control and 283 to intervention. Trial recruitment was
	307	terminated on 31 August 2019 before the planned sample size was reached because of budget and
32	308	time constraints. In the intervention arm, 227 (80.2%) participants completed the first MI (MI 1)
33 34 35 36 37 38 39	309	session, 199 (70.3%) MI 2 and 150 (53.0%) MI 3. In the intervention arm, at least one message was
	310	delivered to 208 (73.5%) participants, while 99 (35.0%) received all messages. Of those randomised
	311	to the control and intervention groups, the primary outcome was recorded in 244 (83.8%) and 253
	312	(89.4%) participants, respectively. (Figure 1)
40 41	313	
42	314	Figure 1 Consort flow diagram
43 44	315	
45 46	316	Baseline participant characteristics of the intervention and control arm
47	317	Socio-demographic; socio-economic and clinical characteristics
48 49 50 51 52	318	Baseline characteristics were distributed similarly in the intervention and control arms for most
	319	variables but with some imbalances in educational level. A total of 513 (91.3%) participants were
	320	new patients with TB, 129 (22.5%) women, and nearly all had PTB (International Classification of
53 54	321	Diseases-10 A15) without extrapulmonary TB manifestations (553 (98.9%)). About half of the
55 56	322	participants were HIV positive (305 (53.2%)), of whom 204 (65.4%) were on cotrimoxazole and 257
57	323	(82.4%) were on ART. (Table 1) Details of marital status, employment, wealth, depression status and
58 59	324	co-morbidities are presented in Supplementary table 1.
60		

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	325				
49 50					

	Control (N = 291)	Intervention (N = 283)	Total (N=574)
	n (%)*	n (%)*	n (%)*
Age in years: mean (SD)	39.37 (12.60)	38.56 (11.15)	
Female Sex	69 (23.7)	60 (21.2)	129 (22.5)
Education			
No education	7 (2.4)	5 (1.8)	12 (2.1)
Grades 1-5	23 (7.9)	20 (7.1)	43 (7.5)
Grades 6-7	32 (11.0)	35 (12.4)	67 (11.7)
Grades 8-11	96 (33.0)	128 (45.2)	224 (39.0)
Grade 12	87 (29.9)	70 (24.7)	157 (27.4)
Higher	24 (8.2)	8 (2.8)	32 (5.6)
Declined to answer**	22 (7.6)	17 (6.0)	39 (6.8)
TB Patient category			
New patient	264 (92.3)	249 (90.2)	513 (91.3)
Relapse	10 (3.5)	9 (3.3)	19 (3.4)
Re-treatment after default	9 (3.1)	14 (5.1)	23 (4.1)
Re-treatment after failure	1 (0.3)	2 (0.7)	3 (0.5)
Other	2 (0.7)	2 (0.7)	4 (0.7)
B Site of disease Pulmonary only (ICD-10 A15)	281 (98.9)	272 (98.9)	553 (98.9)
B Sputum smear, Gene XPert, or culture result available N=	236	227	463
At least one Sputum smear, Gene XPert, or culture result positive	208 (88.1)	195 (85.9)	403 (87.0)
HV status			
Negative	118 (40.7)	125 (44.2)	243 (42.4)
Positive	163 (56.2)	142 (50.2)	305 (53.2)
Unknown	9 (3.1)	16 (5.7)	25 (4.4)
IIV positive patients			
Using Cotrimoxazole	104 (63.8)	100 (67.1)	204 (65.4)
Using anti-retroviral	139 (85.3)	118 (79.2)	257 (82.4)

 BMJ Open

326	* Frequencies and (percentages) are presented unless otherwise stated
327	**More variables with the option "declined to answer" are listed in the Supplementary table 1
328	

	Control (N=291)	Intervention (N=283)	Total (N=574)
	n (%)*	n (%)*	n (%)*
In the past month, smoked tobacco			
Not at all**	110 (37.8)	92 (32.5)	202 (35.2)
Daily	149 (51.2)	149 (52.7)	298 (51.9)
Less than Daily	32 (11.0)	42 (14.8)	74 (12.9)
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
AUDIT Score (males) : mean (SD) [max: 19]†	12.27 (3.98)	13.02 (3.78)	12.66 (3.89)
AUDIT Score (females): mean (SD) [max: 19] ⁺	11.32 (4.02)	10.98 (4.02)	11.15 (4.0)
Hazardous/harmful drinking and Smoking Combined (Constructed)			
Hazardous/harmful drinking Only‡	110 (37.8)	92 (32.5)	202 (35.2)
Smoking Only	103 (35.4)	77 (27.2)	180 (31.4)
Smoking and hazardous/harmful drinking	78 (26.8)	114 (40.3)	192 (33.4)
 * Frequencies and (percentages) are presented unless otherwise stated *Non-smokers were only included if they were harmful or hazardous drinkers †Only hazardous/harmful drinkers and/or current smokers were included in the sturce (females) or <8 (males) or >19; however, they were included if they were smokers score. These AUDIT scores are thus representative of the mean AUDIT scores in the AUDIT score was measured at 3 and 6-months follow-up ‡Harmful/hazardous drinking is defined as Alcohol Use Disorders Identification Test 	ers independent of whether t entire study sample and differ	hey had a drink in the past year and then r from the AUDIT score in the harmful/haz	refore independent of the

There were 372 current smokers (298 daily, 74 less than daily). Seventy eight participants (26.8 %) in the control arm were dual smokers and drinkers compared to 114 (40.3 %) in the intervention arm. In the control arm, 110 (37.8%) were hazardous/harmful drinkers only and 103 (35.4%) were smokers only, compared to 92 (32.5%) and 77 (27.2) respectively, in the intervention arm. (Table 2) More details of smoking and drinking history, forms of tobacco use, addiction and guit attempts are presented in Supplementary Table 2.

Primary outcome

Overall, 396 (70%) of participants were classified as treated successfully (treatment completed or cured). The remainder either interrupted treatment, failed treatment, developed drug resistance, were transferred out or had an unknown treatment outcome.(Supplementary table 3) The percentage of successful TB treatment did not differ significantly between the control and intervention arm (70.1% vs. 67.8%), odds ratio (OR) for successful TB treatment 0.90 (95%CI: (0.64,1.27)) comparing the intervention arm to the control arm; and was similar to adjusted ORs (Tables 3 and 4).

Secondary outcomes

Cure rates

Among the 403 participants who had at least one positive bacteriological result at baseline, 168 (41.7%) were recorded as cured; of these, 83/205 (39.9%) were in the control arm compared to 85/195 (43.6%) in the intervention arm. The OR of being cured was 1.16 (95% CI: 0.83,1.63) in the intervention versus the control arm; and was similar to the adjusted OR. (Tables 3 and 4)

> Continuous smoking abstinence

Among those who identified as cigarette smokers at baseline (345 (60.1%)), 27 had information (self-report plus biochemical verification) to enable the identification of continuous abstinence at 6-months of which 22 had continuously abstained from smoking. These were similarly distributed across the two study arms: 10 (5.59%) participants in the intervention arm compared to 12 (7.23%) in the control arm, OR 0.76 (95% CI: 0.35,1.63). (Tables 3 and 4) At the 3-month follow-up 20 (11.2%) participants in the intervention arm compared to 27 (16.3%) in the control arm continuously abstained from smoking, OR 0.65 (95% CI: 0.37,1.14). (Tables 3 and 5)

Page 17 of 155

 BMJ Open

	Baseline				-months follow-u	р		6-months follow-ι	р
	n (%)*			n	(%)*			n (%)*	
	Control	Intervention	Total	Control	Intervention	Total	Control	Intervention	Total
TB treatment status ^a									
Successful**							204 (70.1)	192 (67.8)	396 (69.0)
Not Successful							87 (29.9)	91 (32.16)	178 (31.0
Cured ^{a, ***}									
Yes							83 (39.9)	85 (43.6)	168 (41.7)
No							125 (60.1)	110 (56.4)	235 (58.3
Continuous smoking abstinence ^b				- / r-					
Yes				27 (16.3)	20 (11.2)	47 (13.6)	12 (7.2)	10 (5.6)	22 (6.4)
No				139 (83.7)	159 (88.8)	298 (86.4)	154 (92.8)	169 (94.4)	323 (93.6
Harmful/hazardous drinkers [!] : N =	188†	206†	394†	141†	130†	271†	112†	127†	239†
AUDIT score: mean	12.76	13.12	12.94	8.28	8.84	8.55	8.79	8.70	8.74
(SD)	(3.42)	(3.47)	(3.45)	(6.18)	(5.38)	(5.81)	(6.66)	(5.83)	(6.22)
Difference from				-4.61	-4.07	-4.35	-4.25	-4.17	-4.21
baseline: mean (SD)				(6.26)	(5.33)	(5.83)	(6.56)	(6.61)	(6.57)
HIV positive	163†	142†	305+	122†	83†	205†	100†	83+	183†
patients:	(56.2)	(50.2)	(53.2)	01 (74 C)		1 40 (72 7)		74 (00.2)	154 (04 2
Taking ART medication if HIV	139 (85.3)	115 (81.0)	254 (83.3)	91 (74.6)	58 (69.9)	149 (72.7)	80 (80.0)	74 (89.2)	154 (84.2)

ART ۱ adherence	medication 2 ^b							
Optimal	ladherence		101 (99.0)	64 (98.5)	165 (98.8)	75 (97.4)	64 (97.0)	139 (97.2)
	Suboptimal adherence		1 (1.0)	1 (1.54)	2 (1.2)	2 (2.6)	2 (3.0)	4 (2.8)
TB adherenc	medication ce	4						
Optimal	ladherence		181 (92.3)	138 (90.8)	319 (91.7)	61 (89.7)	59 (90.8)	120 (90.2)
	Suboptimal adherence		15 (7.6)	14 (9.2)	29 (8.3)	7 (10.3)	6 (9.2)	13 (9.8)
***Based on h ! hazardous/ha †Denominator	armful drinkers who are not a r for the mean (SD) or denomi	ome among those who were bact cohol dependent= AUDIT score ≥ nator for %	8 for men or ≥ 7 for women b	ut < 20; *! Important d				
***Based on h ! hazardous/ha †Denominator	naving a cured treatment outc armful drinkers who are not a r for the mean (SD) or denomi	ome among those who were bact cohol dependent= AUDIT score ≥	8 for men or ≥ 7 for women b	ut < 20; *! Important d				

	Crude Odds Ratio	P Value*	Adjusted Odds Ratio	P
	(95% CI)*		(95% CI)*	Value*
Primary outcome				
TB treatment status: Successful (Ref: Not successful)	0.90 (0.64,1.27)	0.548	0.86‡ (0.60,1.24)	0.421
Secondary outcomes				
Cured (Ref: Not Cured)	1.16 (0.83,1.63)	0.374	1.07‡ (0.76,1.51)	0.684
Continuous smoking abstinence (Ref: No)***	0.76 (0.35,1.63)	0.482		
TB medication adherence (Ref: Optimal)	0.89 (0.26,3.07)	0.849		
ART medication adherence (Ref: Optimal)	1.17 (0.14,9.94)	0.884		
Taking ART medication (Ref: No)	2.05 [!] (0.80,5.27)	0.136		
AUDIT	-0.04** (-2,1.91)	0.966	0.02 ^{!!} (-1.55,1.6)	0.976

* Analyses accounted for potential clustering by centre.

+ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable.

! Adjusting for art status at baseline

**Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

***Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.73 and 0.76 with similar confidence limits as for the crude estimate.

Secondary outcome	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*
Continuous smoking abstinence (Ref: No)**	0.65 (0.37,1.14)	0.135		
TB medication adherence (Ref: Optimal)	1.22 (0.52,2.87)	0.641		
ART medication adherence (Ref: Optimal)	1.58 (0.10,26.12)	0.750		
Taking ART medication (Ref: No)	0.79 [!] (0.38,1.65)	0.53	0.74‡ (0.35,1.58)	0.443
AUDIT	0.55† (-1.01,2.11)	0.474	0.74" (-0.62,2.1)	0.273

*Analyses accounted for clustering.

! Adjusting for art status at baseline

‡ Adjusted for art status at baseline, district, sex, and smoking/drinking status and HIV status at baseline.

⁺Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

** Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.63 and 0.66 with similar confidence limits as for the crude estimate.

Page 21 of 155

1 2 BMJ Open

3	369	Change in harmful/hazardous drinking
4 5	370	AUDIT scores were about 4 points lower at both follow-up times than at baseline, independent of
6 7	371	the intervention. (Table 3) In the intervention arm, participants had, on average, a reduction of 0.04
8 9	372	points (95% CI: -2,1.91) on the AUDIT score at 6-months, compared to those in the control arm
10	373	controlling for baseline scores; whereas an average increase of 0.55 (95% CI: -1.01,2.11) was
11 12	374	observed at 3-months. (Tables 4 and 5)
13 14	375	
15 16	376	Medication adherence and ART uptake
17	377	At 6-months, the OR of taking ART medication was 2.05 (95% CI: 0.80,5.27) comparing the
18 19	378	intervention arm to the control arm and controlling for ART baseline medication status; whereas it
20 21	379	was 0.79 (95% CI: 0.38,1.65) at 3-months. The proportion of participants who had optimal TB
22	380	medication adherence was 90.2% (120/133) at 6-months and 91.7% (319/348) at 3-months.
23 24	381	Suboptimal TB medication adherence ORs were 0.89 (95%CI: 0.26,3.07) and 1.22 (95%CI: 0.52,2.87)
25 26	382	comparing intervention arm to the control arm at 6-months and 3-months, respectively. The
27	383	proportions of participants on ART who had optimal ART medication adherence were high at both 3-
28 29	384	months (165/167, 98.8%) and 6-months follow-up (139/143, 97.2%). Suboptimal ART medication
30 31	385	adherence ORs were 1.17 (95%CI: 0.14,9.94) and 1.58 (95%CI: 0.10,26.12) comparing the
32 33	386	intervention arm to the control arm at 6-months and 3-months, respectively. (Tables 3, 4 and 5)
34	387	
35 36	388	Intervention fidelity
37 38	389	Motivational interviewing fidelity
39	390	The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In terms
40 41	391	of the global ratings, the LHWs' counselling sessions were above proficiency levels on all items,
42 43	392	namely, cultivating change talk, softening sustain talk, partnership, and empathy (as the mean scores
44	393	were all above 2). In terms of the summary measures, the LHWs' counselling sessions did not
45 46	394	achieve the basic proficiency threshold of 3.5 for the Relational component (Partnership + Empathy)
47 48	395	as their mean score was 3.1 (SD=1.19). However, their mean score on the Technical component
49 50	396	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For
51	397	behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by
52 53	398	"Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the
54 55	399	following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions
56	400	Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize
57 58	401	Autonomy and Seek Collaboration) and 1.2 (SD=2.28) MI non-adherent (Confront and Persuade)
59 60	402	statements per session. (Supplementary Table 4)

1		
2 3	402	
4	403	
5 6	404	SMS-delivery
7 8 9 10 11	405	Of the total number of Information-Motivation-Behaviour messages triggered, 3583 (80.4%) were
	406	delivered. All due SMS messages were delivered to 95 (41.9%) of the participants who completed
	407	the first MI, See Supplementary Table 5 for more details.
12 13	408	
14	409	Costs and health related quality of life
15 16	410	Unit costs used to estimate the mean costs are presented in the Supplementary Table 6. Incremental
17	411	cost-utility ratios are not presented since the intervention was not clinically effective. The mean cost
18 19	412	of the ProLife intervention was ZAR 2601 (SD 6) (\$180.02 (SD \$0.42)) per participant in the
20 21	413	intervention arm (n=283). The mean cost of usual care was ZAR 681 (SD 357) (\$47.13 (SD \$24.71)) in
22	414	the intervention arm (n=122) versus ZAR 706 (SD 302) (\$48.86 (SD \$20.90)) in the control arm
23 24	415	(n=131). The total mean cost of care including the intervention was ZAR 3285 (SD R357) (\$227.37 (SD
25	416	24.71)) in the intervention arm (n=122). EQ-5D-3L data were available at the 3 time points for 137
26 27	417	intervention and 159 control arm participants. The mean QALYs estimated over six months were
28 29	418	0.442 (SD 0.061) in the intervention arm versus 0.430 (SD 0.074) in the control arm (adjusted mean
30	419	difference 0.006 (95% Cl -0.001 to 0.013)).
31 32	420	
33 34	421	DISCUSSION
35	422	
36 37	423	This RCT did not provide evidence for improved TB treatment success rates in those receiving the
38 39	424	
40		ProLife intervention compared to those receiving usual care. We could also not demonstrate
	425	ProLife intervention compared to those receiving usual care. We could also not demonstrate significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption,
41 42	425 426	
42 43		significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption,
42 43 44 45	426	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of
42 43 44	426 427	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex
42 43 44 45 46 47 48	426 427 428 429	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of
42 43 44 45 46 47 48 49 50	426 427 428 429 430	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused
42 43 44 45 46 47 48 49 50 51	426 427 428 429 430 431	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking
42 43 44 45 46 47 48 49 50 51 52 53	426 427 428 429 430 431 432	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in inducing smoking cessation in patients with TB but did not
42 43 44 45 46 47 48 49 50 51 52	426 427 428 429 430 431 432 433	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in inducing smoking cessation in patients with TB but did not improve TB outcomes.(45) Conversely, in another study in India, intensive counselling for alcohol
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	426 427 428 429 430 431 432 433 434	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in inducing smoking cessation in patients with TB but did not improve TB outcomes.(45) Conversely, in another study in India, intensive counselling for alcohol disorders led to significantly better TB treatment outcomes in the intervention group compared to
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58	426 427 428 429 430 431 432 433 434 435	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in inducing smoking cessation in patients with TB but did not improve TB outcomes.(45) Conversely, in another study in India, intensive counselling for alcohol disorders led to significantly better TB treatment outcomes in the intervention group compared to the control group.(46) Smoking cessation also led to better TB treatment outcomes in a secondary
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	426 427 428 429 430 431 432 433 434	significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, medication adherence and ART initiation. To our knowledge there are no other published studies of similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in inducing smoking cessation in patients with TB but did not improve TB outcomes.(45) Conversely, in another study in India, intensive counselling for alcohol disorders led to significantly better TB treatment outcomes in the intervention group compared to

Page 23 of 155

BMJ Open

non-significant result for smoking-related outcomes is not consistent with findings from our previous TB study, which used a single MI session and found that the chance of sustained smoking cessation was twice as high in the MI intervention group compared to the control group,(14) albeit with a less stringent exhaled CO cut-off point. Evidence on the effectiveness of MI for smoking abstinence in non-TB settings has been equivocal.(48) Self-reported alcohol consumption decreased with about 4 points in both intervention and control arms in our study at both follow-up times. Answering questions on drinking in brief intervention trials may alter subsequent self-reported behaviour: exposing non-intervention control groups to an integral component of the intervention may therefore underestimate the effect of the intervention.(49) There have been few previous studies looking at MI and SMS interventions for the modification of hazardous/harmful drinking in the context of TB. A previous trial of a brief counselling intervention to reduce alcohol consumption in patients with TB did not find a significant effect on alcohol reduction.(50) Outside a TB setting, results have been mixed. A meta-analysis showed a small but significant improvement in outcomes when MI was used in conjunction with cognitive behavioural therapy for co-morbid alcohol use and depression.(51) Self-reported TB and ART medication adherence was high overall in our study population, which is consistent with other studies conducted in South Africa.(52,53) It is possible that we did not find a difference in treatment adherence due to a ceiling effect.

There were several key strengths in this RCT. This was an individually RCT with a relatively large sample size and a high follow up rate (87%) for the primary outcome. Primary outcome assessment was blinded. This was a novel intervention, which built on previous successes with both MI and mHealth interventions and was aligned with the WHO's call to increase the use of digital technologies to improve TB care.(15) We utilized a validated alcohol consumption questionnaire (AUDIT) (29) and a four-day timeline follow-back for medication adherence to reduce recall bias as self-reports tend to underreport drinking while overestimating adherence behaviour compared with.(54) (35) Smoking cessation was confirmed with exhaled CO using strict cut-off points. Overall, the quality of the counselling was acceptable. The results of our MI analyses suggest that the LHWs trained as counsellors were more proficient in MI than during the feasibility stage, as observed by their global rating scores on cultivating change talk, softening sustain talk, partnership and empathy. (Supplementary Table 4) These results were achieved by ongoing monitoring and training of LHWs during the trial and adapting the training based on feedback from the feasibility stage. Extra counsellors were also appointed to minimise travel distances to clinics. There were some limitations associated with this RCT. Trial recruitment had to be terminated before the planned sample size because of funding and time constraints. Nevertheless, the calculation of sample size was based on

an anticipated 25% LTFU for the primary outcome, while in reality only 13.4 %, of the TB outcomes were not available. As a result, we achieved a slightly higher power to detect the a 10% difference in primary outcomes, than we had aimed for (83% vs. 80%). The smaller sample size did however reduce the power to detect a difference for secondary outcomes for which the LTFU was much higher than 25%. Also, the calculated sample size was not powered for subgroup analysis which was the case for outcomes relating to smoking, drinking, ART and cure rates. In addition, due to COVID-19 lockdown in March 2020, we had to switch to telephonic follow-up of participants using a shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB treatment outcomes. The low intervention uptake meant that half of the participants received only one or two MI sessions combined with SMS messages. SMS messages were only used for the first half of the study period, and one quarter of participants did not receive their messages, a commonly occurring problem in developing countries.(20,55) It could be argued that in the absence of ongoing text messages, the MI and associated text messages were not enough to keep participants focussed for the second three months of the trial. The 2-arm study design did not permit the untangling of the individual effects of SMS and MI. Understanding their separate effects could have important cost implications as SMS-communication would be cheaper and easier to organise than individual counselling.

The lack of effectiveness of our intervention on the primary outcome (TB treatment success) can have a number of possible explanations. Although intervention uptake was high (80.2%) for the first counselling session, many participants did not return for the second (29.7%) and third (47%) sessions. As a result of this only about half of the intervention arm participants received all three MI sessions. Furthermore, about one quarter of all participants did not receive any SMS-messages. Low intervention uptake leads to a dilution of any potential effects. The lack of effectiveness on TB treatment success could perhaps also be explained by the complexity of the ProLife intervention itself: counsellors had to address multiple behaviours, namely medication adherence, tobacco smoking and hazardous/harmful drinking. Despite having established the feasibility and acceptability of this approach (31) and ongoing on site performance monitoring and feedback of counsellors, it is possible that MI for multiple behaviour change in the ProLife study was counterproductive as counsellors may have ended up not focusing on any of the behaviours at optimal levels. Similarly, patients might have found it difficult to change multiple behaviours simultaneously, especially because smoking and drinking are mutually reinforcing. This integrated approach was nevertheless adopted to avoid the need for multiple vertical counselling services (in addition to TB treatment and HIV treatment), to allow the different elements of the programme to reinforce one another, and to improve the affordability, feasibility and acceptability for a future roll-out of the programme. It is Page 25 of 155

BMJ Open

also possible that sequential interventions may be better, at least for smoking cessation.(56) More intensive counselling (more sessions) or a modified counselling method may have been more appropriate, even more so since a recent review of reviews of MI casts doubt on its efficacy.(48,57,58) For example, more emphasis on increasing patient knowledge in addition to increasing self-efficacy may have been more effective. (59) The cause of the mobile health message delivery problems (such as poor network coverage, no electricity to charge phones) (60) would need to be investigated in order to increase the effectiveness of future mHealth interventions. Messages may also have to be intensified or modified to be more interactive and/or tailored to specific circumstances of each individual. This would improve the personal value of the intervention to the individual, which is likely to increase the chances of their participation in the intervention.(61) Consistent with the normalisation process theory, (62) cognitive participation in the intervention might have been higher had we been deliberate in the implementation to ensure the TB nurse who would have routinely seen the participants, provided additional support and motivated participants to attend MI sessions with the counsellor. In this way, the intervention would have gained 'legitimacy' but this would have led to unblinding of the nurses to the intervention arm.

In conclusion, we could not demonstrate that the ProLife intervention was effective in improving TB treatment outcomes. This may be due to the lack of effect of the intervention, but the study may also have been underpowered for the intermediary secondary outcomes. Valuable lessons were learnt on challenges relating to training LHWs in MI counselling and delivery, SMS-delivery in a challenging socio-economic context and the reasons for loss to follow-up of TB participants with multiple health problems. Further research is needed to provide answers on how to increase intervention uptake in poor resource settings and whether our complex intervention should have been more intensive. Other important questions are whether another counselling method would have been more effective. Lastly, in the light of the already existing evidence of SMS and the costs and implementation challenges relating to MI, intervention studies limited to an mHealth intervention but using different intensities, duration and type of interventions (one-way, two-way, interactive) are needed.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

535 Acknowledgements

We are grateful to the following people: Ms M Malefo for her work as project manager, Ms D Bell for conducting the MI training, Ms N Kitleli for supervising the lay counsellors, Mesadie Machaea-Malinga for conducting the fidelity assessments, the district and clinic TB managers and TB nurses, the fieldworkers and the lay counsellors. The authors are also grateful to the National Department of Health and the three Provincial Departments of Health for granting permission for this study.

15 542

543 Contributors

MK contributed to study design and the manuscript, led on the sample size determination and did the statistical analysis. NKM contributed to study design, particularly with respect to development of the MI intervention, did the analysis of the MI data and contributed to the manuscript writing. AVZ led the data management and SMS-system, monitored data quality and contributed to data analysis and manuscript writing. ASM contributed to study design and led on the preparation of the manuscript. NDM contributed to study design, intervention development and manuscript preparation. JL and SP led on the economic evaluation. AT contributed to the economic evaluation. JT was site lead for the Bojanala sub-district. OBO was site lead for the Sedibeng sub-district. MOB contributed to study design, data interpretation and the manuscript. KS and OAA are co-principal investigators. Both contributed to study design, data interpretation and manuscript writing. All authors read and approved the final draft of the manuscript.

41 557

558 Funding

This project was funded by the SA-Medical Research/Newton Foundation Grant on TB
control implementation science. (UK/South Africa Newton Fund RFA: TB control
implementation science (MRC-RFA-02: TB -05-2015)). This UK funded award is part of
the EDCTP2 programme supported by the European Union.

52 563 The funder had no role in study design; collection, management, analysis, and 53 564 interpretation of data; writing of the report or the decision to submit the report for 55 565 publication.

57 566 Trial sponsor: Sefako Makgatho Health Sciences University, RSA. Contact: <u>lekan.ayo-</u>
 58 567 <u>yusuf@smu.ac.za</u>

1 2		
3	568	
4 5	569	Competing interests
6 7	570	OA Ayo-Yusuf, the principal investigator, received a research grant (MRC-RFA-02: TB -
8 9	571	05-2015) which was allocated to Sefako Makgatho Health Sciences University to pay
10 11	572	for the expenses related to the research project. As co-prinicipal investigator K Siddiqi
12	573	received part of the MRC-Newton research grant (MRC-RFA-02: TB -05-2015) which
13 14	574	was allocated to the University of York to support the research by the authors
15 16	575	affiliated to the University of York (K Siddiqi, ND Mdege, M Kanaan, S Parrot, J Lee).
17	576	Goedele Louwagie received a small monthly remuneration per month from 1 October
18 19	577	2018 until 30 June 2020 as academic research coordinator. André van Zyl was
20 21	578	employed as a research data manager on a part-time basis from 1 September 2017
22	579	and 30 June 2020. OA Ayo-Yusuf received support for attending meetings and for
23 24	580	travel by Tax Justice Network Africa. He is the Vice Chair of the Standing Committee on
25 26	581	Health, Academy of Science, SA (not remunerated). The remaining authors declare no
27	582	competing interests.
28 29	583	
30 31	584	Ethical considerations
32 33	585	This study received ethics approval from the Research Ethics Committees of: Sefako
34 35	586	Makgatho Health Sciences University (SMU; Ref: SMUREC/D/234/2017: IR); the South
36	587	African Medical Research Council (with the SMU Ethics Committee serving as the
37 38	588	Research Ethics Committee Record); the University of Pretoria (Ref: 434/2017); the
39 40	589	University of Witwatersrand (M160455); and the University of York (no reference
41 42	590	number, approval date 15 January 2017 (29).
43 44	591	
45	592	Patient Consent for publication
46 47	593	Not applicable
48 49	594	
50 51	595	Data availability statement
52 53	596	The study protocol was previously published.(30) The de-identified participant and
54	597	SMS data sets are stored in labelled Stata files and are accompanied by a statistical
55 56	598	analysis plan and metadata explaining each variable. Although data can be viewed
57 58	599	immediately, data will be embargoed for data analysis until 30 June 2023. Thereafter,
59 60	600	permission must be obtained from the principal investigators (OA and KS) for any data
		For near review only, http://bmienen.hmi.com/cite/about/cuidelines.yhtml

analysis not yet performed by the primary research group. Data are stored in the institutional data repository at Sefako Makgatho Health Sciences University called Discover research (https://smu-za.figshare.com/) with a CC-BY 4.0 (Attribution) license (Creative Commons - Attribution 4.0 International - CC BY 4.0). The statistical analysis plan is available as supplementary material.

Open access

This is an open access article distributed in accordance with a Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

23	613		
25 26	614	Refer	rences
27 28	615		
29 30	616	1.	World Health Organisation. Global tuberculosis report 2020. Available:
31	617		https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
32 33	618		[Accessed 4 Aug 2021].
34 35	619	2.	Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the
36	620		Sustainable Development Goals. Trans R Soc Trop Med Hyg 2016;110:145–7.
37 38	621	3.	Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis
39 40	622		treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. PLoS ONE
41	623		14(7):e0220507.
42 43	624	4.	Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis:
44 45	625		meta-analyses and burden of disease. <i>Eur Respir J</i> 2017;50: 1700216.
46	626	5.	Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors
47 48	627		in Nigeria, 1990–2016. Tropical Medicine and Health 2018;46:34.
49 50	628	6.	Azeez A, Mutambayi R, Odeyemi A, et al. Survival model analysis of tuberculosis treatment
51	629		among patients with human immunodeficiency virus coinfection. Int J Mycobacteriol
52 53	630		2019;8:244-51.
54 55	631	7.	Mollel EW, Chilongola JO. Predictors for Mortality among Multidrug-Resistant Tuberculosis
56	632		Patients in Tanzania. J Trop Med 2017;2017:9241238. doi: 10.1155/2017/9241238.
57 58	633	8.	Peltzer K. Conjoint alcohol and tobacco use among tuberculosis patients in public primary
59	634		healthcare in South Africa S Afr I Psychiatr 2014:20(1):21–6

healthcare in South Africa. S Afr J Psychiatr 2014;20(1):21-6.

Page 29 of 155

BMJ Open

1 2			
3	635	9.	Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis
4 5	636		treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis
6 7	637		2020;24(1):73–82.
8 9	638	10.	Department of Health of South Africa. National Tuberculosis Management Guidelines.
10	639		Pretoria: 2014. Available from:
11 12	640		http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-
13 14	641		27.5.2014.pdf [Accessed 4 Aug 2021].
15	642	11.	Harder VS, Musau AM, Musyimi CW, et al. A randomized clinical trial of mobile phone
16 17	643		motivational interviewing for alcohol use problems in Kenya. Addiction 2020;115:1050-1060.
18 19	644	12.	Palacio A, Garay D, Langer B, et al. Motivational Interviewing Improves Medication
20	645		Adherence: a Systematic Review and Meta-analysis. Gen Intern Med. 31:929–40. DOI:
21 22	646		10.1007/s11606-016-3685-3.
23 24	647	13.	Madhombiro M, Kidd M, Dube B, et al. Effectiveness of a psychological intervention delivered
25 26	648		by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster
27	649		randomized controlled trial. J Int AIDS Soc 2020 Dec;23:e25641.
28 29	650	14.	Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on
30 31	651		smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomized controlled
32	652		trial. Addiction 2014;109:1942–52
33 34	653	15.	World Health Organization. Handbook for the use of digital technologies to support
35 36	654		tuberculosis medication adherence, 2017. Available:
37	655		https://apps.who.int/iris/handle/10665/259832 [Accessed 4 Aug 2021].
38 39	656	16.	Hirsch-Moverman Y, Daftary A, Yuengling KA, et al. Using mhealth for HIV/TB treatment
40 41	657		support in lesotho: Enhancing patient-provider communication in the start study. J Acquir
42	658		Immune Defic Syndr 2017;74:S37–43.
43 44	659	17.	Shah R, Watson J, Free C. A systematic review and meta-analysis in the effectiveness of
45 46	660		mobile phone interventions used to improve adherence to antiretroviral therapy in HIV
47	661		infection. BMC Public Health 2019;19:915.
48 49	662	18.	Gashu KD, Gelaye KA, Mekonnen ZA, et al. Does phone messaging improves tuberculosis
50 51	663		treatment success? A systematic review and meta-analysis. BMC Infect Dis 2020;20:42.
52 53	664	19.	Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on
54	665		tuberculosis treatment: a systematic review. Eur Respir J. 2018 11;51(1):1701596. doi:
55 56	666		10.1183/13993003.01596-2017
57 58	667	20.	Ggita JM, Ojok C, Meyer AJ, et al. Patterns of usage and preferences of users for tuberculosis-
58 59 60	668		related text messages and voice calls in Uganda. Int J Tuberc Lung Dis 2018;22:530-536.

1 2

3	669	21.	Oosterveen E, Tzelepis F, Ashton L, et al. A systematic review of eHealth behavioral
4 5	670		interventions targeting smoking, nutrition, alcohol, physical activity and/or obesity for young
6 7	671		adults. Prev Med 2017;99:197–206.
8 9	672	22.	Haug S, Paz Castro R, Kowatsch T, et al. Efficacy of a technology-based, integrated smoking
10	673		cessation and alcohol intervention for smoking cessation in adolescents: Results of a cluster-
11 12	674		randomised controlled trial. J Subst Abuse Treat 2017;82:55–66.
13 14	675	23.	Siddiqi K, Stubbs B, Lin Y, et al. TB multimorbidity: a global health challenge demanding
15	676		urgent attention. Int J Tuberc Lung Dis 2021;25:87–90.
16 17	677	24.	Moosa S, Derese A, Peersman W. Insights of health district managers on the implementation
18 19	678		of primary health care outreach teams in Johannesburg, South Africa: A descriptive study
20	679		with focus group discussions. <i>Hum Resour Health</i> 2017;15:1–9.
21 22	680	25.	Marcus TS, Hugo J, Jinabhai CC. Which primary care model? A qualitative analysis of ward-
23 24	681		based outreach teams in South Africa. African J Prim Heal Care Fam Med 2017;9:1–8.
25	682	26.	Seidman G, Atun R. Does task shifting yield cost savings and improve efficiency for health
26 27	683		systems? A systematic review of evidence from low-income and middle-income countries.
28 29	684		Hum Resour Health 2017;15:1–13.
30	685	27.	Heunis C, Wouters E, Kigozi G, et al. TB/HIV-related training, knowledge and attitudes of
31 32	686		community health workers in the Free State province, South Africa. African J AIDS Res
33 34	687		2013;12:113–9.
35 36	688	28.	World Health Organization & Centers for Disease Control (U.S.). Tobacco questions for surveys: a
37	689		subset of key questions from the Global Adult Tobacco Survey (GATS): global tobacco surveillance
38 39	690		system. World Health Organization 2011. Available from:
40	691		https://apps.who.int/iris/handle/10665/87331 [Accessed 16 Nov 2021]
41 42	692	29.	Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT):
43 44	693		validation of a screening instrument for use in medical settings. J Stud Alcohol 1995;56:423-
45 46	694		32.
47	695	30.	Moriarty AS, Louwagie GM, Mdege ND, et al. ImPROving TB outcomes by modifying LIFE-style
48 49	696		behaviours through a brief motivational intervention followed by short text messages
50	697		(ProLife): Study protocol for a randomised controlled trial. <i>Trials</i> 2019;20:1–12.
51 52	698	31.	Louwagie GM, Morojele N, Siddiqi K, et al. Addressing tobacco smoking and drinking to
53 54	699		improve TB treatment outcomes, in South Africa: A feasibility study of the ProLife program.
55	700		Transl Behav Med 2020; 10: 1491–1503.
56 57	701	32.	CommCare. Cambridge, MA: Dimagi; 2017. Available from:
58 59	702		https://play.google.com/store/apps/details?id=org.commcare.dalvik&hl=en_US≷=US.
60	703		[Accessed 15 June 2021].

Page 31 of 155

BMJ Open

1 2			
3	704	33.	Siddiqi K, Khan A, Ahmad M, et al. Action to stop smoking in suspected tuberculosis (ASSIST)
4 5	705		in Pakistan: a cluster randomized, controlled trial. Ann Intern Med 2013;158:667–75.
6 7	706	34.	West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: proposal for a
8 9	707		common standard. Addiction 2005;100:299–303.
10	708	35.	van den Boogaard J, Lyimo RA, Boeree MJ, et al. Electronic monitoring of treatment
11 12	709		adherence and validation of alternative adherence measures in tuberculosis patients: A pilot
13 14	710		study. Bull World Health Organ 2011;89:632–9.
15	711	36.	OECD [Internet]. Available from: https://data.oecd.org/conversion/exchange-rates.htm
16 17	712		[Accessed 26 Oct 2021]
18 19	713	37.	Augustovski FA, Irazola VE, Velazquez AP, et al. Argentine valuation of the EQ-5D health
20	714		states. Value Heal 2009;12:587–96.
21 22	715	38.	StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.
23 24	716	39.	Team RC. R: A language and environment for statistical computing. Vienna, Austria: R
25 26	717		Foundation for Statistical Computing; 2017. Available from: https://www.r-project.org/
27	718		[Accessed 04 Aug 2021]
28 29	719	40.	Moyers TB, Rowell LN, Manuel JK, et al. The Motivational Interviewing Treatment Integrity
30 31	720		Code (MITI 4): Rationale, Preliminary Reliability and Validity. J Subst Abuse Treat 2016;65:36-
32	721		42. doi:10.1016/j.jsat.2016.01.001
33 34	722	41.	International Monetary Fund. IMF DataMapper - GDP per capita, current prices (Purchasing
35 36	723		power parity; international dollars per capita), 2018. Available from:
37	724		https://www.imf.org/external/datamapper/datasets [Accessed 04 Aug 2021]
38 39	725	42.	Richardson GMA. Calculation of quality adjusted life years in the published literature: a
40 41	726		review of methodology and transparency. <i>Health Econ</i> 2004;13:1203–10.
42	727	43.	Khachadourian V, Truzyan N, Harutyunyan A, et al. People-centred care versus clinic-based
43 44	728		DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. BMC Pulm
45 46	729		Med 2020;20:105.
47	730	44.	Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to
48 49	731		tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA
50 51	732		2007;297:380–6.
52 53	733	45.	Goel S, Kathiresan J, Singh P SR. Effect of a brief smoking cessation intervention on adult
54	734		tobacco smokers with pulmonary tuberculosis: A cluster randomized controlled trial from
55 56	735		North India. Indian J Public Heal 2017;61(Suppl 1):S47–53
57 58	736	46.	Manogaran C, Nagarajan K, Ovung S, et al. Alcohol intervention strategy among tuberculosis
59	737		patients: a pilot study from South India. Int J Tuberc Lung Dis 2017;21:947–52
60			

Page 32 of 155


BMJ Open

1

1 2			
3 4	738	47.	Siddiqi K, Keding A, Marshall AM, et al. Effect of quitting smoking on health outcomes during
5	739		treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial. Thorax 2021
6 7	740		Published Online First Jul 16:thoraxjnl-2020-215926. doi: 10.1136/thoraxjnl-2020-215926.
8 9	741	48.	Lindson N, Thompson TP, Ferrey A, et al. Motivational interviewing for smoking cessation.
10	742		Cochrane Database Syst Rev. 2019;2019(7).
11 12	743	49.	McCambridge J, Kypri K. Can simply answering research questions change behaviour?
13 14	744		Systematic review and meta analyses of brief alcohol intervention trials. PLoS One
15	745		2011;6(10):e23748.
16 17	746	50.	Peltzer K, Naidoo P, Louw J, et al. Screening and brief interventions for hazardous and
18 19	747		harmful alcohol use among patients with active tuberculosis attending primary public care
20	748		clinics in South Africa: results from a cluster randomized controlled trial. BMC Public Health
21 22	749		2013;13:699.
23 24	750	51.	Riper H, Andersson G, Hunter SB, et al. Treatment of comorbid alcohol use disorders and
25	751		depression with cognitive-behavioural therapy and motivational interviewing: a meta-
26 27	752		analysis. Addiction 2014;109:394-406.
28 29	753	52.	Moosa A, Gengiah TN, Lewis L, et al. Long-term adherence to antiretroviral therapy in a South
30	754		African adult patient cohort: a retrospective study. BMC Infect Dis 2019;19(1):775. doi:
31 32	755		10.1186/s12879-019-4410-8.
33 34	756	53.	Webb Mazinyo E, Kim L, Masuku S, et al. Adherence to Concurrent Tuberculosis Treatment
35	757		and Antiretroviral Treatment among Co-Infected Persons in South Africa, 2008–2010. PLoS
36 37	758		One 2016;11(7): e0159317. https://doi.org/10.1371/journal.pone.0159317.
38 39	759	54.	Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence
40	760		behavior: recommendations on optimal use. Transl Behav Med 2015;5:470–82.
41 42	761	55.	Wanyama JN, Nabaggala SM, Kiragga A, et al. High mobile phone ownership but low internet
43 44	762		access and use among young adults attending an urban HIV clinic in Uganda. Vulnerable Child
45 46	763		Youth Stud 2018;13:3,207-20.
47	764	56.	Meader N, King K, Wright K et al. Multiple risk behavior interventions: Meta-analyses of RCTs.
48 49	765		Am J Prev Med 2017;53:e19–e30.
50 51	766	57.	Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions.
52	767		Health Psychol 2008;27:379-87.
53 54	768	58.	Frost H, Campbell P, Maxwell M, et al. Effectiveness of Motivational Interviewing on adult
55	769		behaviour change in health and social care settings: A systematic review of reviews. PLoS One
56 57	770		2018;18:13(10):e0204890
58 59	771	59.	Kahwati L, Viswanathan M, Golin CE, et al. Identifying configurations of behavior change
60			

1 2			
2 3 4 5 6 7 8 9 10 11 21 3 14 5 6 7 8 9 10 11 21 3 14 5 16 7 8 9 20 22 22 22 22 22 22 22 22 22 22 22 22	772		techniques in effective medication adherence interventions: a qualitative comparative
	773		analysis. Syst Rev 2016;5(83).
	774	60.	Telerivet. Message Statuses . User Guide, 2021. Available from:
	775		https://guide.telerivet.com/hc/en-us/articles/360038959611-Message-Statuses. [Accessed
	776		21 June 2021]
	777	61.	Lustria MLA, Noar SM, Cortese J, et al. A meta-analysis of web-delivered tailored health
	778		behavior change interventions. Journal of Health Communication 2013;18:1039–69.
	779	62.	Gallacher K, May CR, Montori V, et al. Understanding Patients' Experiences of Treatment
	780		Burden in Chronic Heart Failure Using Normalization Process Theory. Ann Fam Med
	781		2011;9:235-243

to beet terien only



SUPPLEMENTARY TABLES

	Control	Intervention	Total
	(N = 291)	(N = 283)	(N=574
	n (%)*	n (%)*	n (%)*
Marital status	X* 7		X* 7
Married or living together	102 (35.1)	95 (33.6)	197 (34.
Divorced/separated	20 (6.9)	18 (6.4)	38 (6.6)
Widowed	10 (3.4)	7 (2.5)	17 (3.0)
Never married and never lived together	144 (49.5)	150 (53.0)	294 (51.
Declined to answer	15 (5.2)	13 (4.6)	28 (4.9)
Employment			
Self-employed (full-time)	30 (10.3)	36 (12.7)	66 (11.5
Employed full-time (30 hrs a week or more)	62 (21.3)	54 (19.1)	116 (20.
Employed part-time (less than 30 hrs a week)	19 (6.5)	29 (10.2)	48 (8.4)
Retired	17 (5.8)	16 (5.7)	33 (5.7)
Unemployed (but able to work)	125 (43.0)	120 (42.4)	245 (42.
Jnable to work because of long-term disability	9 (3.1)	8 (2.8)	17 (3.0)
or			
ill health			
Full-time student	12 (4.1)	4 (1.4)	16 (2.8)
Caring from my home and family/doing	0 (0.0)	2 (0.7)	2 (0.3)
household work/housewife			
Occasional work ("piece job") 🧹	17 (5.8)	12 (4.2)	29 (5.1)
Declined to answer	0 (0.0)	2 (0.7)	2 (0.3)
Ever worked or spent time in mines			
No	244 (83.8)	237 (83.7)	481 (83.
Yes	46 (15.8)	45 (15.9)	91 (15.9
Household items (Yes is displayed)			
A radio	249 (85.6)	234 (82.7)	483 (84.
A television	255 (87.6)	255 (90.1)	510 (88.
A landline telephone	21 (7.2)	22 (7.8)	43 (7.5)
A desktop or laptop computer	67 (23.0)	48 (17.0)	115 (20.
A refrigerator	248 (85.2)	240 (84.8)	488 (85.
A vacuum cleaner or floor pol	49 (16.8)	35 (12.4)	84 (14.6
A microwave oven	198 (68.0)	189 (66.8)	387 (67.
An electric or gas stove	254 (87.3)	238 (84.1)	492 (85.
A washing machine	153 (52.6)	136 (48.1)	289 (50.
Total number of assets: mean (SD)	5.14 (1.96)	4.94 (1.77)	5.04 (1.8
In the past month, number of days you or			
people in the household went to bed hungry because there was no food to eat			
0 days	244 (83.8)	238 (84.1)	482 (84.
1-7 days	45 (15.5)	34 (12.0)	482 (84. 79 (13.8
More than 7 days	2 (0.7)	9 (3.2)	11 (1.9)
Declined to answer	0 (0.0)	9 (3.2) 2 (0.7)	2 (0.3)
	0 (0.0)	∠ (0.7)	Z (0.5)

2	
3	
4	
5	
6	
/ 0	
0 9	
10	
11	
12	
13	
14	
16	
17	
18	
19	
20	
21	
23	
24	
25	
26	
27 28	
29	
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\end{array}$	
31	
32	
33 34	
35	
36	
37	
38	
39 40	
40 41	
42	
43	
44	
45 46	
40 47	
48	
49	
50	
51 52	
52 53	
53 54	
55	
56	
57	
58	

59 60

	One	197 (92.1)	169 (87.6)	366 (89.
	Two	17 (7.9)	24 (12.4)	41 (10.1
Number of Gene XPert	results recorded			
	One	225 (97.8)	210 (97.2)	435 (97.
	Two	5 (2.2)	6 (2.8)	11 (2.5)
Number of culture res Treatment record	ults recorded on the TB			
	One	54 (94.7)	42 (97.7)	96 (96.0
	Two	3 (5.3)	1 (2.3)	4 (4.0)
Co-morbidities				
	Hypertension	19 (6.93)	11 (4.1)	30 (5.54
	Diabetes	5 (1.84)	4 (1.49)	9 (1.66)
	Epilepsy	3 (1.09)	4 (1.49)	7 (1.29)
	Mental illness	3 (1.09)	0 (0)	3 (0.55)
	Liver disease	1 (0.36)	1 (0.38)	2 (0.37)
	Renal insufficiency	1 (0.36)	1 (0.38)	2 (0.37)
	Allergies	2 (0.76)	0 (0)	2 (0.38)
	Other	1 (0.36)	1 (0.38)	2 (0.37)
Depression score (CESD	10): mean (SD)	8.44 (4.38)	8.74 (4.8)	8.59 (4.5

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Control	Intervention	Total
	n (%)*	n (%)*	n (%)*
Smoking History (current smokers only) N=	181	191	372
On the days that you smoke, how soon after			
you wake up do you have your first cigarette?			
After 60 minutes	30 (16.6)	28 (14.7)	58 (15.6)
31-60 minutes	24 (13.3)	16 (8.4)	40 (10.8)
6- 30 minutes	60 (33.1)	65 (34.0)	125 (33.6)
Within 5 minutes	67 (37.0)	82 (42.9)	149 (40.1)
Duration of smoking in months: mean (SD)	212.09	224.93	218.68
	(134.03)	(127.82)	(130.86)
Duration of smoking in months: median (IQR)	186	206	200.5
<u> </u>	(110, 282)	(135, 294)	(123, 287)
Age started smoking in years: mean (SD)	19.2 (6.3)	19.3 (6.3)	19.3 (6.3)
Age started smoking in years: median (IQR)	18 (15-20)	18 (16-21)	18
			(15.5-20.5
Form of tobacco used			
Manufactured cigarettes (Yes)	166 (91.7)	179 (93.7)	345 (92.7)
Number of days you smoked in the past 7days: mean (SD)	5.3 (2.65)	5.53 (2.33)	5.42 (2.49)
Average number of cigarettes smoked daily: mean (SD)	6.18 (6.43)	6.48 (8.21)	6.34 (7.39)
Hand-rolled cigarettes (Yes)	14 (7.7)	21 (11.0)	35 (9.4)
Number of days you smoked in the past 7days: mean (SD)	4.71 (2.84)	3.71 (2.95)	4.11 (2.91)
verage number of handrolled cigarettes smoked daily: mean (SD)	3.71 (3.97)	3.81 (2.82)	3.77 (3.27)
Pipe (Yes)	4 (2.2)	2 (1.0)	6 (1.6)
Number of days in the past 7days you smoked: median (IQR)	1 (0, 2.5)	4.5 (2, 7)	2 (0, 3)
Average number of daily sessions: median (IQR)	1 (0, 3.5)	3 (1, 5)	1.5 (0 <i>,</i> 5)
Length of one session (on average) in minutes : median (IQR)	90 (60 <i>,</i> 107.5)	60 (30, 90)	90 (30, 90)
Cigars, cheroots or cigarillos (Yes)	1 (0.55)	0 (0)	1(0.27)
Water pipe (Yes)	3 (1.7)	2 (1.0)	5 (1.3)
Other	10 (5.5)	4 (2.1)	14 (3.8)
Heaviness of smoking index >= 4	134(74.03)	158(82.72)	292(78.49
Smoking inside your home restrictions			
Total: Not allowed	96 (53.0)	108 (56.5)	204 (54.8)
Some rules: where/when it is allowed	61 (33.7)	58 (30.4)	119 (32.0)
No rules	24 (13.3)	25 (13.1)	49 (13.2)

7 8 9 10 11 12 13 14 5 16 17 18 9 21 22 32 4 25 27 28 9 30 132 33 4 5 36 37 8 9 0 41 42 43 44 5 6 7 8 9 0 122 34 25 6 7 8 9 30 132 34 5 6 7 8 9 0 41 42 43 44 5 6 7 8 9 0 122 34 25 6 7 8 9 30 132 34 5 6 7 8 9 0 14 5 7 8 9 0 122 34 25 6 7 8 9 30 132 34 5 6 7 8 9 0 41 42 43 44 5 6 7 8 9 0 122 34 25 6 7 8 9 30 132 33 45 36 7 8 9 0 41 42 43 44 5 6 7 8 9 0 122 34 5 5 5 7 8 9 0 122 33 4 5 5 6 7 8 9 0 41 42 43 44 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
49 50 51 52 53 54 55 56 57 58 59
53 54 55 56 57 58 59
57 58 59

Attempts to quit smoking (current smokers only)			
Ever attempted to quit in the past (Yes)	52 (28.7)	64 (33.5)	116 (31.2)
Number of attempts to quit: mean (SD)	2.46 (2.98)	2.64 (1.62)	2.56 (2.32)
Time elapsed since attempt to quit last time, in months: mean (SD)	36.65 (94.62)	25.13 (37.91)	30.29 (69.22)
Longest duration abstinent in previous quit attempts: mean (SD)	6.15 (13.48)	4.22 (8.9)	5.09 (11.18)
Likelihood to TRY TO QUIT smoking completely and permanently in the next three months			
Definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
Probably will not	10 (5.5)	12 (6.3)	22 (5.9)
Probably will	104 (57.5)	109 (57.1)	213 (57.3)
Definitely will	61 (33.7)	65 (34.0)	126 (33.9)
Likelihood that I WILL QUIT smoking completely and permanently in the next three months			
Definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
Probably will not	11 (6.1)	13 (6.8)	24 (6.5)
Probably will	103 (56.9)	104 (54.5)	207 (55.6)
Definitely will	61 (33.7)	69 (36.1)	130 (34.9)
Ever used any methods to help you stop smoking tobacco in the past 3-months? (Yes)	23 (12.7)	16 (8.4)	39 (10.5)
Smokeless tobacco use (all participants)			
In the past month, have you used smokeless tobacco (Snuff) on a daily basis	D.		
Not at all	275 (94.5)	275 (97.2)	550 (95.8)
Daily	12 (4.1)	6 (2.1)	18 (3.1)
Less than Daily	4 (1.4)	2 (0.7)	6 (1.0)
Duration of using ST in months: mean(SD)	113.69 (112.7)	152 (91.16)	126.46 (105.61)
Age started using ST in years: mean (SD)	27.56 (10.57)	25.88 (13.43)	27 (11.33)
Form of ST used (for SLT users)		()	(<i>i</i>)
Snuff (by mouth)	2 (12.5)	0 (0.0)	2 (8.3)
Snuff (by nose)	11 (68.8)	5 (62.5)	16 (66.7)
Chewing tobacco leaves	0(0)	0(0)	0(0)
Other	1 (6.3)	0 (0.0)	1 (4.2)
Help to stop drinking (N= , had a drink in past 12 months)	208	223	431
Ever used any methods to stop drinking alcohol in the past 3-months	21 (11.2)	22 (10.7)	43 (10.9)

* Frequencies and (percentages) are presented unless otherwise stated

Supplementary table 3 Detailed descr months	iptive statistics fo	r primary outcome	by study arm at 6-
TB treatment status detailed	Control	Intervention	Total
	n (%)	n (%)	n (%)
Cured	108 (37.1)	105 (37.1)	213 (37.1)
Treatment completed	96 (33.0)	87 (30.7)	183 (31.9)
Treatment interrupted > 2 months	15 (5.2)	29 (10.2)	44 (7.7)
Treatment failure	5 (1.7)	2 (0.7)	7 (1.2)
Acquired drug resistance	1 (0.3)	4 (1.4)	5 (0.87)
Died	11 (3.8)	15 (5.3)	26 (4.5)
Transfer out	8 (2.75)	11 (3.9)	19 (3.31)
Unknown	42 (14.4)	25 (8.8)	67 (11.7)

n 42 (14.4) 25 (8.8)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
55 54
55
56
57
58
59
60

60

Ratings		Mean (SD)	Range
Global ratings**			
	Cultivating change talk	3.2 (1.17)	1-5
	Softening sustain talk	3.4 (0.96)	1-4
	Partnership	3.4 (1.12)	2-5
	Empathy	2.9 (1.34)	1-5
Behaviour counts ^{&}			
	Giving information	4.8 (8.13)	0-5
	Persuade	0.8 (1.48)	0-5
	Persuade with permission	0.1 (0.24)	0-1
	Question	24.2 (10.42)	12-51
	Simple reflection	4.1 (3.21)	0-10
	Complex reflection	1.6 (2.69)	0-9
	Affirm	5.5 (3.47)	1-12
	Seeking collaboration	2.4 (1.46)	0-6
	Emphasising autonomy	1.4 (1.37)	0-4
	Confront	0.4 (0.74)	0-3
Summary measures			
	Total MI non-adherent †	1.2 (2.28)	0-7
	Total MI adherent [†]	9.3 (4.74)	1-16
	Technical global ratings**	3.3 (0.97)	1.5-4.5
	Relational global ratings**	3.1 (1.19)	1.5-5
R	eflection to question ratio++	0.23 (0.24)	0-0.83
Percentag	ge of complex reflections***	20.4 (21.9)	0-67

*The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In order to assess the fidelity of the counsellors' delivery of motivational interviewing during the trial, we are used the validated Motivational Interviewing Treatment Integrity Coding Manual 4.2.1 (MITI) tool. The table shows the results of the fidelity assessment that was conducted by one rater who is proficient in English, seSotho and seTswana and in motivational interviewing. The rater listened to the recordings and coded a randomly selected 20-min portion of the written transcript. In the case of shorter counselling sessions, the entire recording was assessed.

**The "global ratings" involve assessing, on a 5-point Likert scale (1 for low and 5 for high), how well or poorly the counsellor adheres to the MI practice. Ratings are conducted on four items, two each making up Technical Components (Cultivating change talk and Softening sustain talk) and Relational Components (Partnership and Empathy).

**Scores on Cultivating Change Talk and Softening Sustain Talk are averaged to obtain the Technical global scores.

***Scores on Partnership and Empathy are averaged to obtain Relational global scores. The basic competency threshold scores for fair and good proficiency are 3 and 4, respectively for Technical scores and 3.5 and 4, respectively for Relational scores.

[&]The "behaviour counts" involve counting 10 verbal behaviours of the counsellor during the intervention.

* "MI adherence" is determined by adding up the following verbal behaviours: Seeking Collaboration, Affirm and Emphasising autonomy. "MI non-adherence" is determined by summing instances of Confront and Persuade. No thresholds for MI adherence or non-adherence are specified in the MITI 4.2.1.

⁺⁺The Reflection-to-Question (R:Q) ratio is the total reflections divided by the total questions asked. One reflection to each question is considered a "fair" practice level while two reflections to each question is considered a "good" practice level.

*** The Percentage of Complex Reflections (% CRs) is calculated by dividing the number of complex reflections by the sum of complex reflections and simple reflections. A fair and a good % CRs are 40% and 50%, respectively.

			Interven	tion (N=283)	Control (N=291)
No. of participants who received ALL due IMB messages INDEPENDENT OF WHETHER they completed MI 1				35%)	1/291 (0.3%)
Completion of first MI and initiation of SMS-sequence					
Completed first MI			227/283	(80.2%)	0/291 (0%)
No. of participants who received ALL due messages after receipt of I	MI1		95/227 (41.9%)	0/0 (0%)
SMS delivery for participants for whom the SMS-sequence was initiated (after receipt of first MI)					
	Mean (SD)	Median Range	(IQR)	Mean (SD)	Median (IQR) Range
Average no. adherence messages received per participant (n=227)	7.9 (3.5)	10 (8-10) 0-11		0	0
Average no. tobacco-related messages received (n=153)	5.4 (2.5)	7 (5-7) 0-7		0	0
Average no. alcohol related messages received (n=171)	5.5 (2.5)	7 (5-7) 0-7		0	0
Average no. IMB messages received (n= 227)	15.7 (7.3)	17 (13-22 0-25	2)		

BMJ Open

Item	Unit costs
Personnel	LHWs: R3000/month, 160 hours/month, R18.75/hour; District coordinators: R7500/month, 160 hours/month, R46.88/hour MRC appointed supervisor: R205.79/hour; Trainers: R373.17/hour; Administrative staff: R333.24/hour
Materials	Training manual: R3250; Printing: R3000; Additional printing & stationary: R500
Accommodation / Travel / Refreshments	LHWs accommodation: R540 000; Trainers accommodation/travel: R36 000; Supervision accommodation/travel: R30 000 Refreshment: R12 500
SMS system	Monthly subscription at R433.44 (\$30) for 3-months: R1300
MI sessions	Session 1 (17 minutes): R5.31; Session 2 (16 minutes): R5.00; Session 3 (17 minutes): R5.31
Biochemical investigations	Cost of TB smear microscopy: R28.37; culture: R79.22 and GeneXpert: R201.56 (Source: 2019/20 National Health Laborator Service pricing schedule)*
ART	Atroiza: R3.78/dose; Dumiva: R5.55/dose; Tenemine: R2.34/dose; Zovilam: R1.72/dose; Kavimun: R1.89/dose; Ricovir R1.36/dose; Zidomat: R1.38/dose; Lazena: R0.55/dose; Efrin:R0.63/dose; Efamat: R0.63/dose; Acriptaz: R0.61/dose (Source Western Cape Department of Health. Antiretroviral and TB Stockmaster Worksheet. 2019)
TB medication	Month's supply of RHZE (intensive) @ R65.80; RH (continuation) @ R55.56 (Source: Western Cape Department of Health Antiretroviral and TB Stockmaster Worksheet. 2019)
	Antiretroviral and TB Stockmaster Worksheet. 2019)
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Jan 2020

PROLIFE

Im*proving* TB outcomes by modifying *life*-style behaviours through a brief motivational intervention followed by short text messages (Phase II)

A multi-centre randomised controlled trial looking at the effect of a complex behavioural intervention on TB and lifestyle-related outcomes in South Africa

Version 1.2

Trial Registration number/registry: ISRCTN62728852/ISRCTN registry http://www.isrctn.com/ISRCTN62728852



Department of Health Sciences University of York York, YO10 5DD Version date: 14 Feb 2020 25 Oct 2020 Author(s): Mona Kanaan

Principal Investigator: Olalekan Ayo-Yusuf and Kamran Siddiqi **Trial Coordinator**: Goedele M Louwagie

Sponsor	Olalekan Ayo-Yusuf, Sefako Makgatho
	University/University of Pretoria
Funder	Newton Fund/MRC
Funder Reference Number	MRC-RFA-02: TB -05-2015

STATISTICAL ANALYSIS PLAN V1.2

Contents

1.	Definition of terms	. 4
2.	Trial Objectives	. 5
3.	Design	. 6
4.	Sample Size	. 7
5.	Randomisation	. 7
6.	Outcomes	. 8
е	5.1 Primary outcome	. 8
е	5.2 Secondary outcomes	. 9
	6.2.1 Monitoring adverse events	. 9
е	5.3 Trial assessment schedule	11
е	5.4 Other important information	12
e	5.5 Fidelity of the intervention	12
7.	Data	13
7	7.1 Data collection methods	13
7	7.2 Data management	16
8.	Analysis	17
8	3.1 Participants Flow	18
8	3.2 Baseline data	19
8	3.3 Primary analysis	
	8.3.1 Primary outcome definition:	24
	8.3.2 Primary outcome Analysis	<u>2</u> 4
	8.3.3 Primary outcome Analysis Results	25
8	3.4 Secondary analyses	26
	8.4.1 Secondary outcome definitions that involve defining a positive baseline test:	27
	8.4.2 Continuous Abstinence	<u>29</u>
	8.4.4 Change in harmful or hazardous drinking at month 3 and 6 follow-ups	32
	8.4.5 Proportion of ART uptake of HIV-positive participants at month 3 and 6 follow-ups .	34
ξ	3.5 Subgroup analyses (See above analyses)	35
ε	3.5 Sensitivity analyses	35
ξ	3.6 Adverse events	36
٤	3.7 Planned interim review and analyses	36

Page 2 of 67

Jan 2020

8	.8 List of Tables and Graphs	. 37
9.	SAP amendment log	. 38
10.	Signatures of approval	. 38
11.	References	. 39
12.	Appendix A (Results tables)	. 40
T	able 1:	. 40
13.	Appendix B (Scoring notes +)	ed.
13.	Additional descriptive Statistics	. 65

This analysis plan deals only with the statistical analysis of the trial.

Page 3 of 67 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1. Definition of terms

Abbreviation	Expansion
ACTG	AIDS Clinical Trials Group
AE	Adverse Event
ART	Anti-retroviral therapy
AUDIT	Alcohol Use Disorders Identification Test
CI	Confidence Interval
СО	Carbon monoxide
CONSORT	Consolidated Standards of Reporting Trials
CRF	Case Report Form
EPTB	Extra-pulmonary TB
HIV	Human immunodeficiency virus
LHW	Lay health worker
MI	Motivational interviewing
РТВ	Pulmonary TB
SMS	Short Message Service
SA	South Africa
SADHS	South Africa Demographic and Health Survey
SAE	Serious Adverse Event
SD	Standard deviation
SOPs	Standard Operating Procedures
TB	Tuberculosis
	2

2	
3	
С	
4	
_	
-5	
6	
6	
7	
'	
8	
9	
9	
1	0
- 1	0
1	1
1	2
1	3
1	
1	5
1	6
	0
1	7
1	6 7 8
1	9
1	9
2	0
2	1
2	2
2	
2	3
2	4
2	4
2	5
-	
2	6 7
2	-
2	/
2	8
2	9
- 3	0
3	1
3	h
3	3
3	3
3 3	3 4
3 3	3
3 3 3	3 4 5
3 3 3	3 4 5
3 3 3	3 4 5
3 3 3 3 3	3 4 5 6 7
3 3 3 3 3	3 4 5 6 7
3 3 3 3 3 3	3 4 5 6 7 8
3 3 3 3 3 3	3 4 5 6 7
3 3 3 3 3 3 3	3 4 5 6 7 8 9
3 3 3 3 3 3 4	3 4 5 6 7 8 9 0
3 3 3 3 3 3 4	3 4 5 6 7 8 9 0
3 3 3 3 3 3 4 4	3 4 5 6 7 8 9 0
3 3 3 3 3 3 4	3 4 5 6 7 8 9 0
3 3 3 3 3 3 4 4 4	3 4 5 6 7 8 9 0 1 2
3 3 3 3 3 3 4 4	3 4 5 6 7 8 9 0 1 2
3 3 3 3 3 4 4 4 4	3 4 5 6 7 8 9 0 1 2 3
3 3 3 3 3 4 4 4 4 4 4	3 4 5 6 7 8 9 0 1 2 3 4
3 3 3 3 3 4 4 4 4 4 4	3 4 5 6 7 8 9 0 1 2 3 4
3 3 3 3 3 4 4 4 4 4 4 4	3456789012345
3 3 3 3 3 4 4 4 4 4 4	3456789012345
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4	34567890123456
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4	345678901234567
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4	345678901234567
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4	3456789012345678
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4	345678901234567
3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	34567890123456789
3 3 3 3 3 4 4 4 4 4 4 4 4 4 5	345678901234567890
3 3 3 3 3 4 4 4 4 4 4 4 4 4 5	345678901234567890
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5	3456789012345678901
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5	3456789012345678901
3 3 3 3 3 4 4 4 4 4 4 4 4 5 5 5	34567890123456789012
3 3 3 3 3 4 4 4 4 4 4 4 4 5 5 5	34567890123456789012
3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5	345678901234567890123
3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5	34567890123456789012
3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	3456789012345678901234
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	34567890123456789012345
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	34567890123456789012345
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	345678901234567890123456
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	345678901234567890123456
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	3456789012345678901234567
3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5	34567890123456789012345678

Jan 2020

2. Trial Objectives

The PROLIFE model is a complex behavioural intervention comprised of a brief motivational interviewing (MI) counselling strategy augmented with subsequent SMS messaging. To be delivered in three brief sessions, the MI intervention will target three main areas, as appropriate:

- Tobacco smoking
- Alcohol drinking
- Tuberculosis (TB) and Anti-retroviral therapy (ART) adherence or ART initiation

Primary objective:

• To assess the <u>effectiveness</u> of the PROLIFE model delivered by lay health workers (LWH) compared to usual care in improving Pulmonary TB (PTB) treatment outcomes

Secondary objective: (this element will not be addressed in this SAP)

• To estimate the <u>cost-effectiveness</u> of the PROLIFE model



PROLIFE Trial

3. Design

This is a pragmatic, prospective, multicentre, two-arm, parallel, individual RCT taking place in 27 purposively selected primary care clinics with the highest TB case-load in three districts in South Africa: Welkom in the Free State; Bojanala in the North West province; and Sedibeng in Gauteng province. The intervention will be delivered by LHWs and three district coordinators who will each cover 1–2 clinics.

This is a pragmatic parallel superiority individually randomised controlled trial. There are two treatment arms:

<u>The control arm (Arm1)</u>: Intervention arm – participants will receive the PROLIFE

programme;

The intervention arm (Arm2): Control arm – participants will receive usual treatment and

support provided to TB patients in TB treatment clinics in South Africa ('usual care').

Full details of the background and design of the trial are presented in the protocol (version 1.2 Prolife Protocol_15 Dec 17_with markup) and the published protocol in Moriarty et al (2019) <u>https://doi.org/10.1186/s13063-019-3551-9</u>.

Participants

The inclusion criteria for participants are:

- adult patients (aged ≥ 18 years)
 - with drug-sensitive (bacteriologically or clinically confirmed) PTB;
- initiating TB treatment or on TB treatment for < 1 month (these include both 'new' and 'retreatment' patients);
- current smokers and/or
- hazardous/harmful drinkers who are not alcohol dependent (Alcohol Use Disorders Identification Test [AUDIT] score ≥ 8 for men or ≥ 7 for women but < 20);
- access to a functional mobile phone; and
- understand one of the four languages used for the trial (Sesotho, Setswana, Isizulu or English).

Exclusion criteria:

- alcohol-dependent participants (AUDIT score ≥ 20);
- Extrapulmonary TB without PTB; or
- Resistance to one or more TB drugs at baseline

PROLIFE Trial

Jan 2020

4. Sample Size

We will recruit 696 participants (348 per study arm). The sample size calculations were based on the following assumptions:

- Detection a 10% difference in TB treatment success rates (0.86 vs 0.76) in the ProLife group versus the control group
- 80% power,
- a significance level of 0.05, and
- 25% attrition.

The sample size per clinic was in the range of 14–74 participants per clinic with a median of 24. The assumed success rates in the control group are based on actual success rates in TB patients in the studied provinces that were available at the time of sample size calculations in 2015.

5. Randomisation

Patients will be randomised using a randomised sequence generator performed by the trial statistician (MK) who will remain blind to the arm allocation. We will use block randomisation with varying block sizes stratified by the clinic to achieve equal numbers in intervention and control groups within each clinic. Allocation concealment will be done with consecutively numbered, sealed, opaque envelopes.

Lay health workers delivering the intervention, field researchers, and participants cannot be blinded to the intervention. However, the determination of the primary outcome will be completed by TB nurses who are blinded to the intervention status of the participants based on routinely collected data.

The statistician will be blinded to the intervention or control arm allocation of participants during the analysis stage.

Page **7** of **67**

PROLIFE Trial

6. Outcomes

6.1 Primary outcome

The primary outcome is TB treatment success at six to nine months of follow-up. This is a binary variable defined as

- Success: cured or treatment completed
- Failure: failed treatment, death, acquired drug resistance, loss to follow-up or 'default', or not outcome evaluated.

The different mutually exclusive treatment outcomes are summarised here

Treatment outcome	Definition
Cure	Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last month of treatment and on at least one previous occasion at least 30 days prior According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is considered 'Cured'.
Treatment completed	Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological findings who have shown clinical improvement and completed the prescribed course of treatment. <i>N.B. The smear examination may not have been done or the results may not be available at the end of treatment.</i>
Treatment failure	Patient whose baseline smear or culture was positive and remains or becomes positive again at 5 months or later during treatment. Patients who were negative at baseline but were later found to be positive. <i>N.B. This definition excludes those patients who are diagnosed with RR-TB or</i> <i>MDR-TB during treatment.</i>
Died	Patient who dies for any reason during the course of TB treatment.
Treatment default	Patient whose treatment was interrupted for two consecutive months or more during the treatment period.
Transfer out	Patient who was referred to a facility in another district to continue treatment and for whom the treatment outcome is not known.
Acquired resistance	Participants who are subsequently referred for MDR treatment.

PROLIFE Trial

Jan 2020

6.2 Secondary outcomes

The following outcome measures will be recorded at the six-month follow-up:

- sputum conversion at the end of treatment in the group of participants who had bacteriology confirmed PTB at baseline¹
- continuous smoking abstinence for identified smokers at baseline²

Whereas, the following will be assessed at three and six months follow-up:

- reduction in harmful or hazardous drinking³
- TB and ART medication adherence will be measured using a modified version of the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire⁴; using an adherence index calculated by the formula (using the four-day recall table):

[Total number of doses taken/Total number of doses prescribed] x 100

Patients with at least 95% of adherence will be considered as having optimal adherence otherwise will be considered as having low (or suboptimal) adherence.

• increase in proportion of HIV-positive participants on ART at three and six months from baseline using standardised questions on the CRF.

6.2.1 Monitoring adverse events

Adverse events (AE) and serious adverse events (SAE) will be defined *apriori* and relevant information will be collected.

A **Serious Adverse Event (SAE)** is actually a special case of an adverse event where adverse outcomes are severe. It includes following events: Death of any of the participants associated with a clinical trial. **Examples of events**: Death, a lifethreatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant.

An **adverse event (AE)** is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

The events are reported to ethics committee within 72 hours

¹ i.e. cure rates in intervention group versus control group for participants who initially had sputum AFBpositive, culture-positive or GeneXpert-positive PTB

² defined as a self-report of not smoking > 5 cigarettes six months from the start of the abstinence period, supported by a negative biochemical test CO < 7 ppm

³ alcohol use will be measured using the AUDIT questionnaire. The questionnaire will be administered at screening (which will take place on the same day or shortly after the baseline assessment) and again at three months and six months.

⁴ The questionnaire is a validated tool for measuring adherence specifically to ART and we will use an adapted version to also measure TB medication adherence [<u>40</u>].

PROLIFE Trial

The following information were collected to report the events:

Participants identification number, Gender, Age, Date of Enrollment, Arm (Control or intervention), Date of death notification to staff, Date of death , If death is related or not related to study.

For occur teries only

Page **10** of **67**

Г

6.3 Trial assessment schedule

Table 2 details the trial assessment schedule

Table 2: Trial assessment schedule							
Assessment	Items	Pre randomisation	Timeline (post randomisation)				on)
Assessment		Eligibility (Day 0)	Baseline (Day 0)	2 months	3 months	6-9 months	Trial end
ELIGIBILITY							
Smoking status		Х					
Smoking profile			Х				
Alcohol profile	0	Х					
Medical eligibility	0	Х					
Eligible, consenting	C	Х					
MEASURES		-					
Trial ID, visit date		O,	Х				
Socio-demographic history		5.	Х				
Depression screen		0	Х		Х	Х	
Clinical review of TB Treatment record for disease information		-	X				Х
Smoking history			X				
Smoking abstinence (self-report)					X	Х	
Exhaled CO					Х	Х	
Record sputum culture or smear or Gene Expert result			Х	Х	Х	Х	
HIV Status			Х				
ART Status (if HIV positive)			Х		X	Х	
AUDIT		Х			Х	Х	
Modified ACTG (Follow up)					Х	Х	
Economic evaluation			Х		Х	Х	

Page **11** of **67**

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

6.4 Other important information

In addition to the above, the following information was collected at baseline. Socio-demographic history included age, gender, marital status, education, employment status, and comorbidities. For details about these variables, see Table 3.

6.5 Fidelity of the intervention

The main fidelity analysis will be published somewhere else. Some descriptive statistics regarding fidelity will be added here once the main analysis is completed and the statistician is unblinded to the treatment arm.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 12 of 67

```
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
```

PROLIFE Trial

Jan 2020

7. Data

7.1 Data collection methods

The fieldworkers will screen all TB patients for eligibility immediately after the TB nurse at the clinic has initiated TB treatment and opened the TB "blue card". Consent will be obtained for this screening phase as the alcohol related questions are sensitive and the fieldworkers must gain insight in the patient files.

Eligible and consenting patients will be enrolled in the trial and the baseline questionnaire and record review completed. Patients will be given a unique Trial Number that will be used on all research documents. Data will be collected and recorded by field workers equipped with Android phones with a mobile data collection application installed.

Participants in the control arm will continue with the routine TB care. Intervention arm study participants will be referred by the fieldworker to the lay counsellor for motivational interviewing. The first MI session will be on the same day of the completion of the screening questionnaire, where possible (with a 2-week window period). The second and third MI session will be scheduled 4 weeks and 8 weeks from the first counselling session respectively each time with a 2-week window period.

MI counselling and data collection will take place in a well-ventilated private area inside or outside the clinic, and audio-recorded after consent obtained. Fieldworkers and LHWs will be provided with high particulate respirator masks to minimise the risk of infection.

Fieldworkers will follow-up all participants in both arms at 3 and 6 months within a window period of 2-weeks before and 2-weeks after the ideal 3 and 6-month visit. Participants will receive SMS reminders 3 days before each planned visit. Participants will also be in a position to send "please call me "messages to the fieldworkers or district coordinators, who will then call the participant to solve problems that may have arisen with the appointment.

Patients who did not return for the planned 3 and 6 months visit will be contacted by telephone up to 3-times, as needed. Home visits will also be undertaken by existing clinic "tracer teams" or Community Based Outreach teams -where feasible - for participants who cannot be traced by telephone. The data collection process is illustrated in Table 3.

PROLIFE Trial

Time-point	a Collection Process by time-point and details of dat Information required at time-point	Data collection method
Baseline	1. <u>Socioeconomic and demographic status (to</u>	
interview	include history of mine work)	
	• Age	TB Treatment
	• Gender	Record
	Marital status	Recolu
	• Educational level achieved	CDE Oraștiana
	• Employment	CRF – Questions
	• Mine work/type of mine work	to participant –
		demographic
	2. Clinical information:	details
	• Patient category (First episode vs recurrence)	
	• Site of disease	
	• Results of sputum smear, culture and Gene	
	Xpert	CRF – Questions
	• HIV status	to participant and
	ART information	information from
	Co-morbidities	the TB Treatment
		Record (as
	3. Current smoking status and quit history,	indicated in CRF
	second hand smoke exposure	
	second hand smoke exposure	
	\sim	
	4. Alcohol history	
	5. Depression	
	5. Depression	Overtiens edente.
	4	Questions adapted
		from Global Adu
		Tobacco Survey
	O.	Questionnaire
		Baseline AUDIT
		score
		CES-D
3 months	1. ART information	CRF – Question t
		patient
	2. TB and ART medication adherence	1
	(modified ACTCG)	ACTG
		questionnaire for
	3. Alcohol history (repeat AUDIT)	both TB
	5. Alconor history (repeat AUDIT)	
	4 Curaling history	medication and
	4. Smoking history	ART
	5. SLT use	
		AUDIT score at 3
		month

BMJ Open

Statistical Analysis Plan

Jan 2020

	6. Depression	Follow-up questions as per Russell's Standard and exhaled CO
6 months	1. TB treatment status (Primary outcome)	CES-D TB treatment outcome from TB
	 Sputum smear or culture result ART information TB and ART medication adherence 	Treatment Record combined with information from TB record on cultures and smea results.
	5. Alcohol history (repeat AUDIT)	CRF- Question to patient
	6. Smoking history and exhaled CO7. Depression	Follow-up ACTG questionnaire at 6 months AUDIT at 6
		Mobilitation months Questions as per Russell's Standar and exhaled CO
		CES-D

Page **15** of **67**

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

7.2 Data management

Sefako Makgatho University (SMU) appointed a data manager who will utilise an electronic platform for data collection, ensuring data quality, and facilitating the SMS messages.

Fieldworkers collecting research data will be equipped with Android mobile phones, which will have a mobile application installed on them to allow for data collection in areas with poor internet connectivity. The electronic data captured will be stored on secure and password protected storage servers and mobile phones, which ensure data privacy through only allowing authorised research staff access to the data.

The electronic data collection system used for the study requires an SMS gateway to send and receive messages to the research participants. Consenting participants' phone numbers, participant IDs, and associated SMS messages will be stored on the SMS gateway's secured and password-protected server.

Data quality will be ensured by providing fieldworkers with standard operating procedures (SOPs), training, and ongoing support on the importance of data quality, data collection, and data collection problem-solving. The data manager will continuously monitor the captured data for missing variables and inconsistencies in order to resolve any data problems.

The data manager will export the data from the secured server, conceal the participants study arm allocation, and de-identify the data before sharing the data in STATA and R compatible formats. The exported de-identified data will be stored in Dropbox, a secure cloud storage platform, for sharing with the lead trial statistician at the University of York for analysis.

All research data and documents referring to the PROLIFE trial will be stored and maintained in a secured storage space at SMU for a minimum of 15 years from the end of the PROLIFE trial. Study materials will be destroyed 15 years after the study.

PROLIFE Trial

Jan 2020

8. Analysis

The computer packages STATA 16 (StataCorp. 2019) and R 3.5.3 (ref) will be used. Significance tests will be two-sided and the significance level is set at 0.05. The statistician will remain blind to allocation until results are finalised. We will follow the CONSORT statement guidelines in reporting.

Below, we detail the analyses that we will carry out for the data collected at baseline, the primary outcome, the secondary outcomes, and adverse events. We also list the sensitivity analyses that we might perform and subgroup analyses.

ve might perior mane v


4 5

6

7 8 9 **PROLIFE Trial**

8.1 Participants Flow

Statistical Analysis Plan



Page 18 of 67

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Figure 1 CONSORT DIAGRAM SHOWING FLOW OF PARTICIPANTS

PROLIFE Trial

Jan 2020

8.2 Baseline data

Baseline data Analysis Plan:

Baseline data including demographic variables will be summarised descriptively by trial arm, but no formal statistical comparisons will be undertaken. Continuous measures will be reported as means and standard deviations (SD) while categorical data will be reported as counts and percentages, see Tables 1 to 4 in Appendix A. For skewed continuous measures, we will also provide medians and interquartile ranges.

Baseline data results:

Consent:

In the control arm (Arm1) 286 gave written consent and 5 verbal consent for participation in the study and for access to their medical records In the intervention arm (Arm2) 279 gave written consent and 4 verbal consent for participation in the study and for access to their medical records

Baseline Imbalances

Education:

It seems that for education there is imbalance between the two arms for Grades 8-11/Grade 12/Higher; the control arm (Arm1) had a higher educated group the difference in percentage points 8.2% as opposed to 2.8% in the intervention arm, see Table 2 for further details. There are 9 participants who are not literate in the study (7 in the control arm (Arm1) and 5 in the intervention arm (Arm2)).

Drinking

In the intervention arm, 223 (78.8%) had a drink in the past 12-months compared to 208 (71.5%) in the control arm, see Table 3.

In the control arm (Arm1), 110 (37.8%) were drinkers only, 83 (28.5%) were smokers only, and 98 (33.7%) were smokers and drinkers compared to 92 (32.5%), 60 (21.2%), and 131 (46.3%) in the intervention arm (Arm2), respectively.

BMJ Open


Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Assets:

The vast majority had a radio (84%), a television (89%), a refrigerator (85%), an electric or gas stove (86%), and a microwave (67%), however, only 50% had a washing machine. Furthermore, a minority had a landline telephone (7.5%), a desktop or laptop computer (20%:), and a vacuum cleaner or floor polisher (15%). Figure 2 is a boxplot of the total number of assets by study arm. The spread in the control arm (Arm1) is greater than that in the intervention arm (Arm2). However, the mean number of assets is similar across the two groups of 5 (SD: 1.87).



Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Medical History:

There were 305 (53.2%) **HIV positive** participants out of which 204 (65.38%) were using Cotrimoxazole and 257 (82.37%) were undergoing anti-retroviral therapy, see Table 2.

TB History: The vast majority of participants were New TB patients 513(91.3%), with Pulmonary only (ICD-10 A15) being the site of disease for the vast majority 553 (98.9%). Among those with results known, the majority had one pre-treatment smear result 366 (89.9%), one Gene XPert recorded 435 (97.5%), and one culture result recorded 96 (96%).

Among those with results available, 220 (58.51%) had at least **one positive smear** result,362 (87.23%) had at least **one positive Gene XPert result**, and 35 (47.95%) at least **one positive culture result**.

However, 85 (53.46%) in the control arm had at least one positive smear result within 60 days of the TB treatment start date compared to 96 (61.15%) in the intervention arm.

In addition, only 34 had their culture results within 60 days from the TB start dates of which 21 had positive results; 11 in the control arm compared to 10 in the intervention arm.

The vast majority of participants did not have any **co-morbidities** 525 (96.3%) and 18 (3.3%) had one.

Statistical Analysis Plan

PROLIFE Trial

Baseline Smoking Related variables:

Thirty five percent (202) did not smoke in the past month, whereas 52% smoked daily and the remaining 13% smoked in the past month but less frequently than on a daily basis, see Table 3.

In the past 30 days, the vast majority were exposed to smoke for seven days or less at: home 462 (80.5%); cafes/restaurants 464 (80.8%); Shebeens, bars or clubs 432 (75.3%); Bus/train/taxi/ vehicle 448 (78.0%); and Shops/shopping mall 461 (80.3%) and where applicable at the workplace 173 (66.8%).

Among those who smoked in the past month 372: 181 in the control arm (Arm1) vs 191 in the intervention arm (Arm2),

345 (92.7%) **smoked manufactured cigarettes** of which 225(65%) did so on a daily basis in the past seven days whereas 40 (11.6%) did not smoke in the past week. The mean number of days smoked was 5.42 days in the past week (SD: 2.49) with 6.34 cigarettes (SD: 7.39) smoked daily on average.

Hand-Rolled cigarettes were used by 35 participants of which 16 (45.7%) smoked daily in the past week. They smoked on average for 4.11 (SD:2.91) days in the past week and on average smoked 3.77 (SD: 3.27) hand-rolled cigarettes per day.

There was only one person who exclusively smoked waterpipe, two who exclusively smoked pipe, and seven who exclusively used other formats of tobacco other than the ones that are listed here.

For the vast majority the total number of cigarettes smoked is based on their answer to manufactured cigarettes. In 27 cases, they supplemented this with other sources and 8 used only other forms to report the number smoked on average per day.

Over the past 3 months, they **spent** on average 174.58 (SD: 181.61) Rands per week on tobacco products.

PROLIFE Trial

Smoking restrictions

No smoking was allowed **inside home** for 204(54.8%) participants, whereas 119(32.0%) had some rule where/when it is allowed and 49(13.2%) had no rules in place.

Quit Attempts:

Among smokers, 116 (31.2%) made an **attempt to quit**; the mean number of attempts to quit was 2.56 (SD: 2.32).

Furthermore, 213 (57.3%) said they will probably **try to quit** smoking completely and permanently in the next three months and 126 (33.9%) said that they definitely will.

Whereas, 207 (55.6%) said they will probably **quit** smoking completely and permanently in the next three months and 130 (34.9%) said that they definitely will.

Only 39 (10.5%) have ever used any methods in the past 3 months to help them stop smoking tobacco. These spent on average 136.64 (SD: 205.36) Rands on methods to help you stop smoking in the past 3 months.

Smokeless tobacco was used by only 24 participants (4.2%). They have been using ST for an average of 10.5 years (SD: 8.8) and have started using it at the age of 27 (SD: 11.33) years on average.

Heaviness of smoking:

In the control arm (Arm1), 67(37.0%) of smokers reported smoking within 5 minutes of waking up whereas 82(42.9%) did so in the intervention arm (Arm2).

Among those who smoked and who reported the number of cigarettes/pipes/cigars they used on average per day, 134(74.03%) in the control arm (Arm1) and 158(82.72%) in the intervention arm (Arm2) were considered as heavy smokers.

Page 67 of 155

BMJ Open

8.3 Primary analysis

8.3.1 Primary outcome definition:

As per section 6.1, we would define the primary outcome as those who had a successful treatment versus not. Where successful treatment is considered if the patient is considered to have been cured or treatment completed; all other categories will be deemed as not successful. The successful treatment⁵ categories are defined as follows:

Cure	Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last month of treatment and on at least one previous occasion at least 30 days prior According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is considered 'Cured'.
Treatment completed	Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological findings who have shown clinical improvement and completed the prescribed course of treatment. <i>N.B. The smear examination may not have been done or the results</i> <i>may not be available at the end of treatment.</i>

8.3.2 Primary outcome Analysis

For the primary outcome, we will conduct analysis on an intention-to-treat basis. We will use binary logistic regression to compare the main outcome between the

⁵ Following discussion with the team, we will take this at face value as it is not possible to query some of the anomalies found in the recording of dates of tests.

PROLIFE Trial

intervention and the usual care arm. We will also investigate any potential clustering at the centre level and account for it. We will present the results for this analysis in Table 6.

We will also adjust for HIV status, sex, alcohol versus tobacco versus both, and district; if these differ between trial arms at baseline.

8.3.3 Primary outcome Analysis Results

Table 4 gives the descriptive statistics for the initial outcome and the derived dichotomised outcome; these indicate that overall, 69% were classified as successful treatment based on the medical professional assessment (cured/treatment completed). This percentage was similar for the two arms with the control arm (Arm1) having a slightly higher percentage of success of 70.1% compared to 67.8% in the intervention arm (Arm2)⁶. Table 9 gives the distribution per centre by study arm. Generally, these are fairly balanced any imbalance observed is most probably due to the early termination of the study.

For 203 participants, the TB treatment outcome date was not available, with those participants more likely to not have been cured (59% not cured), however, the percentage was similar across the two study arms for those with missing TB treatment outcome date.

The odds of successful treatment is 0.9 (95% CI: (0.64,1.27)) in the intervention arm (Arm2) compared to the control arm (Arm1). This estimate is very similar to the estimate adjusting for district and drinking/smoking status. This is also the case if you further adjust for sex and HIV status at baseline where the OR is 0.86 (95% CI: (0.60,1.24)); see Table 6 for further details.

⁶ Primary outcome Control: 204/291, 95% CI proportion 0.70 (0.64,0.75) Primary outcome Intervention:192/283, 95% CI proportion 0.68 (0.62,0.73)

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

8.4 Secondary analyses

Secondary analyses plan

In the group of participants who had bacteriology confirmed at baseline, we will use logistic regression to compare cured versus not cured, as indicated by the outcome at the end of treatment, between the two study arms. We will also control for baseline characteristics and other covariates such as sex, alcohol use, HIV-status, district, and account for any potential clustering by centre.

We will use a similar approach for the six-months continuous smoking abstinence outcome. This analysis will be performed on the group of participants who were current tobacco smokers at baseline. We will also control for baseline characteristics and other covariates such as age, duration of smoking, alcohol problem (hazardous, harmful, non-drinker/light drinker), heaviness of smoking index⁷, depression, and potentially HIV-status.

For the reduction in harmful or hazardous drinking, we will use linear regression to measure difference in total AUDIT score between control and intervention groups accounting for the baseline AUDIT scores. Separate analyses for the AUDIT at 3 and 6 months will be performed.

The <u>AUDIT is a 10-items questionnaire</u> with a range between 0 and 40 where higher values indicate higher dependency.⁸ It is worth mentioning that a score of 8 or more

⁷ [Goedele's Comment on an earlier Version]Definitely a measure of severity of smoking and duration of smoking. For example Heaviness of Smoking Index which can be derived as follows:

HSI=Heaviness of smoking index \geq 4, calculated based on sum of time to first cigarette (0: 61+min, 1:31-60 min, 2: 6-30 min, 3: \leq 5 min) and number of cigarettes smoked per day (0: 0-10 cigarettes per day [CPD]

Also: age, duration of smoking, alcohol problem (hazardous, harmful, non-drinker/light drinker), maybe HIV-status, (adding this may reduce your sample size too much, because of missing HIV-status, unless you include HIVstatus unknown as a category of HIV-status). Depression

⁸ Scoring the audit

Scores for each question range from 0 to 4, with the first response for each question (eg never) scoring 0, the second (eg less than monthly) scoring 1, the third (eg monthly) scoring 2, the fourth (eg weekly) scoring 3, and the last response (eg. daily or almost daily) scoring 4. For questions 9 and 10, which only have three responses, the scoring is 0, 2 and 4 (from left to right).

A score of 8 or more is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence.

PROLIFE Trial

Jan 2020

is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence. Eligibility criteria for our study is an AUDIT score \geq 8 for men or \geq 7 for women but <20. However, if assumptions of linear regression are not met we will either transform the data or use alternative regression analyses such as ordinal logistic regression.

Adherence to TB and ART medication will be measured using an adherence index based on a modified version of the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire; where patients with at least 95% of adherence will be considered as having optimal adherence otherwise will be considered as having low (or suboptimal) adherence. We will use logistic regression to model patient's characteristics (age, sex, alcohol, smoking status, depression) that might influence adherence at 6-month; we will also compare adherence between study arms. Similar to the previous outcomes, we will account for any potential clustering by centre.

We will also report the proportion of HIV-positive participants on ART at six months and compare these to the baseline using standardised questions on the CRF.

8.4.1 Secondary outcome definitions that involve defining a positive baseline test:

To operationalise the above we need to define how we determine if someone has a positive baseline smear or culture. Each participant might have up to two tests of the following: smear test, GeneExpert test, and culture test.

If a test was administered two times then to be considered negative both tests should be negative, otherwise it is considered positive. If a test was administered only once, then the result of that instance is taken as is.

¹Saunders JB, Aasland OG, Babor TF et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — II. Addiction 1993, 88: 791–803

If for a patient more than one test was administered, then to be considered negative the result should be negative under both tests.

This is illustrated in the following table.

Baseline	P=+, N = -		
		XXXX Test at run 2 (Result 2)	
XXXX Test run 1 (Result 1)		N	Р
	N	NN	NP
	Р	PN	PP
XXXX=Smear or Culture or GeneXpert			
Smear test at baseline	N1	NN	
	P1	NP, PN, PP	
Genexpert	N2	NN	
	P2	NP, PN, PP	
culture	N3	NN	
	P3	NP, PN, PP	
Positive at baseline	PB	P1 or P2 or P3	
Negative at baseline	NB	N1 and N2 and N3	

To define a conversion among those who were positive at baseline, we used the primary outcome response category cured to indicate a negative result at month 6 per the nurse's assessment.

Among the 403 participants who were positive at baseline 168(41.69%) were recorded as cured by 6-month of these 83 (39.9%) in the control arm compared to 85 (43.59%) see Table 4. The odds ratio of conversion is 1.16 (95% CI: (0.83,1.63)) comparing the intervention arm to the control arm. When adjusting for district, sex, and smoking/drinking status and HIV status at baseline, the OR reduces to 1.07 (95% CI: (0.76,1.51))

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

8.4.2 6-months Continuous Abstinence

For this outcome, those who smoked cigarettes at baseline were considered as the analytic sample. In addition, those where the following could not be ascertained: self-report of not smoking > 5 cigarettes six months from the start of the abstinence period and supported by a negative biochemical test CO < 7 ppm were considered as smokers for the analysis of this variable. The number of participants who identified as cigarette smokers at baseline were 345 (60.1%)⁹.

23 (85.19%) out of 27 with three measurements available¹⁰ managed to abstain continuously for six months. These were similarly distributed across the two study arms, see Table 4. Among those who identified as cigarette smokers, 10 (5.59%) participants in the intervention arm continuously abstained. In the control arm there were 12 (7.23%) who continuously abstained for 6-months.

The crude odds of 6-months continuous abstinence is 0.76 (95% CI: (0.35,1.63)) in the intervention arm compared to the control arm among baseline cigarette smokers. Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm did not differ much from the crude estimate of 0.76. The adjusted estimate for the various models ranged between 0.73 and 0.76 with similar confidence limits as for the crude estimate. Furthermore, we did not have evidence that any of the adjusting variables were statistically significantly correlated to continuous abstinence in these models.

We carried an additional analysis where those who died and were smokers at baseline, 22 in total, 20 were cigarette smokers and were removed from the analytical sample for the continuous abstinence outcome. This resulted in a crude

⁹ Any type of tobacco smoking at baseline 372 (64.8%). The numbers reflect those who used manufactured cigarettes which were the vast majority.

¹⁰ We had only 27 participants who had self-report of not smoking at 3 months, 6 months and a carbon monoxide reading at 6 months. Continuous abstinence was defined as a self-report of not smoking > 5 cigarettes six months from the start of the abstinence period and supported by a negative biochemical test CO < 7 ppm</p>

BMJ Open

PROLIFE Trial

OR of 0.78 which is similar to the OR when the larger analytic sample was considered; this was also the case for the associated 95% CI. Similar estimates were observed when adjusting for the aforementioned variables.

We carried an additional analysis where the analytic sample was all those who were smokers regardless of the type used. There were a total of 372 that identified as smokers. The crude odds ratio in this case changes to 0.86 (95% CI: (0.38,1.95)). The 95% CI is similar to that of the smaller analytic sample. When adjusting for the heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm did not differ much from the crude estimate.

3-months Continuous Abstinence

Among those who identified as cigarette smokers, 20 (11.17%) participants in the intervention arm continuously abstained for 3-months while in the control arm there were 27 (16.27%) who continuously abstained for 3-months.

The crude odds of 3-months continuous abstinence is 0.65 (95% CI: (0.37,1.14)) in the intervention arm compared to the control arm among baseline cigarette smokers. Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm did not differ much from the crude estimate of 0.65. The adjusted estimate for the various models ranged between 0.63 and 0.66 with similar confidence limits as for the crude estimate.

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Point Abstinence

There were 57 participants who indicated that they stopped smoking tobacco completely at the 3-month follow-up, of which one had more than 5 cigarettes in the past 3 months. There were 81 participants who indicated that they stopped smoking tobacco completely at the 6-month follow-up, of which three had more than 5 cigarettes in the past 3 months. Only 30 participants had information for the entirety of the 6-month period, of which none consumed more than 5 cigarettes over the past 6-month period. Of these, 23 had a confirmed CO < 7 ppm, 4 had these levels >= 7, and 3 were missing.

182 responded that they continued smoking either as usual or at a reduced rate but regularly at month 3; whereas 133 done so at month 6 of these we had 97 that had measurements at both time points thus resulting in a total of 218 where they have smoked on a regular basis over the past 6 month period. 11 had responded as not smoking in the past three months at month 6 but had missing information for the first three months; 9 of these had carbon monoxide readings available at month 6. Of these nine, two had their CO >= 7 (in fact these were 10 & 10.1).

Page **31** of **67**

Page 75 of 155

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

8.4.4 Change in harmful or hazardous drinking at month 3 and 6 follow-ups

Alcohol use was measured using the AUDIT questionnaire. We will assess whether there has been a reduction in alcohol consumption three months and six months following recruitment. This analysis will be performed on the group of participants who were harmful or hazardous drinkers at baseline. Figure YYY provides histograms of the AUDIT score at baseline, 3-months and 6-months, respectively, among those who were considered as hazardous or harmful drinkers. It also presents scatterplots of the 3-months and 6-months scores versus the baseline scores for this group by trial arm, respectively.

Among those who were harmful or hazardous drinkers at baseline those in the intervention arm had on average a reduction of 0.04 points (95% CI: (-2,1.91)) on the AUDIT score at 6-months compared to those in the control arm controlling for their baseline score, see Table 6. However, when additionally adjusting for district, sex, and smoking/drinking status (which effectively flags smokers/non-smokers who are also drinkers) and HIV status at baseline; the intervention arm had an average increase of 0.02 points on the AUDIT score (95% CI: (-1.55,1.6)) compared to the control arm. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable. It seems that those in district "S" score on average 5.8 points less than those in "B" (95% CI: (-11.26,-0.35)); similarly those in "L" score 5 points less than those in "B" on AUDIT but we do not have evidence that this difference is statistically significant (95% CI: (-10.35,0.26)), see Table 6 for further details.

At 3-month, the estimates were an average increase of 0.55 (95% CI: (-1.01,2.11)) on the AUDIT score in the intervention arm compared to the control arm when only accounting for the baseline scores; whereas it increased to 0.74 (95% CI: (0.62,2.1)) when adjusting for other covariates in the model, for further details see Table 7.

Statistical Analysis Plan

PROLIFE Trial

Jan 2020




Figure YYY: Graphs (a), (b), and (c) are histograms of the AUDIT score at baseline, 3-months and 6-months, respectively, among those who were considered as hazardous or harmful drinkers. (d) and (e) are scatterplots of the 3-months and 6-months scores versus the baseline scores for this group, respectively.

Statistical Analysis Plan

PROLIFE Trial

8.4.5 Proportion of ART uptake of HIV-positive participants at month 3 and 6 follow-ups

We will assess whether there has been an increase in proportion of HIV-positive participants on ART at three and six months from baseline using standardised questions on the CRF.

There were 171 HIV-positive participants whose baseline ART medication status was known and whose ART medication status was known as well at 6-months. Of these, 123 remained on their medication, 19 took up medication at 6-months compared to not taking medication at baseline, whereas 29 stopped taking their medication at 6-months but were on medication at baseline, see Table 6 for further details.

There were 10 who had an unknown status in terms of medication at baseline and no information was available about them at 6-months, 12 who were initially of unknown medication status who took up medication at 6-months (these were equally distributed between the two arms). Furthermore, there were 10 who were not taking medication at baseline and 102 who were taking medication at baseline whose 6-months medication status was not recorded.

At 6-months, the odds ratio of taking medication at 6-months was 2.05 (95% CI: (0.80,5.27)) in the intervention arm compared to the control arm, controlling for ART baseline medication status.

There were 188 HIV-positive participants whose baseline ART medication status was known and whose ART medication status was known as well at 3-months. Of these, 122 remained on their medication, 16 took up medication at 3-months compared to not taking medication at baseline, whereas 50 stopped taking their medication at 3-months but were on medication at baseline, see Table 7 for further details.

There were 9 who had an unknown status in terms of medication at baseline and no information was available about them at 3-months, 11 who were initially of unknown

PROLIFE Trial

medication status who took up medication at 3-months, and two who were initially of unknown medication status who were not taking medication at 3-months. Furthermore, there were 9 who were not taking medication at baseline and 82 who were taking medication at baseline whose 3-months medication status was not recorded. Furthermore, there were 4 who carried on not taking medication at 3months.

At 3-months, the odds ratio of taking medication at 6-months was 0.79 (95% CI: (0.38,1.65)) in the intervention arm compared to the control arm, controlling for ART baseline medication status.

Medicine Adherence:

At 3-months 165 (98.8%) of 167 participants had optimal ART medication adherence, whereas 139(97.2%) of 143 had optimal ART medication adherence. These were similar across the two arms.

Similarly, at 3-months 319(91.67%) of 348 participants had optimal TB medication adherence, whereas 120(90.23%) of 133 had optimal TB medication adherence. These were similar across the two arms.

8.5 Subgroup analyses (See above analyses)

We will conduct subgroup analyses to determine whether TB treatment outcomes differ between subgroups, as follows: HIV-positive versus HIV-negative participants; participants with an alcohol problem only versus smokers only versus participants who are conjoint smokers and drinkers; and participants who were GeneXpert positive versus participants who were GeneXpert negative at baseline.

8.5 Sensitivity analyses

In case of missing data, multiple imputations and appropriate sensitivity analyses will be conducted. As it is likely that more than one variable will have missing data we will use multiple imputations using chained equations (**MICE**). A minimum of 10 imputations will be performed; however, the final number of imputations will depend on the missing in the data. We will report the decisions that we make with regard to the number of imputations and the

Page 36 of 67

variables we use in the imputations. We will also conduct a sensitivity analysis to explore the implications of the missing at random assumption [21p,22p].

8.6 Adverse events

Analysis of adverse events and serious AE will explore whether these differ by treatment arm using Chi-square tests.

8.7 Planned interim review and analyses

ric ned. The main analyse. No interim analysis is planned. The main analyses will be completed after three months of the data closing.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Statistical Analysis Plan

8.8 List of Tables and Graphs

Measures of central tendency and percentages will be reported to two decimal places whereas measures of variability and p-values will be reported to three decimal places.

The following is a list of suggested tables and graphs; the templates are included in Appendix A.

TABLE 1: Numbers in the study at Baseline and follow-ups at month 3, and 6 by centre and study arm.

TABLE 2: Descriptive statistics for socio-demographic and socio-economic characteristics at baseline and as analysed by study arm. Frequencies and (percentages) are presented unless otherwise stated

TABLE 3: Descriptive statistics for smoking history, alcohol history, clinical characteristics and depression score at baseline and as analysed by study arm. Frequencies and (percentages) are presented unless otherwise stated.

TABLE 4: Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3 month (where available) and 6 month. Frequencies and (percentages) are presented unless otherwise stated.

TABLE 5: Number and type of adverse events at month 2, 3, and 6 by centre and study arm.

TABLE 6: Regression analysis results for the primary and secondary outcomes at 6 month. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.

TABLE 7: Regression analysis results for the secondary outcomes that are measured at 3 month. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.

9. SAP amendment log

Amendment/addition to SAP and reason for change	New version number, name and date
SAP completed and signed-off	V1.0,
Updated verion	V1.1, May 2020

10. Signatures of approval

Sign-off of the final approved version of the Statistical Analysis Plan by the principle investigator and trial statistician(s) (can also include Trial Manager/Co-ordinator)

<u>Name</u>	Trial Role	<u>Signature</u>	Date	

Page 38 of 67 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Page 39 of 67

11. References

Moriarty, A.S., Louwagie, G.M., Mdege, N.D. *et al.* ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial. *Trials* **20**, 457 (2019) doi:10.1186/s13063-019-3551-9

Department of Health, Republic of South Africa. National Tuberculosis Management Guidelines. 2014.

http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-27.5.2014.pdf. Accessed 8 Jan 2018

21p. James R Carpenter and Michael G Kenward. Missing data in clinical trials — a practical guide. Birmingham: National Health Service Co-ordinating Centre for Research Methodology, 2008.

22p. James R Carpenter, Michael G Kenward, and Ian R White. Sensitivity analysis after multiple imputation under missing at random — a weighting approach. Statistical Methods in Medical Research, 16:259–275, 2007.

StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC.

R Core Team (201?). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.

 BMJ Open

Statistical Analysis Plan

PROLIFE Trial

12. Appendix A (Results tables)

Table 1: Numbers in the study at Baseline and follow-ups at month 3 and 6 by centre and study arm. (SEE FLOWCHART)

Centre	Baseline		Month 3	Month 3		Month 6	
	Intervention	Control	Intervention	Control	Intervention	Control	
		0r					
					U h/		
					9		
Total							

BMJ Open

Г

PROLIFE Trial

Jan 2020

TABLE 2: Descriptive statistics for socio-demographic, socio-economic, and clinical characteristics at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated

			Baseline	
	N1/N2	Control	Intervention	Total
O,		Arm 1	Arm 2	
A	201/282	20.27/12.00		
Age in years: mean (SD)	291/283	39.37 (12.60)	38.56 (11.15)	
Age in years: median (IQR)				
Gender				
Female		69 (23.7)	60 (21.2)	129 (22.5)
Male		222 (76.3)	223 (78.8)	445 (77.5)
Do not want to disclose		191		
Marital status				
Married or living together		102 (35.1)	95 (33.6)	197 (34.3)
Divorced/separated		20 (6.9)	18 (6.4)	38 (6.6)
Widowed		10 (3.4)	7 (2.5)	17 (3.0)
Never married and never lived together		144 (49.5)	150 (53.0)	294 (51.2)
Declined to answer		15 (5.2)	13 (4.6)	28 (4.9)
Education				
No education		7 (2.4)	5 (1.8)	12 (2.1)
Grades 1-5		23 (7.9)	20 (7.1)	43 (7.5)
Grades 6-7		32 (11.0)	35 (12.4)	67 (11.7)

Page 85 of 155

 Statistical Analysis Plan

BMJ Open

PROLIFE Trial

Grades 8-11		96 (33.0)	128 (45.2)	224 (39.0)
Grade 12		87 (29.9)	70 (24.7)	157 (27.4)
Higher		24 (8.2)	8 (2.8)	32 (5.6)
Declined to answer		22 (7.6)	17 (6.0)	39 (6.8)
Employment				
Self-employed (full-time)		30 (10.3)	36 (12.7)	66 (11.5)
Employed full-time (30 hrs a week or more)		62 (21.3)	54 (19.1)	116 (20.2)
Employed part-time (less than 30 hrs a week)		19 (6.5)	29 (10.2)	48 (8.4)
Retired	5	17 (5.8)	16 (5.7)	33 (5.7)
Unemployed (but able to work)	20	125 (43.0)	120 (42.4)	245 (42.7)
Unable to work because of long-term disability or ill health	Cr,	9 (3.1)	8 (2.8)	17 (3.0)
Full-time student		12 (4.1)	4 (1.4)	16 (2.8)
Caring from my home and family/doing household work/housewife		0 (0.0)	2 (0.7)	2 (0.3)
Occasional work ("piece job")		17 (5.8)	12 (4.2)	29 (5.1)
Declined to answer		0 (0.0)	2 (0.7)	2 (0.3)
			26,	
Ever worked or spent time in mines				
No		244 (83.8)	237 (83.7)	481 (83.8)
Yes		46 (15.8)	45 (15.9)	91 (15.9)
Socioeconomic status				

Page **42** of **67**

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Household items (Yes is displayed)				
A radio		249 (85.6)	234 (82.7)	483 (84.1)
A television		255 (87.6)	255 (90.1)	510 (88.9)
A landline telephone		21 (7.2)	22 (7.8)	43 (7.5)
A desktop or laptop computer		67 (23.0)	48 (17.0)	115 (20.0)
A refrigerator		248 (85.2)	240 (84.8)	488 (85.0)
A vacuum cleaner or floor pol		49 (16.8)	35 (12.4)	84 (14.6)
A microwave oven		198 (68.0)	189 (66.8)	387 (67.4)
An electric or gas stove		254 (87.3)	238 (84.1)	492 (85.7)
A washing machine		153 (52.6)	136 (48.1)	289 (50.3)
Total number of assets: mean (SD)		5.14 (1.96)	4.94 (1.77)	5.04 (1.87)
In the past month, number of days you or people in the household went to bed hungry because there was no food to eat	D _Q			
0 days		244 (83.8)	238 (84.1)	482 (84.0)
1-7 days		45 (15.5)	34 (12.0)	79 (13.8)
More than 7 days		2 (0.7)	9 (3.2)	11 (1.9)
Declined to answer		0 (0.0)	2 (0.7)	2 (0.3)
		en.		
TB and medical history				
TB history			61	
Patient category				
New patient		264 (92.3)	249 (90.2)	513 (91.3)
Relapse		10 (3.5)	9 (3.3)	19 (3.4)
Re-treatment after default		9 (3.1)	14 (5.1)	23 (4.1)
Re-treatment after failure		1 (0.3)	2 (0.7)	3 (0.5)
Other		2 (0.7)	2 (0.7)	4 (0.7)
Site of disease				
Pulmonary and Extra Pulmonary (ICD-10 A17-A19)		3 (1.1)	3 (1.1)	6 (1.1)

Page **43** of **67**

 BMJ Open

PROLIFE Trial

Pulmonary only (ICD-10 A15)		281 (98.9)	272 (98.9)	553 (98.9)
Number of pre-treatment smear results				
One		197 (92.1)	169 (87.6)	366 (89.9)
Two		17 (7.9)	24 (12.4)	41 (10.1)
Smear result	N =	196	180	376
At least one positive smear result		111 (56.63)	109 (60.56)	220 (58.51)
Number of Gene XPert results recorded				
One		225 (97.8)	210 (97.2)	435 (97.5)
Two	6	5 (2.2)	6 (2.8)	11 (2.5)
Gene XPert result	N =	211	204	415
At least one positive Gene XPert result	~ (C)	184 (87.2)	178 (87.25)	362 (87.23)
Number of culture results recorded on the TB Treatment record	1	0.		
One		54 (94.7)	42 (97.7)	96 (96.0)
Two		3 (5.3)	1 (2.3)	4 (4.0)
Culture result	N =	41	32	73
At least one positive culture result		20 (48.78)	15 (46.88)	35 (47.95)
Co-morbidities			Ω	
Hypertension		19 (6.93)	11 (4.1)	30 (5.54)
Diabetes		5 (1.84)	4 (1.49)	9 (1.66)
Epilepsy		3 (1.09)	4 (1.49)	7 (1.29)
Mental illness		3 (1.09)	0 (0)	3 (0.55)
Liver disease		1 (0.36)	1 (0.38)	2 (0.37)
Renal insufficiency		1 (0.36)	1 (0.38)	2 (0.37)
Allergies		2 (0.76)	0 (0)	2 (0.38)

PROLIFE Trial

Jan 2020

Other		1 (0.36)	1 (0.38)	2 (0.37)
Other		1 (0.50)	1 (0.38)	2 (0.37)
Total Number of comorbidities				
0		265 (96.0)	260 (96.7)	525 (96.3)
1		10 (3.6)	8 (3.0)	18 (3.3)
2		0 (0.0)	1 (0.4)	1 (0.2)
5		1 (0.4)	0 (0.0)	1 (0.2)
HIV status				
Negative	¢	118 (40.7)	125 (44.2)	243 (42.4)
Positive	6	163 (56.2)	142 (50.2)	305 (53.2)
Unknown		9 (3.1)	16 (5.7)	25 (4.4)
HIV positive patients				
CD4 Count: mean(SD)				
Using Cotrimoxazole		104 (63.8)	100(67.11)	204 (65.38)
Using anti-retroviral		139 (85.28)	118 (79.19)	257 (82.37)

 BMJ Open

Statistical Analysis Plan

PROLIFE Trial

TABLE 3: Descriptive statistics for smoking history, alcohol history and depression score at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated.

TABLE 3: Descriptive statistics for smoking history, alcohol history and depression score at Ipresented unless otherwis	-	by study arm. Frequen	cies and (percentages) are
	Baseline		
	Control	Intervention	Total
	Arm 1	Arm 2	Total
In the past month, smoked tobacco			
Not at all	110 (37.8)	92 (32.5)	202 (35.2)
Daily	149 (51.2)	149 (52.7)	298 (51.9)
Less than Daily	32 (11.0)	42 (14.8)	74 (12.9)
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
AUDIT Score (males): mean (SD) [max :19] [min = 8 if drinkers only]	12.27 (3.98)	13.02 (3.78)	12.66 (3.89)
AUDIT Score (females): mean (SD) [max :19] [min = 7 if drinkers only]	11.32 (4.02)	10.98 (4.02)	11.15 (4)
Drinking and Smoking Combined (Constructed)			
Drinkers Only	110 (37.8)	92 (32.5)	202 (35.2)
Smokers Only	83 (28.5)	60 (21.2)	143 (24.9)
Smokers and Drinkers	98 (33.7)	131 (46.3)	229 (39.9)

PROLIFE Trial

Jan 2020

	Arm 1	Arm 2	Total
Smoking History (current smokers only)	181	191	372
On the days that you smoke, how soon after you wake up do you have your first cigarette?			
After 60 minutes	30 (16.6)	28 (14.7)	58 (15.6)
31-60 minutes	24 (13.3)	16 (8.4)	40 (10.8)
6- 30 minutes	60 (33.1)	65 (34.0)	125 (33.6)
Within 5 minutes	67 (37.0)	82 (42.9)	149 (40.1)
Duration of smoking in months : mean (SD)	212.09 (134.03)	224.93 (127.82)	218.68 (130.86)
Duration of smoking in months : median (IQR)	186 (110, 282)	206 (135, 294)	200.5 (123, 287)
Age started smoking in years : mean (SD)	19.2 (6.3)	19.3 (6.3)	19.3 (6.3)
Age started smoking in years : median (IQR)	18 (15-20)	18 (16-21)	18 (15.5-20.5)
Form of tobacco used	, (
Manufactured cigarettes (Yes)	166 (91.7)	179 (93.7)	345 (92.7)
Number of days in the past 7days you smoked: mean (SD)	5.3 (2.65)	5.53 (2.33)	5.42 (2.49)
Average number of cigarettes smoked daily: mean (SD)	6.18 (6.43)	6.48 (8.21)	6.34 (7.39)
Hand-rolled cigarettes (Yes)	14 (7.7)	21 (11.0)	35 (9.4)
Number of days in the past 7days you smoked: mean (SD)	4.71 (2.84)	3.71 (2.95)	4.11 (2.91)
Average number of handrolled cigarettes smoked daily: mean (SD)	3.71 (3.97)	3.81 (2.82)	3.77 (3.27)
Pipe (Yes)	4 (2.2)	2 (1.0)	6 (1.6)
Number of days in the past 7days you smoked: median (IQR)	1 (0, 2.5)	4.5 (2, 7)	2 (0, 3)
Average number of daily sessions: median (IQR)	1 (0, 3.5)	3 (1, 5)	1.5 (0, 5)
Length of one session (on average) in minutes : median (IQR)	90 (60, 107.5)	60 (30, 90)	90 (30, 90)
Cigars, cheroots or cigarillos (Yes)	1 (0.55)	0 (0)	1(0.27)

Page **47** of **67**

Page 91 of 155

 BMJ Open

PROLIFE Trial

Water pipe (Yes)	3 (1.7)	2 (1.0)	5 (1.3)
Other	10 (5.5)	4 (2.1)	14 (3.8)
Heaviness of smoking index >= 4	134(74.03)	158(82.72)	292(78.49)
Smoking inside your home restrictions			
Total: Not allowed	96 (53.0)	108 (56.5)	204 (54.8
Some rules: where/when it is allowed	61 (33.7)	58 (30.4)	119 (32.0
No rules	24 (13.3)	25 (13.1)	49 (13.2
Attempts to quit smoking (current smokers only) (Yes)			
Ever attempted to quit in the past			
Yes	52 (28.7)	64 (33.5)	116 (31.2
No	129 (71.3)	127 (66.5)	256 (68.8
Number of attempts to quit: mean (SD)	2.46 (2.98)	2.64 (1.62)	2.56 (2.32
Time elapsed since attempt to quit last time in months: mean (SD)	36.65 (94.62)	25.13 (37.91)	30.29 (69.22
Longest duration abstinent in previous quit attempts: mean (SD)	6.15 (13.48)	4.22 (8.9)	5.09 (11.18
Likelihood to TRY TO QUIT smoking completely and permanently in the next three months	-		
definitely will not	6 (3.3)	5 (2.6)	11 (3.0
probably will not	10 (5.5)	12 (6.3)	22 (5.9
probably will	104 (57.5)	109 (57.1)	213 (57.3
definitely will	61 (33.7)	65 (34.0)	126 (33.9
	Control	Intervention	

Page **48** of **67**

	Arm 1	Arm 2	Total
Likelihood that I WILL QUIT smoking completely and permanently in the next three months			
Likelihood that I will got shoking completely and permanently in the next three months	C (2 2)	F (2 C)	11 (2.0
definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
probably will not	11 (6.1)	13 (6.8)	24 (6.5)
probably will	103 (56.9)	104 (54.5)	207 (55.6)
definitely will	61 (33.7)	69 (36.1)	130 (34.9)
Ever used any methods to help you stop smoking tobacco in the past 3 months? (Yes)	23 (12.7)	16 (8.4)	39 (10.5)
O			
Out of your pocket spend (in Rands) on methods to help you stop smoking in the past 3	134.87 (237.58)	139.19 (155.07)	136.64 (205.36
months: mean (SD)	168.77 (178.15)	190 20 (195 27)	174.58 (181.61
Average spend per week on cigarettes over the past 3 months: mean (SD)	108.77 (178.15)	180.29 (185.27)	1/4.58 (181.01
Smokeless tobacco use (all participants)	•		
In the past month, have you used smokeless tobacco (Snuff) on a daily basis			
Not at all	275 (94.5)	275 (97.2)	550 (95.8)
Daily	12 (4.1)	6 (2.1)	18 (3.1)
Less than Daily	4 (1.4)	2 (0.7)	6 (1.0)
Duration of using ST in months: mean(SD)	113.69 (112.7)	152 (91.16)	126.46 (105.61)
Age started using ST in years: mean (SD)	27.56 (10.57)	25.88 (13.43)	27 (11.33)
Form of ST used (for SLT users)			
Snuff (by mouth)	2 (12.5)	0 (0.0)	2 (8.3)
Snuff (by nose)	11 (68.8)	5 (62.5)	16 (66.7)
Chewing tobacco leaves	0(0)	0(0)	0(0)
Other	1 (6.3)	0 (0.0)	1 (4.2)
	Arm 1	Arm 2	Total

Page **49** of **67**

 BMJ Open

Statistical Analysis Plan

PROLIFE Trial

	Control	Intervention	
Tobacco smoke exposure: number of days in the past 30 days, you were in a place where someone smoked close to you (all participants?)			
Home			
7 days or less	233 (80.1)	229 (80.9)	462 (80.5)
More than 7 days	58 (19.9)	54 (19.1)	112 (19.5)
Workplace (Missing 315; probably Not Applicable)			
7 days or less	84 (65.6)	89 (67.9)	173 (66.8)
More than 7 days	44 (34.4)	42 (32.1)	86 (33.2)
Cafes/restaurants			
7 days or less	230 (79.0)	234 (82.7)	464 (80.8)
More than 7 days	61 (21.0)	49 (17.3)	110 (19.2)
Shebeens, bars or clubs			
7 days or less	219 (75.3)	213 (75.3)	432 (75.3)
More than 7 days	72 (24.7)	70 (24.7)	142 (24.7)
Bus/train/taxi/ vehicle			
7 days or less	229 (78.7)	219 (77.4)	448 (78.0)
More than 7 days	62 (21.3)	64 (22.6)	126 (22.0)
Shops/shopping mall			
7 days or less	235 (80.8)	226 (79.9)	461 (80.3)
More than 7 days	56 (19.2)	57 (20.1)	113 (19.7)
	Arm 1	Arm 2	Total

PROLIFE Trial

Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
	208 (71.3)	223 (78.8)	431 (73.1)
Help to stop drinking (drinkers only)			
Ever used any methods to stop drinking alcohol in the past 3 months	21 (11.2)	22 (10.7)	43 (10.9)
Average spend in Rands per week on alcohol over the past 3 months: mean (SD)	363.76 (531.56)	337.03 (387.94)	349.79 (461.66)
Depression: CESD 10 how often you felt or behaved this way during the past week			
I was bothered by things that usually don't bother me.			
Rarely or None of the Time (Less than 1 day)	180 (61.9)	159 (56.2)	339 (59.1
Some or a Little of the Time (1-2 days)	71 (24.4)	78 (27.6)	149 (26.0
Occasionally or a Moderate Amount of the Time (3-4 days)	24 (8.2)	31 (11.0)	55 (9.6
Most or All of the Time (5-7 days)	16 (5.5)	15 (5.3)	31 (5.4
I had trouble keeping my mind on what I was doing.	\mathbf{N}		
Rarely or None of the Time (Less than 1 day)	150 (51.5)	136 (48.1)	286 (49.8
Some or a Little of the Time (1-2 days)	93 (32.0)	85 (30.0)	178 (31.0
Occasionally or a Moderate Amount of the Time (3-4 days)	31 (10.7)	38 (13.4)	69 (12.0
Most or All of the Time (5-7 days)	17 (5.8)	24 (8.5)	41 (7.1
I felt depressed.			
Rarely or None of the Time (Less than 1 day)	152 (52.2)	171 (60.4)	323 (56.3
Some or a Little of the Time (1-2 days)	94 (32.3)	70 (24.7)	164 (28.6
Occasionally or a Moderate Amount of the Time (3-4 days)	37 (12.7)	30 (10.6)	67 (11.7
Most or All of the Time (5-7 days)	8 (2.7)	12 (4.2)	20 (3.5
I felt that everything I did was an effort.			

Statistical Analysis Plan

Rarely or None of the Time (Less than 1 day)	140 (48.1)	117 (41.3)	257 (44.8)
Some or a Little of the Time (1-2 days)	77 (26.5)	87 (30.7)	164 (28.6
Occasionally or a Moderate Amount of the Time (3-4 days)	38 (13.1)	43 (15.2)	81 (14.1
Most or All of the Time (5-7 days)	36 (12.4)	36 (12.7)	72 (12.5
felt hopeful about the future.			
Rarely or None of the Time (Less than 1 day)	85 (29.2)	84 (29.7)	169 (29.4
Some or a Little of the Time (1-2 days)	78 (26.8)	70 (24.7)	148 (25.8
Occasionally or a Moderate Amount of the Time (3-4 days)	53 (18.2)	56 (19.8)	109 (19.0
Most or All of the Time (5-7 days)	75 (25.8)	73 (25.8)	148 (25.8
felt fearful.			
Rarely or None of the Time (Less than 1 day)	175 (60.1)	159 (56.2)	334 (58.2
Some or a Little of the Time (1-2 days)	82 (28.2)	79 (27.9)	161 (28.0
Occasionally or a Moderate Amount of the Time (3-4 days)	25 (8.6)	32 (11.3)	57 (9.9
Most or All of the Time (5-7 days)	9 (3.1)	13 (4.6)	22 (3.8
My sleep was restless.			
Rarely or None of the Time (Less than 1 day)	142 (48.8)	135 (47.7)	277 (48.3
Some or a Little of the Time (1-2 days)	95 (32.6)	89 (31.4)	184 (32.1
Occasionally or a Moderate Amount of the Time (3-4 days)	31 (10.7)	33 (11.7)	64 (11.1
Most or All of the Time (5-7 days)	23 (7.9)	26 (9.2)	49 (8.5
l was happy.			
Rarely or None of the Time (Less than 1 day)	85 (29.2)	74 (26.1)	159 (27.7
Some or a Little of the Time (1-2 days)	70 (24.1)	65 (23.0)	135 (23.5
Occasionally or a Moderate Amount of the Time (3-4 days)	73 (25.1)	86 (30.4)	159 (27.7
Most or All of the Time (5-7 days)	63 (21.6)	58 (20.5)	121 (21.1
I felt lonely.			

Page **52** of **67**

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

	Rarely or None of the Time (Less than 1 day)	158 (54.3)	161 (56.9)	319 (55.6)
	Some or a Little of the Time (1-2 days)	89 (30.6)	83 (29.3)	172 (30.0)
	Occasionally or a Moderate Amount of the Time (3-4 days)	23 (7.9)	26 (9.2)	49 (8.5
	Most or All of the Time (5-7 days)	21 (7.2)	13 (4.6)	34 (5.9
could not get "going".				
	Rarely or None of the Time (Less than 1 day)	168 (57.7)	174 (61.5)	342 (59.6
	Some or a Little of the Time (1-2 days)	78 (26.8)	69 (24.4)	147 (25.6
	Occasionally or a Moderate Amount of the Time (3-4 days)	35 (12.0)	29 (10.2)	64 (11.1
		10 (3.4)	11 (3.9)	21 (3.7
Total CESD 10: mean (SD)		8.44 (4.38)	8.74 (4.8)	8.59 (4.59
	Most or All of the Time (5-7 days)			

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

Table 4: Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3 month (where available) and 6 month. Frequencies and (percentages) are presented unless otherwise stated

BMJ Open

1 2

42 43

44 45 46 Jan 2020

Page **55** of **67**

		Baseline		Fol	low-up 3-mon ⁻	th	I	Follow-up 6-mor	nth
	Control	Intervention	Total	Control	Interventio n	Total	Control	Intervention	Total
	Arm1	Arm2	Total	Arm1	Arm2	Total	Arm1	Arm2	Tota
TB treatment status detailed									
Cured							108 (37.11)	105 (37.1)	213 (37.12
Treatment completed							96 (33.0)	87 (30.74)	183 (31.88
Treatment default							15 (5.2)	29 (10.25)	44 (7.67
Treatment failure							5 (1.7)	2 (0.7)	7 (1.2
Acquired drug resistance							1 (0.34)	4 (1.41)	5 (0.8
Died							11 (3.78)	15 (5.30)	26 (4.53
Transfer out							8 (2.75)	11 (3.89)	19 (3.31
Unknown							42 (14.43)	25 (8.83)	67 (11.67
Missing							5 (1.72)	5 (1.77)	10 (1.74
TB treatment status binary (Primary outcome**)					Ć				
Not Successful							87 (29.9)	91 (32.16)	178 (31.02
Successful							204 (70.10)	192 (67.84)	396 (68.99
At least one positive smear result			181						
	85 (53.46)	96 (61.15)	(57.28)						
At least one positive Gene XPert result	184 (87.20)	178 (87.25)	362 (87.23)						
At least one positive culture result	11 (57.89)	10 (66.67)	21 (61.76)						

40 41

42 43

44 45 46 BMJ Open

PROLIFE Trial

Sputum smear, Gene XPert, or culture result									
Negative	29 (12.45)	32 (14.16)	61 (13.29)						
Positive	204 (87.55)	194 (85.84)	398 (86.71)						
Conversion from positive to negative***									
Yes							83(39.9)	85(43.59)	168(41.6
No							125(60.1)	110(56.41)	235(58.3
		2	0						
Continuous smoking abstinence									
among cigarette smokers at baseline									
Yes				27(16.27)	20(11.17)	47(13.62)	12(7.23)	10(5.59)	22(6.3
No				139(83.73)	159(88.83)	298(86.38)	154(92.77)	169(94.41)	323(93.6
				5					
Harmful or hazardous drinking ¹									
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)						
AUDIT score: mean (SD)	12.03 (4)	12.53 (3.93)	12.29 (3.96)						
Harmful or hazardous drinkers out of those who had a drink in the past 12-months at baseline (%)	188(90.38)	206(92.38)	394(91.42)	141	130	271	112	127	23
AUDIT Score (males): mean (SD) [max :19; min = 8]*!	13.14 (3.31)	13.61 (3.29)	13.39 (3.31)	8.20(6.08)	9.08(4.97)	8.63(5.58)	9.21(6.58)	8.24(5.41)	8.69(5.99
AUDIT Score (females): mean (SD) [max :19; min = 7]*!	11.73 (3.52)	11.55 (3.6)	11.64 (3.54)	8.5(6.52)	8.15(6.44)	8.33(6.44)	7.67(6.84)	9.97(6.79)	8.89(6.86
AUDIT score: mean (SD)	12.76 (3.42)	13.12 (3.47)	12.94 (3.45)	8.28(6.18)	8.84(5.38)	8.55(5.81)	8.79(6.66)	8.70(5.83)	8.74(6.22
Difference from baseline				-4.61 (6.26)	-4.07(5.33)	-4.35(5.83)	-4.25(6.56)	-4.17(6.61)	-4.21(6.5

BMJ Open

PROLIFE Trial

Jan 2020

Statistical Analysis Plan			PROL	IFE Trial					Jan 2020
2 3 4 5 2 3 4 5 4 5 7 7 7 7 7 7 7 7 7 7 7 7 7	[163 (56.2)]	[142 (50.2)]	[305 (53.2)]	[122]	[83]	[205]	[100]	[83]	[183]
6 Yes 7	139 (85.28)	115 (80.99)	254 (83.28)	91 (74.6)	58 (69.9)	149 (72.7)	80 (80.0)	74 (89.2)	154 (84.2)
8 9 ART medication adherence									
10 11 Optimal adherence				101(99.02)	64(98.46)	165(98.8)	75(97.4)	64(96.97)	139(97.2)
12 13 Suboptimal adherence	- 0	6		1(0.98)	1(1.54)	2(1.2)	2(2.6)	2(3.03)	4(2.8)
14 15 16 TB medication adherence									
17 18 Optimal adherence			24	181(92.35)	138(90.79)	319(91.67)	61(89.71)	59(90.77)	120(90.23)
19 Suboptimal adherence				15(7.65)	14(9.21)	29(8.33)	7(10.29)	6(9.23)	13(9.77)
21 22									
 23 24 ¹ hazardous/harmful drinkers who are not alcount 	ohol depende	nt= AUDIT sco	re≥8 for men	or \geq 7 for wor	men but < 20				
²⁵ **Primary Outcome: in the published protoc					essful treatm	ent (cured or	treatment co	ompleted) or f	ailed
27		-			ng thoso who	wore positiv	o at bacalina		
 28 *** Conversion from positive to negative: this 29 *! Important distinction at baseline for eligibities 		i naving a cure			ing those who	o were positiv	e at Daseille.		
30	iity purposes.								
31 32									
33 34									
35									
36									
37 38									
39									
40 41									
41								Pag	ge 57 of 67
43	For pe	er review only -	http://bmiope	n.bmj.com/site	/about/quide	lines.xhtml			
44 45									
45									

 BMJ Open

Statistical Analysis Plan

PROLIFE Trial

TABLE 5: Number and type of adverse events at month 2, 3, and 6 by centre and study arm (see other document)

<i>TABLE 5: Nu</i> Centre		Month 2		Month 3		Month 6	
	TYPE	Intervention	Control	Intervention	Control	Intervention	Contro
		- Or					
			A				
			Co				
				1			
						7/	

Page 58 of 67

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

TABLE 6: Regression analysis results for the primary and secondary outcomes at 6	5 months. Estimates presented with corresponding 95% Cl. Crude and
adjusted estimates are provided.	

	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*	
Primary outcome					
TB treatment status: Successful (Ref: Not successful)	0.9 (0.64,1.27)	0.548	0.86 (0.60,1.24)	0.421	
Secondary outcomes		6			
Sputum smear or culture result: converted from positive to negative (Ref: Not converted)	1.16 (0.83,1.63)	0.374	1.07‡ (0.76,1.51)	0.684	
Six-month continuous smoking abstinence among cigarette smokers at baseline (Ref: No)	0.76 (0.35,1.64)	0.482	· er	10	
, , , , , , , , , , , , , , , , ,					
Taking ART medication among HIV positive patients ^{!!}	2.05 (0.80,5.27)	0.136			06.
TB medication adherence (Reference: Optimal)	0.89 (0.26,3.07)	0.849			J.
ART medication adherence (Reference: Optimal)	1.17 (0.14,9.94)	0.884			

45 46 BMJ Open

PROLIFE Trial

<form> hazardous drinkers at baseline**: </form>	regression coefficient regression coefficient AUDIT for those who were harmful or hazardous drinkers at baseline**: -0.04 (-2,1.91) 0.966 0.02! (-1.55,1.6) 0.976 * analyses accounted for potential clustering by centre. - - - - - * unber of participants whose outcome was treatment successful among the total number in the group. + Adjusted for district, sex, and smoking/drinking status and HIV status at baseline	Statistical Analysis Plan		PROLIFE Trial			
<form>hazardous drinkers at baseline**:</form>	hazardous drinkers at baseline**:		regression		regression		
Pumber of participants whose outcome was treatment successful among the total number in the group. Hadjusted for district, sex, and smoking/drinking status at haseline "Controlling for the AUDT baseline values. Controlling for the AUDT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline Hadjusting for art status at baseline.	 Number of participants whose outcome was treatment successful among the total number in the group. Adjusted for district, sex, and smoking/drinking status at HIV status at baseline Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline Adjusting for at status at baseline Adjusting for at status at baseline 	AUDIT for those who were harmful or hazardous drinkers at baseline**:	-0.04 (-2,1.91)	0.966	0.02 [!] (-1.55,1.6)	0.976	
		* Number of participants whose outcome was trea * Adjusted for district, sex, and smoking/drinking s **Controlling for the AUDIT baseline values.	ment successful among the status and HIV status at ba	aseline		aseline	
				100			
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtm						
For peer review only - http://bmionen.hmi.com/site/about/quidelines.yhtml	r or peer review only - http://binjopen.binj.com/site/about/guidelines.xhtm		For per	er review only	- http://hmiopen.hm	ni com/site/a	hout/auidelines.vhtml

BMJ Open

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

TABLE 7: Regression analysis results for secondary outcomes measured at 3-months. Estimates presented with corresponding 95% Cl. Crude and adjusted estimates are provided.

	Crude Odds Ratio (95% CI)	P Value	Adjusted Odds Ratio (95% CI)	P Value	
Secondary outcome					
3-months continuous smoking abstinence among cigarette smokers at baseline	0.65 (0.37,1.14)	0.135			
Taking ART medication among HIV positive patients ^{!!}	0.79 (0.38,1.65)	0.53	0.74‡ (0.35,1.58)	0.443	
TB medication adherence	1.22 (0.52,2.87)	0.641			
(Reference: Optimal)	1.22 (0.32,2.07)	0.041			
ART medication adherence (Reference: Optimal)	1.58 (0.10,26.12)	0.750			
				-	
	Study arm regression coefficient		Adjusted estimates		h/1
AUDIT for those who were harmful	0.55 (-1.01,2.11)	0.474	0.74 (-0.62,2.1)	0.273	
or hazardous drinkers at baseline**:					

!! Adjusting for art status at baseline

Additional tables SMS-fidelity

Variable	Intervention (N=) (=no. of <u>participants</u> allocated to intervention group, for example 245)	Control (N=) (=no. <u>participants</u> allocated to control group, for example 248)
No. of participants who received ALL due IMB messages INDEPENDENT OF WHETHER they completed MI 1 (i.o.w this is ITT analysis)	For example 120/245 (49 %)	For example 2/248 (%)
	pletion of first MI and initiation o	of SMS-sequence
Completed first MI	n/N (%) (=No. who completed first MI in intervention arm/ no. participants allocated to intervention arm [%] For example 170/245 [69%])	n/N (%) (=No. who completed first MI in control/ no. participants allocated to control [%] For example 2/248)
No. of participants who received ALL due messages after receipt of MI1 and SMS sequence was generated (this is a type of Per Protocol analysis:	For example 120/170 (71%)	2/2

PROLIFE Trial

Jan 2020

• • • • •					
denominator limited					
to those who had					
MI1)		1 01/0	1		
SMS delivery for parti	cipants for whor	n the SMS-seque first MI)	nce was initiated	(after receipt of	
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
		Range		incului (iqit)	
Average no.	For example		Expected to be	Expected to be	
adherence	8 (3.4)	9 (7-10)	0 or close to it	0 or close to it	
messages received					
per participant		Range 0-10			
(n=) (n = the no. of					
participants who			0.		
completed first MI,					
in this example 170)			· /_		
Average no.	For example		Expected to be	Expected to be	
tobacco-related	7 (3.4)	7 (6-7)	0 or close to it	0 or close to it	
messages received					
(n=) (n=no of		Range 0-7		<u> </u>	
participants who					
completed first MI					
AND were current					
tobacco users at					
baseline, for					
example 90)					
Average no. alcohol	For example		Expected to be	Expected to be	
related messages	7 (3.4)	7 (6-7)	0 or close to it	0 or close to it	
received					
(n=) <mark>(n=no.</mark>		Range 0-7			
participants who					
completed first MI					

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Other variables not yet analysed:						
completed first MI)		Range 0-24				
(n= total no who	10 (4.5)	15 (10-20)				
Average no. IMB messages received	For example 16 (4.5)	15 (10-20)	Expected to be 0 or close to it	Expected to be 0 or close to it		
example 100)						
at baseline=for						

ait intense. ng to SLT) Other smoking related questions at 3 and 6 month (quit intentions etc) but also SLT use at 3 and 6 month. (important because

participants may have switched from tobacco smoking to SLT)

Other non-HE questions not yet analysed

PROLIFE Trial

Jan 2020

13. Additional descriptive Statistics

TABLE 8: Additional Descriptive statistics for characteristics at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated

			Baseline		
	N1/N2	Intervention	Control	Total	
		Arm 1	Arm 2		
TYPE OF MINE WORK	46/45		5	91	
Coal		7 (15.2)	3 (6.7)	10 (11.0)	
Diamond		3 (6.5)	1 (2.2)	4 (4.4)	
Gold		13 (28.3)	17 (37.8)	30 (33.0)	
Platinum and palladium		24 (52.2)	17 (37.8)	41 (45.1)	
Chromium		11 (23.9)	12 (26.7)	23 (25.3)	
Uranium		1 (2.2)	1 (2.2)	2 (2.2)	en ont
Manganese		0(0)	0(0)	0(0)	
Other		0(0)	0(0)	0(0)	
Total Types of Mines worked					
in					
1	73				
2	12				
3	3				
4	1				

BMJ Open

Statistical Analysis Plan


PROLIFE Trial

Jan 2020

Exact Distribution for number				
smoked in the past seven days		16 (8.9)	40 (11.6)	
0	24 (14.5)			
1	4 (2.4)	4 (2.2)	8 (2.3)	
2	4 (2.4)	3 (1.7)	7 (2.0)	
3	5 (3.0)	13 (7.3)	18 (5.2)	
4	13 (7.8)	8 (4.5)	21 (6.1)	
5	5 (3.0)	17 (9.5)	22 (6.4)	
6	1 (0.6)	3 (1.7)	4 (1.2)	
7	110 (66.3)	115 (64.2)	225 (65.2)	
new_a_positive_TB		50		
0	29 (11.98)	33 (14.35)	62 (13.14)	
1	122 (50.41)	104 (45.22)	226 (47.88)	
2	80 (33.06)	81 (35.22)	161 (34.11)	
3	11 (4.55)	12 (5.22)	23 (4.87)	

PROLIFE Trial

Jan 2020



Page 111 of 155

BMJ Open



CONSORT 2010 checklist of information to include when reporting a randomised trial* Item Reported Section/Topic No **Checklist item** on page No Title and abstract Identification as a randomised trial in the title <u>1</u> 2 1a 1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) Introduction Scientific background and explanation of rationale Background and 4-5 2a Specific objectives or hypotheses 5-7 objectives 2b

CONSORT 2010 checklist		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Page
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	6
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	6
concealment mechanism		describing any steps taken to conceal the sequence until interventions were assigned	
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	6
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Sequence	8a	Method used to generate the random allocation sequence	6
Randomisation:	10	when applicable, explanation of any interim analyses and stopping guidelines	
Sample size	7a 7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Sampla siza	6b 7a	Any changes to trial outcomes after the trial commenced, with reasons How sample size was determined	<u>NA</u> 8
	Gh	were assessed	
Outcomes	6a	actually administered Completely defined pre-specified primary and secondary outcome measures, including how and when they	7-8
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were	6
	4b	Settings and locations where the data were collected	5
Participants	4a	Eligibility criteria for participants	5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
Methods			

Page 112 of 155

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	9
Results			
Participant flow (a diagram is strongly	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	10, Figure 1
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	10, Fig 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	5-6
	14b	Why the trial ended or was stopped	10,21
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1 and
		D	2, Supp Tabl 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Fig 1, Table
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Table 3,4,5
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Only relative effect
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Table 4, 5
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	No harms
			reported
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	21-22
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	NA, no effect
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	21
Other information			
Registration	23	Registration number and name of trial registry	2
Protocol	24	Where the full trial protocol can be accessed, if available	Published
			paper referenced
CONSORT 2010 checklist		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Pa

BMJ Open

Funding 25 Sources of funding and other support (such as supply of drugs), role of funders

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see <u>www.consort-statement.org</u>.

For peer review only

CONSORT 2010 checklist

2		
3 4	1	Effect of a brief motivational interview and text message intervention targeting tobacco smoking,
5	2	alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult
6 7	3	patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in
8 9	4	South Africa
9 10	5	Goedele Maria Louwagie ^{1, 2} , Mona Kanaan ³ , Neo Keitumetse Morojele ^{4, 5} , André van Zyl ¹ , Andrew
11	6	Stephen Moriarty ³ , Jinshuo Li ³ , Kamran Siddiqi ³ , Astrid Turner ² , Noreen Dadirai Mdege ³ , Olufemi
12 13	7	Babatunde Omole ⁶ , John Tumbo ¹ , Max Oscar Bachmann ⁷ , Steve Parrott ³ , Olalekan Ayo-Yusuf ^{1, 2}
14 15	8	Correspondence to Goedele Maria Louwagie; goedele.louwagie@up.ac.za
16	9	
17	10	¹ Goedele Maria Louwagie, Sefako Makgatho Health Sciences University and ² School of Health
18 19	11	Systems and Public Health, University of Pretoria, RSA; goedele.louwagie@up.ac.za
20	12	
21 22	13	³ Mona Kanaan, Department of Health Sciences, University of York, UK; <u>mona.kanaan@york.ac.uk</u>
23	14	
24	15	⁴ Neo Keitumetse Morojele, Department of Psychology, University of Johannesburg and ⁵ Alcohol,
25 26	16	Tobacco and Other Drug Research Unit, South African Medical Research Council, RSA;
20	17	nmorojele@uj.ac.za
28	18	
29	19	¹ André van Zyl, Sefako Makgatho Health Sciences University, RSA; drevanzyl@gmail.com
30	20	
31 32	21	³ Andrew Stephen Moriarty, Department of Health Sciences and the Hull York Medical School,
33	22	University of York, UK; <u>andrew.moriarty@york.ac.uk</u>
34	23	
35	24	³ Jinshuo Li, Department of Health Sciences, University of York, UK; jinshuo.li@york.ac.uk
36 37	25	
38	26	³ Kamran Siddigi, Department of Health Sciences and the Hull York Medical School, University of York,
39	27	UK; kamran.siddigi@york.ac.uk
40	28	
41 42	29	² Astrid Turner, School of Health Systems and Public Health, University of Pretoria, RSA;
43	30	astrid.turner@up.ac.za
44	31	
45	32	³ Noreen Dadirai Mdege, Department of Health Sciences, University of York, UK;
46 47	33	noreen.mdege@york.ac.uk
47 48	34	noreen.maege@york.ac.ak
49		60 Unioni Debetunde Omele, Department of Femily Medicine, University of Witwetersrand, DCA.
50	35	⁶ Olufemi Babatunde Omole, Department of Family Medicine, University of Witwatersrand, RSA;
51	36	Olufemi.Omole@wits.ac.za
52 53	37	
55 54	38	¹ John Tumbo, Department of Family Medicine, Sefako Makgatho Health Sciences University, RSA;
55	39	<u>tumbo@lantic.net</u>
56	40	
57 59	41	⁷ Max Oscar Bachmann, Norwich Medical School, University of East Anglia, UK;
58 59	42	<u>m.bachmann@uea.ac.uk</u>
60	43	
		1

BMJ Open

1 2		
3	44	³ Steve Parrott, Department of Health Sciences, University of York, UK; <u>steve.parrott@york.ac.uk</u>
4 5	45	
6	46	¹ Olalekan Ayo-Yusuf, Africa Centre for Tobacco Industry Monitoring & Policy Research, Sefako
7 8	47	Makgatho Health Sciences University, and ² School of Health Systems and Public Health, University of
9	48	Pretoria, RSA [;] <u>lekan.ayo-yusuf@smu.ac.za</u>
10 11	49	
12	50	ABSTRACT
13 14	51	Objectives: tto investigate the effectiveness of a complex behavioural intervention, ProLife, on
15 16	52	tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking.
17 18	53	Design: mmulti-centre, individual, randomised controlled trial where participants were assigned
19	54	(1:1) to the ProLife intervention or usual care.
20 21	55	Setting: 27 primary care clinics in South Africa.
22 23	56	Participants: 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or
24	57	reported harmful/hazardous alcohol use.
25 26 27 28 29 30 31	58	Interventions: The intervention, delivered by lay health workers (LHWs), consisted of 3 brief
	59	motivational interviewing (MI) sessions-, augmented with Short Message Service (SMS) messages,
	60	targeting medication adherence, alcohol use and tobacco smoking.
	61	Outcome measures: the primary outcome was successful versus unsuccessful TB treatment at 6 to 9
32 33	62	months, from TB records; secondary outcomes: biochemically confirmed sustained smoking
34 35 36 37 38 39 40	63	cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and
	64	antiretroviral treatment (ART) adherence and ART initiation, each measured at 3 and 6 months by
	65	questionnaires; cure rates in patients who had bacteriology-confirmed TB at baseline, from TB
	66	records.
41	67	Results: Between 15 November 2018 and 31 August 2019, 574 participants were randomised to
42 43	68	receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not
44 45	69	differ significantly between intervention (67.8%) and control (70.1%) (OR=0.9 (95% CI: 0.64,1.27)).
46	70	There was no evidence of an effect at 3- and 6-months respectively- on continuous smoking
47 48	71	abstinence (OR=0.65 (95% CI: 0.37,1.14); OR=0.76 (95% CI: 0.35,1.63)), TB medication adherence
49 50	72	(OR=1.22 (95%CI: 0.52,2.87); OR=0.89 (95%CI: 0.26,3.07)), taking ART (OR=0.79 (0.38,1.65), OR=2.05
51	73	(0.80,5.27)) or AUDIT scores (mean score difference 0.55 (95% CI: -1.01,2.11); -0.04 (95% CI: -2,1.91);
52 53	74	and adjusting for baseline values. Cure rates were not significantly higher (OR=1.16 (0.83,1.63)).
54 55	75	Conclusions: Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs
56	76	may not be an effective approach to improve TB outcomes.
57 58	77	
59		

Trial registration: ISRCTN62728852, Registered on 13th April 2018.
Key words: Tuberculosis, smoking, alcohol, motivational interviewing, mHealth, anti-retroviral
therapy, adherence
STRENGTHS AND LIMITATIONS OF THIS STUDY
• The use of motivational interviewing combined with Short Text Messaging to address the
effect of multiple risk behaviours (smoking, drinking and poor adherence) on tuberculosis TB
treatment outcomes is a novel and much needed intervention.
• Our study design was strong: this was a multi-site individually randomised controlled trial
with a large sample size and a high follow up rate for the primary outcome.
• We used validated measurement tools; furthermore data analysis and primary outcome
assessment were blinded, thereby limiting measurement bias.
• <u>The study was underpowered</u> for secondary outcomes. FLow he intervention uptake may
have diluted any potential intervention effects.
Ciew only

93 INTRODUCTION

Tuberculosis (TB) is among the most common chronic infectious diseases in the world today. In 2019, 1.4 million deaths worldwide were attributed to TB, and the majority of these occurred in low-income and middle-income countries (LMICs).(1) South Africa not only has one of the highest TB burdens in the world; it is faced with high TB treatment interruption and loss to follow-up rates. of the 30 high TB burden countries. It also has a high prevalence of human immunodeficiency virus (HIV) co-infection in patients with TB and a relatively high mortality in these co-infected patients.(1) Studies of interventions to advance the goal of ending the TB epidemic and improving treatment outcomes are therefore research priorities in South Africa and other LMICs.(2)

Mortality and morbidity from TB is strongly associated with health risk behaviours, particularly smoking and hazardous or harmful alcohol use, both of which are prevalent and often co-occur in TB patients with TB.(3–10) Strategies are also required to improve TB medication adherence in patients with TB and adherence to TB medication and anti-retroviral therapy (ART) in TB-HIV co-infected patients co-infected with TB and HIV, both of which may be negatively influenced by excessive alcohol use.(1) There is very limited research on how to concurrently tackle these three risk behaviours - namely smoking, harmful alcohol use and poor medication adherence - in patients with TB, particularly in LMICs.

Motivational Interviewing (MI) is a counselling technique known to facilitate behaviour change,(11) and has been shown to effectively support reduced drinking, smoking cessation in TB patients and TB treatment and/or antiretroviral therapy (ART) medication adherence.(11-13) MI interventions can be effectively delivered by lay health workers (LHWs).(14) The more widespread use of LHWs and the increased use of mobile health (mHealth) digital technologies represent promising ways to increase the scalability of MI interventions. Indeed, the World Health Organisation (WHO) has called for researchers to capitalise on advances in mobile phone technology, network coverage and the increased use of common and widely available digital technologies (including the mobile phone short message service (SMS)) to improve TB care.(15) There is robust evidence that mHealth technologies can have modest beneficial effects on a range of health outcomes, including medication adherence. (16)(16,17) Mobile phone messaging also shows a modest effect in improving TB treatment success rates.(18,19) The evidence is however stronger for two-way messaging and interactive systems for which smart phones are required.(18) These are often not available to patients with TB in Africa.(20) An SMS intervention in co-infected TB/HIV patients demonstrated effectiveness in increasing adherence to ART,(17) although the existing evidence is not of sufficient quality to know if this consistently applies to medication adherence in TB patients.(18)

1 2		
3	126	
4 5	127	A limitation of existing MI and mHealth interventions is that they have been studied in the context of
6 7	128	modifying a single lifestyle factor. Integrated interventions are likely to be better accepted and more
8	129	effective than multiple interventions targeting different health risk factors.(21,22) In the case of TB,
9 10 11 12 13 14	130	there is a need for an intervention that has the flexibility to target multiple lifestyle factors as
	131	appropriate and in line with patient preferences. This could be achieved through increased
	132	integration of TB and non-communicable disease services.(23)
15	133	
16 17	134	Recent re-engineering of primary health care in South Africa has seen the introduction of municipal
18 19	135	ward-based primary healthcare outreach teams of community health workers (CHWS). CHWs work
20	136	in an integrated, team-based manner, supported by nurses, and take responsibility for health
21 22	137	education and promotion, counselling and support for a range of health conditions.(24,25) Task
23 24	138	shifting in this context has been shown to improve population health in LMICs (26) and these teams
25 26	139	can be trained and supported to take responsibility for TB/HIV care.(27) Integrated interventions
27	140	could be implemented within this framework in a feasible and scalable way to improve outcomes for
28 29	141	patients with TB across South Africa and beyond.
30 31	142	
31 32 33 34 35 36	143	Building on previous successes with MI and mHealth interventions, we developed a complex
	144	behavioural intervention (ProLife) comprising MI-based counselling and SMS, targeting three
	145	lifestyle risk behaviours for poor TB outcomes (smoking, hazardous/harmful alcohol consumption
37	146	and poor medication adherence), and delivered by LHWs. We then conducted a randomised
38 39	147	controlled trial (RCT) to assess the effectiveness of the ProLife intervention on improving TB
40 41	148	treatment outcomes, smoking abstinence, reducing alcohol consumption and improving adherence
42	149	to TB and ART medication compared to usual care. The cost-effectiveness of the intervention was
43 44	150	also assessed but only the costing results will be presented in this paper.
45 46	151	
47 48	152	METHODS
49	153	
50 51	154	Study design and participants
52 53	155	This was a prospective, two-arm, multi-centre, individually randomised controlled trialRCT, which
54	156	took place across 27 primary care clinics in 3 districts in South Africa (Lejweleputswa in the Free
55 56	157	State province; Bojanala in the North West province; and Sedibeng in Gauteng province). Adult
57 58	158	patients (18 years or older) were eligible for the study if they had drug-sensitive Pulmonary TB (PTB),
59	159	and were initiating TB treatment or had been on TB treatment for less than a month for this

BMJ Open

treatment episode (both "new" and "retreatment patients"). They had to be tobacco smokers (defined as smoking daily or non-daily in the last four weeks on the Global Adult Tobacco Survey questionnaire)(28) and/or hazardous/harmful drinkers who were not alcohol dependent (Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20).(29) They also had to have access to a mobile phone and understand one of the 4 languages used for the trial (English, lisiZulu, SeSotho and Setswana). Potential participants were recruited consecutively at the participating clinics between 15 November 2018 and 31 August 2019. Trained field workers identified those interested in the study and screened them for eligibility. If eligible and willing to be enrolled into the trial, written informed consent was obtained. The RCT received ethics approval from the Research Ethics Committees of the five participating research institutions.(30)

Randomisation and blinding

Patients were centrally randomised (1:1) to the ProLife intervention or control group using a randomised sequence generator by the trial statistician (MK) who was blind to the arm allocation. We used block randomisation with varying block sizes stratified by clinic so as to achieve equal numbers in intervention and control groups within each clinic. Fieldworkers used sequentially numbered, sealed, opaque envelopes to allocate participants to intervention or control. ProLife involved a complex behavioural intervention therefore LHWs and participants could not be blinded to the intervention. However, the determination of the primary outcome was done by the TB nurses who were blinded to the intervention status of the participants, based on routinely collected data. The statistician (MK) was blinded to the intervention or control arm allocation of participants during the analysis.

Intervention and procedures

The ProLife intervention was developed based on a conceptual framework, following a review of pre-existing evidence.(31) This framework assumed that smoking cessation, reducing harmful alcohol use and improved adherence to TB and HIV treatment would result in improved TB treatment outcomes.(30) The intervention consisted of 3 brief MI counselling sessions, lasting 15-20 minutes, one month apart, delivered by trained LHWs at their TB clinic. The first MI session took place immediately or shortly after the randomisation and involved prioritisation and agenda setting, wherein the participant determined which factor should be prioritised (either a plan to quit tobacco smoking, or reduce or quit drinking, or deal with barriers relating to ART or TB medication adherence). The second and third sessions built on the previous one until all relevant behavioural problems had been addressed. These sessions were reinforced with follow-up SMS text messages, twice a week over 12 weeks.(30) Study patients received 10 TB-related messages followed by seven alcohol reduction- and/or seven smoking cessation-related messages, as appropriate. Messages were aimed at giving information, and augmenting motivation or behavioural skills (we refer to the feasibility paper for more details).(31) Applicable SMS-messages were automatically activated after

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1

2 3	198	the first MI had taken place. Thereafter the remaining messages were delivered even if the
4 5	199	participant did not attend the second or third MI session.
6	200 201	
7 8	201	
9 10	202	Participants randomised to the ProLife intervention also received the same "usual care" as those in
11	204	the control group. The control group received the usual care and routine treatment and support
12 13	204	offered to TB-patients with TB in South Africa, which varies by district but includes: health education;
14 15		
16	206	dietetic input; social support; point of care biochemical testing; and HIV testing with preand post-
17 18	207	test HIV test counselling.
19	208	
20 21	209	Data were collected at baseline, 3- and 6-months and recorded by fieldworkers equipped with
22	210	mobile phones with the ProLife mobile data collection application (built with CommCare)(32)
23 24	211	installed. They used a standardised electronic case report form (CRF) and followed standard
25 26 27	212	operating procedures (SOPs) to ensure quality. Details of data collection, protection and storage
	213	procedures have been reported elsewhere.(30)
28 29	214	
30 31 32	215	Patient and public involvement
	216	Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
33 34	217	plans of our research.
35	218	
36 37	219	Outcomes
38 39	220	Primary Outcome
40	221	The primary outcome of TB treatment success at 6 to 9 months follow-up (depending on when it was
41 42	222	recorded) was as per the WHO definitions adopted in South Africa,(10) that is, either successful
43 44	223	treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss
45	224	to follow-up (defined as treatment interruption of more than 2 months), or outcome not evaluated.
46 47	225	It was measured using the routinely collected TB treatment outcomes in patients' individual files.
48 49	226	
50	227	Secondary Outcomes
51 52	228	For those participants with bacteriologically confirmed PTB at baseline (either sputum acid fast
53	229	bacilli (AFB) positive, culture positive or GeneXpert positive PTB), sputum conversion at the end of
54 55	230	treatment ("cure rate") was measured as a secondary outcome.(10) Continuous smoking abstinence
56 57	230	was assessed at 3- and 6-months follow-up in those participants who were current cigarette smokers
58		
59 60	232	at baseline. It was defined as having quit smoking completely and a self-report of not smoking more

BMJ Open

2		
3	233	than 5 ci
4 5	234	Carbon N
6	235	AUDIT qu
7 8	236	-
9	250	hazardou
10 11	237	HIV posit
12		•
13	238	standardi
14 15	220	
16	239	TB and AI
17 18	240	Group Ad
19	241	Adherenc
20 21	242	recall): [T
21	243	95% adhe
23	244	classed as
24 25	244	classed as
26	245	During CO
27 28	246	
20 29		participar
30	247	measurer
31 32		
33	248	Training a
34 35	249	The trair
36	250	papers.(3
37 38	251	counsellir
39	252	structure
40 41	253	MI, as w
42	254	assessed
43 44		described
45	255	
46 47	256	also asses
48	257	
49 50	258	Economic
51	259	The ProLi
52 53	260	interventi
54	261	accommo
55 56	262	estimated
57		
58 59	263	biochemi
39	201	المعاملا معام

garettes from the start of the study, in addition to a negative biochemical test (exhaled 1onoxide (CO) < 7 ppm).(33,34) Changes in alcohol consumption were computed using the estionnaire scores measured at 3- and 6-months follow-up in those participants who were s/harmful drinkers at baseline.

tive participants were asked about ART status at baseline, 3- and 6-months using sed questions on the CRF and change in ART status as measured at the 2 follow-up times.

RT medication adherence was measured using modified versions of the AIDS Clinical Trials lherence Questionnaire, a validated tool for measuring adherence specifically to ART.(35) e was measured using an adherence index calculated by the formula (using the 4-day otal number of doses taken/Total number of doses prescribed] x 100. Patients with at least erence were classed as having optimal adherence and those with less than 95% were s having low (or suboptimal) adherence. This was assessed at 3- and 6-months.

OVID-19 lockdown (in the second term of 2020) we switched to telephonic follow-up of nts using a shortened questionnaire whereby only strictly needed information for the nent of outcomes was inquired about.

and Intervention Fidelity Monitoring

ning and intervention fidelity monitoring is described in more detail in previous 0,31) In brief, 18 LHWs, 3 district coordinators and 1 research assistant who focused on ng supervision underwent MI training over 5 days. LHWs completed a post-session semid form onto which they indicated the extent to which they implemented each element of ell as their general qualitative impressions of that particular session. In addition, we MI intervention fidelity based on ratings of the counsellors' recorded MI sessions, as below and in footnotes to the relevantSupplementary-table 4. SMS-message delivery was sed.

evaluation

fe intervention costs consisted of the costs of training and the delivery of the ProLife ion, including relevant personnel involvement (trainers and LHWs), materials used, travel, dation and refreshments, and digital infrastructure for the intervention. These were d based on research team records. Usual care costs consisted of TB medication costs, cal investigations, and ART costs if applicable. These were estimated based on information obtained through routine records. The country specific version of Eurogol with 5 dimensions and 264 60

265 <u>with-3 levels of response categories</u> (EQ-5D-3L) for South Africa was administered to participants at
 266 baseline, 3- and 6-months follow-up to measure health-related quality of life.(36,37)

268 Statistical analysis

The sample size was estimated at 696 in total (348 participants per arm), to detect a 10% difference in TB treatment success rates (0.86 vs. 0.76) in the ProLife arm (intervention) vs. the control arm with 80% power, a significance level of 0.05 and 25% attrition rate. The assumed success rates in the control group were based on actual success rates in TB-patients with TB in the studied provinces obtained from TB managers at the time of the grant application for this study.

We summarised baseline data descriptively by trial arm. For the primary outcome, we conducted statistical analysis on an intention-to-treat basis. We used binary logistic regression to compare the main outcome (TB treatment success rate) between the intervention and the usual care arm. Where treatment outcome data were missing, the outcome was coded as unsuccessful. TB treatment outcomes recorded by the TB nurse were taken on face value as inconsistencies in the dates of bacteriological results did not permit us to verify the correctness of the nurse assessment. We carried out similar statistical analyses for the secondary outcomes with appropriate regression techniques. For the reduction in harmful or hazardous drinking, we used linear regression to estimate the difference in total AUDIT score between control and intervention groups accounting for the baseline AUDIT score as covariate. Separate analyses at 3- and 6-months were performed.

For our main analyses we adjusted for baseline characteristics if these differed between trial arms at
 baseline. The covariates that we controlled for in each model are specified when a model is
 presented. The statistical packages STATA (38) and R (39) were used to carry out the analyses, with a
 P-value < 0.05 considered statistically significant.

The validated Motivational Interviewing Treatment Integrity (MITI) coding tool (version 4.2.1) was used to assess MI intervention fidelity.(40) The coding entailed making 'Global Ratings' (on 4 dimensions: Cultivating change talk, Softening sustain talk, Partnership and Empathy) and 'Behaviour' counts (with respect to the items: giving information, persuade, persuade with permission, question, simple reflection, complex reflection, affirm, seeking collaboration, emphasising autonomy and confront). A score was assigned to each of these items and the scores compared against the competency and proficiency thresholds that are specified in the MITI manual.

Page 123 of 155

1

BMJ Open

2	
3 4	296
5	297
6 7	298
8	
9 10	299 300
11 12	301
13	302
14 15	
16	303 304
17 18	304 305
19 20	
21	306
22 23	307
24	308
25 26	309
27 28	310
29	311
30 31	312
32	313
33 34	314
35	315
36 37	316
38 39	317
40	318
41 42	319
43 44	320
44 45	321
46 47	
48	322
49 50	323
51	324
52 53	325
54 55	326
55	327

296 For the analysis of the costs, all costs were collected in South Africa Rand (ZAR) except for the data 297 management system subscription. Results are presented in both ZAR and US dollar (\$) using the 298 2019 OECD exchange rate (1 USD = 14.448 Rand).(36) No South African specific valuation set was 299 available for EQ-5D-3L. The valuation set of Argentina, based on a Visual Analogue Scale-for EQ-5D-300 3L, was used to derive utility values, because the GDP per capita in international dollars was the 301 closest between the two countries at the time of analysis.(37,41) Quality-adjusted life years (QALYs) 302 were derived from the utility values at the time points by calculating the area under the curve.(42) 303 No missing data imputation was performed.

306 RESULTS

308 Participant enrolment and follow-up

309 A total of 2099 TB-patients with TB were screened for eligibility out of which 574 consenting and eligible participants were randomised: 291 to control and 283 to intervention. Trial recruitment was 310 terminated on 31 August 2019 before the planned sample size was reached because of budget and 311 312 time constraints. In the intervention arm, 227 (80.2%) participants completed the first MI (MI 1) session, 199 (70.3%) MI 2 and 150 (53.0%) MI 3. In the intervention arm, at least one message was 313 314 delivered to 208 (73.5%) participants, while 99 (35.0%) received all messages. Of those randomised 315 to the control and intervention groups, the primary outcome was recorded in 244 (83.8%) and 253 316 (89.4%) participants, respectively. -(Figure 1)

318 Figure 1 Consort flow diagram

320 Baseline participant characteristics of the intervention and control arm

321 Socio-demographic; socio-economic and clinical characteristics

322 Baseline characteristics were distributed similarly in the intervention and control arms for most 323 variables but with some imbalances in educational level. A total of 513 (91.3%) participants were 324 new TB-patients with TB, 129 (22.5%) women, and nearly all had PTB (International Classification of 325 Diseases-10 A15) without extrapulmonary TB manifestations (553 (98.9%)). About half of the participants were HIV positive (305 (53.2%)), of whom 204 (65.4%) were on cotrimoxazole and 257 326 327 (82.4%) were on ART. (Table 1) Details of marital status, employment, wealth, depression status and 57 328 co-morbidities are presented in Supplementary table 1. 58

59 60

	Control (N = 291)	Intervention (N = 283)	Total (N=574)
	n (%)*	n (%)*	n (%)*
Age in years: mean (SD)	39.37 (12.60)	38.56 (11.15)	
Female Sex	69 (23.7)	60 (21.2)	129 (22.5)
ducation			
No educatio		5 (1.8)	12 (2.1)
Grades 1		20 (7.1)	43 (7.5)
Grades 6	· · · /	35 (12.4)	67 (11.7)
Grades 8-2	. ,	128 (45.2)	224 (39.0)
Grade	· · ·	70 (24.7)	157 (27.4)
High		8 (2.8)	32 (5.6)
Declined to answer	** 22 (7.6)	17 (6.0)	39 (6.8)
B Patient category			
New patie	nt 264 (92.3)	249 (90.2)	513 (91.3)
Relap	se 10 (3.5)	9 (3.3)	19 (3.4)
Re-treatment after defau	ılt 9 (3.1)	14 (5.1)	23 (4.1)
Re-treatment after failu	re 1 (0.3)	2 (0.7)	3 (0.5)
Oth	er 2 (0.7)	2 (0.7)	4 (0.7)
B Site of disease Pulmonary only (ICD-10 A15)	281 (98.9)	272 (98.9)	553 (98.9)
3 Sputum smear, Gene XPert, or culture result available N=	236	227	463
At least one Sputum smear, Gene XPert, or culture result posit	ive 208 (88.1)	195 (85.9)	403 (87.0)
V status			
Negati	ve 118 (40.7)	125 (44.2)	243 (42.4)
Positi	ve 163 (56.2)	142 (50.2)	305 (53.2)
Unknov	yn 9 (3.1)	16 (5.7)	25 (4.4)
IV positive patients			
Using Cotrimoxazo	le 104 (63.8)	100 (67.1)	204 (65.4)
Using anti-retrovir	al 139 (85.3)	118 (79.2)	257 (82.4)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

330	* Frequencies and (percentages) are presented unless otherwise stated
331	**More variables with the option "declined to answer" are listed in the Supplementary table 1
332	

	Control (N=291)	Intervention (N=283)	Total (N=574)
	n (%)*	n (%)*	n (%)*
In the past month, smoked tobacco			
Not at all**	110 (37.8)	92 (32.5)	202 (35.2)
Daily	149 (51.2)	149 (52.7)	298 (51.9)
Less than Daily	32 (11.0)	42 (14.8)	74 (12.9)
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
AUDIT Score (males) : mean (SD) [max: 19]†	12.27 (3.98)	13.02 (3.78)	12.66 (3.89)
AUDIT Score (females): mean (SD) [max: 19] [†]	11.32 (4.02)	10.98 (4.02)	11.15 (4.0)
Hazardous/harmful drinking and Smoking Combined (Constructed)	CV:		
Hazardous/harmful drinking Only‡	110 (37.8)	92 (32.5)	202 (35.2)
Smoking Only	103 (35.4)	77 (27.2)	180 (31.4)
Smoking and hazardous/harmful drinking‡	78 (26.8)	114 (40.3)	192 (33.4)

[†]Only hazardous/harmful drinkers and/or current smokers were included in the study. Therefore **TB** patients with **TB** were excluded if they were non-current smokers and had an AUDIT

score <7 (females) or <8 (males) or >19; however, they were included if they were smokers independent of whether they had a drink in the past year and therefore independent of the

AUDIT score. These AUDIT scores are thus representative of the mean AUDIT scores in the entire study sample and differ from the AUDIT score in the harmful/hazardous drinkers whose

change in AUDIT score was measured at 3 and 6-months follow-up (see Table 3)

‡Harmful/hazardous drinking is defined as Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

There were 372 current smokers (298 daily, 74 less than daily). Seventy eight participants (26.8 %) in the control arm were dual smokers and drinkers compared to 114 (40.3 %) in the intervention arm. In the control arm, 110 (37.8%) were hazardous/harmful drinkers only and 103 (35.4%) were smokers only, compared to 92 (32.5%) and 77 (27.2) respectively, in the intervention arm. (Table 2) More details of smoking and drinking history, forms of tobacco use, addiction and guit attempts are presented in Supplementary Table 2.

Primary outcome

Overall, 396 (70%) of participants were classified as treated successfully (treatment completed or cured). The remainder either interrupted treatment, failed treatment, developed drug resistance, wereas transferred out or had an unknown the treatment outcome. (Supplementary table 3) The percentage of successful TB treatment did not differ significantly between the control and intervention arm (70.1% vs. 67.8%), odds ratio (OR) for successful TB treatment 0.90 (95%CI: (0.64,1.27)) comparing the intervention arm to the control arm; and was similar to adjusted ORs. (Tables 3 and 4)

Secondary outcomes

Cure rates

Among the 403 participants who had at least one positive bacteriological result at baseline, 168 (41.7%) were recorded as cured; of these, 83/205 (39.9%) were in the control arm compared to 85/195 (43.6%) in the intervention arm. The OR of being cured was 1.16 (95% CI: 0.83,1.63) in the intervention versus the control arm; and was similar to the adjusted OR. (Tables 3 and 4)

> Continuous smoking abstinence

Among those who identified as cigarette smokers at baseline (345 (60.1%)), 27 had information (self-report plus biochemical verification) to enable the identification of continuous abstinence at 6-months of which 22 had continuously abstained from smoking. These were similarly distributed across the two study arms: 10 (5.59%) participants in the intervention arm compared to 12 (7.23%) in the control arm, OR 0.76 (95% CI: 0.35,1.63). (Tables 3 and 4) At the 3-month follow-up 20 (11.2%) participants in the intervention arm compared to 27 (16.3%) in the control arm continuously abstained from smoking, OR 0.65 (95% CI: 0.37,1.14). (Tables 3 and 5)

 BMJ Open

	Baseline n (%)*				-months follow-u	р		6-months follow-ւ n (%)*	р
	Control	Intervention	Total	Control	Intervention	Total	Control	Intervention	Total
TB treatment status ^a									
Successful**							204 (70.1)	192 (67.8)	396 (69.0
Not Successful							87 (29.9)	91 (32.16)	178 (31.0
Cured ^{a, ***}									
Yes							83 (39.9)	85 (43.6)	168 (41.7
No							125 (60.1)	110 (56.4)	235 (58.3
Continuous smoking abstinence ^b				ST p					
Yes				27 (16.3)	20 (11.2)	47 (13.6)	12 (7.2)	10 (5.6)	22 (6.4)
No				139 (83.7)	159 (88.8)	298 (86.4)	154 (92.8)	169 (94.4)	323 (93.6
Harmful/hazardous drinkers [!] : N =	188†	206†	394†	141†	130†	271†	112†	127†	239†
AUDIT score: mean (SD)	12.76 (3.42)	13.12 (3.47)	12.94 (3.45)	8.28 (6.18)	8.84 (5.38)	8.55 (5.81)	8.79 (6.66)	8.70 (5.83)	8.74 (6.22)
Difference from baseline: mean (SD)				-4.61 (6.26)	-4.07 (5.33)	-4.35 (5.83)	-4.25 (6.56)	-4.17 (6.61)	-4.21 (6.57)
HIV positive patients:	163† (56.2)	142† (50.2)	305† (53.2)	122†	83†	205†	100†	83†	183†
Taking ART medication if HIV positive‡	139 (85.3)	115 (81.0)	254 (83.3)	91 (74.6)	58 (69.9)	149 (72.7)	80 (80.0)	74 (89.2)	154 (84.2

ART adheren	medication							
	nal adherence		101 (99.0)	64 (98.5)	165 (98.8)	75 (97.4)	64 (97.0)	139 (97.2)
·	Suboptimal adherence		1 (1.0)	1 (1.54)	2 (1.2)	2 (2.6)	2 (3.0)	4 (2.8)
TB adhere	medication ence	~						
Optin	nal adherence		181 (92.3)	138 (90.8)	319 (91.7)	61 (89.7)	59 (90.8)	120 (90.2)
	Suboptimal adherence		15 (7.6)	14 (9.2)	29 (8.3)	7 (10.3)	6 (9.2)	13 (9.8)
***Based o ! hazardous †Denomina	han 2 months, or outcome not evaluated on having a cured treatment outcome a is/harmful drinkers who are not alcohol ator for the mean (SD) or denominator f ion on HIV-positivity was obtained from	mong those who were bacteriolog dependent= AUDIT score ≥ 8 for n or %	nen or≥7 for women bi	ut < 20; *! Important d				
***Based o ! hazardous †Denomina	on having a cured treatment outcome a is/harmful drinkers who are not alcohol ator for the mean (SD) or denominator f	mong those who were bacteriolog dependent= AUDIT score ≥ 8 for n or %	nen or≥7 for women bi	ut < 20; *! Important d				

	Crude Odds Ratio	P Value*	Adjusted Odds Ratio	Р
	(95% CI)*		(95% CI)*	Value*
Primary outcome				
TB treatment status: Successful (Ref: Not successful)	0.90 (0.64,1.27)	0.548	0.86‡ (0.60,1.24)	0.421
Secondary outcomes				
Cured (Ref: Not Cured)	1.16 (0.83,1.63)	0.374	1.07‡ (0.76,1.51)	0.684
Continuous smoking abstinence (Ref: No)***	0.76 (0.35,1.63)	0.482		
TB medication adherence (Ref: Optimal)	0.89 (0.26,3.07)	0.849		
ART medication adherence (Ref: Optimal)	1.17 (0.14,9.94)	0.884		
Taking ART medication (Ref: No)	2.05 [!] (0.80,5.27)	0.136		
AUDIT	-0.04** (-2,1.91)	0.966	0.02 ^{!!} (-1.55,1.6)	0.976

* Analyses accounted for potential clustering by centre.

+ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable.

! Adjusting for art status at baseline

**Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

TABLE 4 Regression analysis results for the primary and secondary outcomes at 6-months

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

***Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.73 and 0.76 with similar confidence limits as for the crude estimate.

Secondary outcome	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*
Continuous smoking abstinence (Ref: No)**	0.65 (0.37,1.14)	0.135		
TB medication adherence (Ref: Optimal)	1.22 (0.52,2.87)	0.641		
ART medication adherence (Ref: Optimal)	1.58 (0.10,26.12)	0.750		
Taking ART medication (Ref: No)	0.79 [!] (0.38,1.65)	0.53	0.74‡ (0.35,1.58)	0.443
AUDIT	0.55† (-1.01,2.11)	0.474	0.74" (-0.62,2.1)	0.273

*Analyses accounted for clustering.

Adjusting for art status at baseline

‡ Adjusted for art status at baseline, district, sex, and smoking/drinking status and HIV status at baseline.

⁺Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

** Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.63 and 0.66 with similar confidence limits as for the crude estimate.

Page 131 of 155

3	373	Change in harmful/hazardous drinking
4 5	374	AUDIT scores were about 4 points lower at both follow-up times than at baseline, independent of
6	375	the intervention.(Table 3) In the intervention arm, participants had, on average, a reduction of 0.04
7 8	376	points (95% CI: -2,1.91) on the AUDIT score at 6-months, compared to those in the control arm
9 10		
11	377	controlling for baseline scores; whereas an average increase of 0.55 (95% CI: -1.01,2.11) was
12 13	378	observed at 3-months. (Tables 4 and 5)
14 15	379	
16	380	Medication adherence and ART uptake
17 18	381	At 6-months, the OR of taking ART medication was 2.05 (95% CI: 0.80,5.27) comparing the
19	382	intervention arm to the control arm and controlling for ART baseline medication status; whereas it
20 21	383	was 0.79 (95% CI: 0.38,1.65) at 3-months. The proportion of participants who had optimal TB
22 23	384	medication adherence was 90.2% (120/133) at 6-months and 91.7% (319/348) at 3-months.
24	385	Suboptimal TB medication adherence ORs were 0.89 (95%CI: 0.26,3.07) and 1.22 (95%CI: 0.52,2.87)
25 26	386	comparing intervention arm to the control arm at 6-months and 3-months, respectively. The
27 28	387	proportions of participants on ART who had optimal ART medication adherence were high at both 3-
29	388	months (165/167, 98.8%) and 6-months follow-up (139/143, 97.2%). Suboptimal ART medication
30 31	389	adherence ORs were 1.17 (95%CI: 0.14,9.94) and 1.58 (95%CI: 0.10,26.12) comparing the
32 33	390	intervention arm to the control arm at 6-months and 3-months, respectively. (Tables 3, 4 and 5)
34	391	
35 36	392	Intervention fidelity
37 38	393	Motivational interviewing fidelity
39	394	The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In terms
40 41	395	of the global ratings, the LHWs' counselling sessions were above proficiency levels on all items,
42 43	396	namely, cultivating change talk, softening sustain talk, partnership, and empathy (as the mean scores
44	397	were all above 2). In terms of the summary measures, the LHWs' counselling sessions did not
45 46	398	achieve the basic proficiency threshold of 3.5 for the Relational component (Partnership + Empathy)
47 48	399	as their mean score was 3.1 (SD=1.19). However, their mean score on the Technical component
	222	as then mean score was 5.1 (5D-1.15). However, then mean score on the reclinical component
49	400	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For
49 50		
49 50 51 52	400	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For
49 50 51 52 53 54	400 401	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by
49 50 51 52 53	400 401 402	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by "Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the
49 50 51 52 53 54 55 56 57	400 401 402 403	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by "Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions
49 50 51 52 53 54 55 56 57 58 59	400 401 402 403 404	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by "Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize
49 50 51 52 53 54 55 56 57 58	400 401 402 403 404 405	(Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by "Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize Autonomy and Seek Collaboration) and 1.2 (SD=2.28) MI non-adherent (Confront and Persuade)

1 2		
3	407	
4 5	408	SMS-delivery
6 7	409	Of the total number of Information-Motivation-Behaviour messages triggered, 3583 (80.4%) were
8 9	410	delivered. All due SMS messages were delivered to 95 (41.9%) of the participants who completed
10	411	the first MI, See Supplementary Table 5 for more details.
11 12	412	
13 14	413	Costs and health related quality of life
15	414	Unit costs used to estimate the mean costs are presented in the Supplementary Table 6. Incremental
16 17	415	<u>c</u> Cost-utility ratios are not presented since the intervention was not <u>clinically</u> effective. The mean
18 19	416	cost of the ProLife intervention was ZAR 2601 (SD 6) (\$180.02 (SD \$0.42)) per participant in the
20	417	intervention arm (n=283). The mean cost of usual care was ZAR 681 (SD 357) (\$47.13 (SD \$24.71)) in
21 22	418	the intervention arm (n=122) versus ZAR 706 (SD 302) (\$48.86 (SD \$20.90)) in the control arm
23 24	419	(n=131). The total mean cost of care including the intervention was ZAR 3285 (SD R357) (\$227.37 (SD
25	420	24.71)) in the intervention arm (n=122). EQ-5D-3L data were available at the 3 time points for 137
26 27	421	intervention and 159 control arm participants. The mean QALYs estimated over six months were
28 29	422	0.442 (SD 0.061) in the intervention arm versus 0.430 (SD 0.074) in the control arm (adjusted mean
30	423	difference 0.006 (95% Cl -0.001 to 0.013)).
31 32	424	
33 34	425	difference 0.006 (95% CI -0.001 to 0.013)). DISCUSSION
35 36	426	
37	427	This RCT did not finprovided evidence for improved TB treatment success rates in those receiving the
38 39	428	ProLife intervention compared to those receiving usual care. We could also There was also not
40 41	429	demonstrate significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol
42	430	consumption, medication adherence and ART initiation. To our knowledge there are no other
43 44	431	published studies of similar complex interventions that aim to improve TB treatment outcomes in
45 46	432	patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other
47	433	studies were either complex interventions or complex-SMS-based interventions aimed at improving
48 49	434	TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking
50 51	435	intervention component (43,44) or <u>or</u> focused on a single behaviour, namely smoking or
52	436	drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in
53 54	437	inducing smoking cessation in TB-patients with TB but did not improve TB outcomes.(45) Conversely,
55 56	438	in another study in India, intensive counselling for alcohol disorders led to significantly better TB
20		
57	439	treatment outcomes in the intervention group compared to the control group.(46) Smoking
57 58 59 60	439 440	treatment outcomes in the intervention group compared to the control group.(46) Smoking cessation also led to better TB treatment outcomes in a secondary analysis of a large tobacco

BMJ Open

cessation trial in TB-patients with TB in Bangladesh and Pakistan.(47) Our non-significant result for smoking-related outcomes is not consistent with findings from our previous TB study, which used a single MI session and found that the chance of sustained smoking cessation was twice as high in the MI intervention group compared to the control group,(14) albeit with a less stringent exhaled CO cut-off point. Evidence on the effectiveness of MI for smoking abstinence in non-TB settings has been equivocal.(48) Self-reported alcohol consumption decreased with about 4 points in both intervention and control arms in our study at both follow-up times. Answering questions on drinking in brief intervention trials may alter subsequent self-reported behaviour.(51): eExposing non-intervention control groups to an integral component of the intervention may therefore underestimate the effect of the intervention.(49) There have been few previous studies looking at MI and SMS interventions for the modification of hazardous/harmful drinking in the context of TB. A previous trial of a brief counselling intervention to reduce alcohol consumption in patients with TB did not find a significant effect on alcohol reduction.(50) Outside a TB setting, results have been mixed. A meta-analysis showed a small but significant improvement in outcomes when MI was used in conjunction with cognitive behavioural therapy for co-morbid alcohol use and depression.(51) Self-reported TB and ART medication adherence was high overall in ourthis study population, which is consistent with other studies conducted in South Africa.(52,53) It is possible that we did not find a difference in treatment adherence due to a ceiling effect.

There were several key strengths in this RCT. This was an individually RCT with a relatively large sample size and a high follow up rate (87%) for the primary outcome. Primary outcome assessment was blinded. This was a novel intervention, which built on previous successes with both MI and mHealth interventions and was aligned with the WHO's call to increase the use of digital technologies to improve TB care.(15) We utilized a validated alcohol consumption questionnaire (AUDIT) (29) and a four-day timeline follow-back for medication adherence to reduce recall bias as self-reports tend to underreport drinking while overestimating adherence behaviour compared with.(54) (35) Smoking cessation was confirmed with exhaled CO using strict cut-off points. Overall, the quality of the counselling was acceptable. The results of our MI analyses suggest that the LHWs trained as counsellors were more proficient in MI than during the feasibility stage, as observed by their global rating scores on cultivating change talk, softening sustain talk, partnership and empathy. (Supplementary Table 4) These results were achieved by ongoing monitoring and training of LHWs during the trial and adapting the training based on feedback from the feasibility stage. Extra counsellors were also appointed to minimise travel distances to clinics. There were some limitations associated with this RCT. Trial recruitment had to be terminated before the planned sample size

because of funding and time constraints. Nevertheless the calculation of sample size was based on an anticipated 25% LTFU for the primary outcome, while in reality only 13.4 %, of the TB outcomes were not available. As a result, we achieved a slightly higher power to detect the a 10% difference in primary outcomes, than we had aimed for (83% vs. 80%). The smaller sample size did however reduce the power to detect a difference for secondary outcomes for which the LTFU was much higher than 25%. Also, the calculated sample size was not powered for subgroup analysis which was the case for outcomes relating to smoking, drinking, ART and cure rates. In addition, due to COVID-19 lockdown in March 2020, we had to switch to telephonic follow-up of participants using a shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB treatment outcomes. The low intervention uptake meant that half of the participants received only one or two MI sessions combined with SMS messages. SMS messages were only used for the first half of the study period, and one quarter of participants did not receive their messages, a commonly occurring problem in developing countries.(20,55) It could be argued that in the absence of ongoing text messages, the MI and associated text messages were not enough to keep participants focussed for the second three months of the trial. The 2-arm study design did not permit the untangling of the individual effects of SMS and MI. Understanding their separate effects could have important cost implications as SMS-communication would be cheaper and easier to organise than individual 1.04 counselling. The lack of effectiveness of our intervention consisting of three sessions of MI combined with SMS on the primary outcome (TB treatment success) can have a number of possible explanations.

Although intervention uptake was high (80.2%) for the first counselling session, many participants did not return for the second (29.7%) and third (47%) sessions. As a result of this only about half of the intervention arm participants received all three MI sessions. Furthermore, about one quarter of all participants did not receive any SMS-messages. Low intervention uptake leads to a dilution of any potential effects. There were a number of possible technical barriers to SMS delivery: invalid phone numbers, phones that are off for a long duration of time, numbers that are deactivated, and phones that are disconnected from the network leading.(41) The proportion of participants with TB treatment outcomes recorded was high, but follow-up rates at 3- and 6-months were low. Due to COVID-19 lockdown, we had to switch to telephonic follow-up of participants using a shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB treatment outcomes.

BMJ Open

1 2		
3 4	509	
5	510	The lack of effectiveness on TB treatment success couldmay perhaps also be explained by the
6 7	511	complexity of the ProLife intervention itself: counsellors had to address multiple behaviours, namely
8 9	512	medication adherence, tobacco smoking and hazardous/harmful drinking. This integrated approach
10	513	was nevertheless adopted to avoid the need for multiple vertical counselling services (in addition to
11 12	514	TB treatment and HIV treatment), to allow the different elements of the programme to reinforce
13 14	515	one another, and to improve the affordability, feasibility and acceptability for a future roll-out of the
15	516	programme. Despite having established the feasibility and acceptability of this approach_ $_{7}$ (31) and
16 17	517	ongoing on site performance monitoring and feedback of counsellors, it is possible that MI for
18 19	518	multiple behaviour change in the ProLife study was counterproductive as counsellors may have
20	519	ended up not focusing on any of the behaviours at optimal levels. Similarly, patients might have
21 22	520	found it difficult to change multiple behaviours simultaneously, especially because smoking and
23 24	521	drinking are mutually reinforcing. This integrated approach was nevertheless adopted to avoid the
25	522	need for multiple vertical counselling services (in addition to TB treatment and HIV treatment), to
26 27	523	allow the different elements of the programme to reinforce one another, and to improve the
28 29	524	affordability, feasibility and acceptability for a future roll-out of the programme. It is also possible
30 31	525	There is some indirect evidence that sequential interventions may be better, at least for smoking
32	526	cessation.(56) More intensive counselling (more sessions) or a modified counselling method with or
33 34	527	without MI may have been more appropriate, even more so since a recent review of reviews of MI
35 36	528	<u>casts doubt on its efficacy</u> .(48,57,58) For example <u>, m</u> , more emphasis on increasing patient
37	529	knowledge in addition to increasing self-efficacy may have been more effective.(59) The cause of the
38 39	530	mobile health message delivery problems (such as poor network coverage, no electricity to charge
40 41	531	phones)_(60)_would need to be investigated in order to increase the effectiveness of future mHealth
42	532	interventions. Messages may also have to be intensified or modified to be more interactive and/or
43 44	533	tailored to specific circumstances of each individual. This would improve the personal value of the
45 46	534	intervention to the individual, which is likely to increase the chances of their participation in the
47	535	intervention.(61) Consistent with the normalisation process theory,(62) cognitive participation in the
48 49	536	intervention might have been higher had we been deliberate in the implementation to ensure the TB
50 51	537	nurse who would have routinely seen the participants, provided additional support and motivated
52	538	participants to attend MI sessions with the counsellor. In this way, the intervention would have
53 54	539	gained 'legitimacy' but this would have led to unblinding of the nurses to the intervention arm.
55 56	540	
57	541	In conclusion, Thwe could not demonstrate that the ProLife intervention was is RCT provided
58 59	542	evidence that the ProLife intervention was not effective in modifying the primary o improving TB
60	1	

treatment outcomes. This may be due to the lack of effect of the intervention, but r-the study may also have been underpowered for the intermediary secondary outcomessecondary outcomes. Valuable lessons were learnt on challenges relating to training LHWs in MI counselling and delivery, the-SMS-delivery in a challenging socio-economic context and the reasons for loss to follow-up of TB participants with multiple health problems. Further research is needed to provide answers on how to increase intervention uptake in poor resource settings and whether our complex intervention should have been more intensive (with several sessions for each behavioural problem). Other important questions are whether another counselling method would have been more effective. Lastly, in the light of the already existing evidence of SMS and the costs and implementation challenges relating to MI, intervention studies limited to an mHealth intervention but using different intensities, duration and type of interventions (oneway, twoway, interactive) are needed.

Acknowledgements

We are grateful to the following people: Ms M Malefo for her work as project manager, Ms D Bell for conducting the MI training, Ms N Kitleli for supervising the lay counsellors, Mesadie Machaea-Malinga for conducting the fidelity assessments, the district and clinic TB managers and TB nurses, the fieldworkers and the lay counsellors. The authors are also grateful to the National Department of Health and the three Provincial Departments of Health for granting permission for this study.

Contributors

GML has led on study design and manuscript preparation and contributed to the monitoring of the study implementation. MK contributed to study design and the manuscript, led on the sample size determination and did the statistical analysis. NKM contributed to study design, particularly with respect to development of the MI intervention, did the analysis of the MI data and contributed to the manuscript writing. AVZ led the data management and SMS-system, monitored data quality and contributed to data analysis and manuscript writing. ASM contributed to study design and led on the preparation of the manuscript. NDM contributed to study design, intervention development and manuscript preparation. JL and SP led on the economic evaluation. AT contributed to the economic evaluation. JT was site lead for the Bojanala sub-district. OBO was site lead for the Sedibeng sub-district. MOB contributed to study design, data interpretation and the manuscript. KS and OAA are co-principal investigators. Both contributed to study design, data interpretation and manuscript writing. All authors read and approved the final draft of the manuscript.

Funding

This project was funded by the SA-Medical Research/Newton Foundation Grant on TB control implementation science. (UK/South Africa Newton Fund RFA: TB control implementation science (MRC-RFA-02: TB -05-2015)). This UK funded award is part of the EDCTP2 programme supported by the European Union.

The funder had no role in study design; collection, management, analysis, and interpretation of data; writing of the report or the decision to submit the report for publication.

Trial sponsor: Sefako Makgatho Health Sciences University, RSA. Contact: lekan.ayo-yusuf@smu.ac.za

1 2		
3 4	589	
5	590	Competing interests
6 7	591	OA Ayo-Yusuf, the principal investigator, received a research grant (MRC-RFA-02: TB -
8 9	592	05-2015) which was allocated to Sefako Makgatho Health Sciences University to pay
10 11	593	for the expenses related to the research project. As co-prinicipal investigator K Siddiqi
12	594	received part of the MRC-Newton research grant (MRC-RFA-02: TB -05-2015) which
13 14	595	was allocated to the University of York to support the research by the authors
15 16	596	affiliated to the University of York (K Siddiqi, ND Mdege, M Kanaan, S Parrot, J Lee).
17	597	Goedele Louwagie received a small monthly remuneration per month from 1 October
18 19	598	2018 until 30 June 2020 as academic research coordinator. André van Zyl was
20 21	599	employed as a research data manager on a part-time basis from 1 September 2017
22	600	and 30 June 2020. OA Ayo-Yusuf received support for attending meetings and for
23 24	601	travel by Tax Justice Network Africa. He is the Vice Chair of the Standing Committee on
25 26	602	Health, Academy of Science, SA (not remunerated). The remaining authors declare no
27	603	competing interests.
28 29	604	
30 31	605	Ethical considerations
32 33	606	This study received ethics approval from the Research Ethics Committees of: Sefako
34 35	607	Makgatho Health Sciences University (SMU; Ref: SMUREC/D/234/2017: IR); the South
36	608	African Medical Research Council (with the SMU Ethics Committee serving as the
37 38	609	Research Ethics Committee Record); the University of Pretoria (Ref: 434/2017); the
39 40	610	University of Witwatersrand (M160455); and the University of York (no reference
41	611	number, approval date 15 January 2017 (29).
42 43	612	number, approval date 15 January 2017 (29).
44 45	613	Patient Consent for publication
46 47	614	Not applicable
48 49	615	
49 50 51	616	Data aAvailability statementof data and material
52	617	The study protocol was previously published (ImPROving TB outcomes by modifying
53 54	618	LIFE-style behaviours through a brief motivational intervention followed by short text
55 56	619	messages (ProLife): study protocol for a randomised controlled trial). The de-identified
57	620	participant and SMS data sets are stored in labelled Stata files and are accompanied by
58 59	621	a statistical analysis plan and metadata explaining each variable. Although data can be
60	I	

3	622	viewed immediately, data will be embargoed for data analysis until 30 June 2023.
4 5	623	Thereafter, permission must be obtained from the principal investigators (OA and KS)
6 7	624	for any data analysis not yet performed by the primary research group. Data are
8	625	stored in the institutional data repository at Sefako Makgatho Health Sciences
9 10	626	University called Discover research (https://smu-za.figshare.com/) with a CC-BY 4.0
11 12	627	(Attribution) license (Creative Commons — Attribution 4.0 International — CC BY
13 14	628	4.0). The statistical analysis plan are available as supplementary material.
15	629	Data are stored in the institutional data repository at Sefako Makgatho Health
16 17	630	Sciences University called Discover research (<u>https://smu-za.figshare.com/</u>). Data
18 19	631	access will be embargoed until 30 June 2023.
20 21	632	
22 23	633	Open access
24	634	This is an open access article distributed in accordance with a Creative Commons
25 26	635	Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix,
27 28	636	transform and build upon this work for any purpose, provided the original work is
29 30	637	properly cited, a link to the licence is given and indication of whether changes were
31	638	made. See: https://creativecommons.org/licenses/by/4.0/.
32 33	639	
34 35	640	References
35 36	640 641	References1.World Health Organisation. Global tuberculosis report 2020. Available:
35 36 37 38		
35 36 37	641	1. World Health Organisation. Global tuberculosis report 2020. Available:
35 36 37 38 39 40 41	641 642	1.World Health Organisation. Global tuberculosis report 2020. Available:https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
35 36 37 38 39 40 41 42 43	641 642 643	1. World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021].
35 36 37 38 39 40 41 42 43 44 45	641 642 643 644	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the
35 36 37 38 39 40 41 42 43 44	641 642 643 644 645	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyg</i> 2016;110:145–7.
35 36 37 38 39 40 41 42 43 44 45 46 47 48	641 642 643 644 645 646	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyg</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507.
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	641 642 643 644 645 646 647	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyg</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i>
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	641 642 643 644 645 646 647 648 649 650	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyg</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507.
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	641 642 643 644 645 646 647 648 649 650 651	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyq</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. <i>Eur Respir J</i> 2017;50: 1700216. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	 641 642 643 644 645 646 647 648 649 650 651 652 	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyg</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. <i>Eur Respir J</i> 2017;50: 1700216. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990–2016. <i>Tropical Medicine and Health</i> 2018;46:34.
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	641 642 643 644 645 646 647 648 649 650 651 651 652 653	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyq</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. <i>Eur Respir J</i> 2017;50: 1700216. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990–2016. <i>Tropical Medicine and Health</i> 2018;46:34. Azeez A, Mutambayi R, Odeyemi A, et al. Survival model analysis of tuberculosis treatment
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	 641 642 643 644 645 646 647 648 649 650 651 652 653 654 	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyg</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. <i>Eur Respir J</i> 2017;50: 1700216. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990–2016. <i>Tropical Medicine and Health</i> 2018;46:34. Azeez A, Mutambayi R, Odeyemi A, et al. Survival model analysis of tuberculosis treatment among patients with human immunodeficiency virus coinfection. <i>Int J Mycobacteriol</i>
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58	641 642 643 644 645 646 647 648 649 650 651 651 652 653	 World Health Organisation. Global tuberculosis report 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf [Accessed 4 Aug 2021]. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the Sustainable Development Goals. <i>Trans R Soc Trop Med Hyq</i> 2016;110:145–7. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. <i>PLoS ONE</i> 14(7):e0220507. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. <i>Eur Respir J</i> 2017;50: 1700216. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990–2016. <i>Tropical Medicine and Health</i> 2018;46:34. Azeez A, Mutambayi R, Odeyemi A, et al. Survival model analysis of tuberculosis treatment

2			
3 4 5 6 7 8 9 10 11 12	656	7.	Mollel EW, Chilongola JO. Predictors for Mortality among Multidrug-Resistant Tuberculosis
	657		Patients in Tanzania. J Trop Med 2017;2017:9241238. doi: 10.1155/2017/9241238.
	658	8.	Peltzer K. Conjoint alcohol and tobacco use among tuberculosis patients in public primary
	659		healthcare in South Africa. S Afr J Psychiatr 2014;20(1):21–6.
	660	<u>9.</u>	Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis
	661		treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis
13 14	662		<u>2020;24(1):73–82.</u>
15	663	<u>10.</u>	Department of Health of South Africa. National Tuberculosis Management Guidelines.
16 17	664		Pretoria: 2014. Available from:
18 19 20	665		http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-
	666		27.5.2014.pdf [Accessed 4 Aug 2021].
21 22	667	<u>11.</u>	Harder VS, Musau AM, Musyimi CW, et al. A randomized clinical trial of mobile phone
23 24	668		motivational interviewing for alcohol use problems in Kenya. Addiction 2020;115:1050-1060.
25	669	<u>12.</u>	Palacio A, Garay D, Langer B, et al. Motivational Interviewing Improves Medication
26 27	670		Adherence: a Systematic Review and Meta-analysis. Gen Intern Med. 31:929–40. DOI:
28 29	671		<u>10.1007/s11606-016-3685-3.</u>
30	672	<u>13.</u>	Madhombiro M, Kidd M, Dube B, et al. Effectiveness of a psychological intervention delivered
31 32	673		by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster
33 34	674		randomized controlled trial. J Int AIDS Soc 2020 Dec;23:e25641.
35	675	<u>14.</u>	Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on
36 37	676		smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomized controlled
38 39	677		trial. Addiction 2014;109:1942–52
40	678	<u>15.</u>	World Health Organization. Handbook for the use of digital technologies to support
41 42 43 44 45	679		tuberculosis medication adherence, 2017. Available:
	680		https://apps.who.int/iris/handle/10665/259832 [Accessed 4 Aug 2021].
	681	<u>16.</u>	Hirsch-Moverman Y, Daftary A, Yuengling KA, et al. Using mhealth for HIV/TB treatment
46 47	682		support in lesotho: Enhancing patient-provider communication in the start study. J Acquir
48 49	683		Immune Defic Syndr 2017;74:S37–43.
50 51 52 53 54 55 56 57	684	<u>17.</u>	Shah R, Watson J, Free C. A systematic review and meta-analysis in the effectiveness of
	685		mobile phone interventions used to improve adherence to antiretroviral therapy in HIV
	686		infection. BMC Public Health 2019;19:915.
	687	<u>18.</u>	Gashu KD, Gelaye KA, Mekonnen ZA, et al. Does phone messaging improves tuberculosis
	688		treatment success? A systematic review and meta-analysis. BMC Infect Dis 2020;20:42.
58 59	689	<u>19.</u>	Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on
60	1		

1 2			
2 3 4 5 6 7	690		tuberculosis treatment: a systematic review. Eur Respir J. 2018 11;51(1):1701596. doi:
	691		10.1183/13993003.01596-2017
	692	20.	Ggita JM, Ojok C, Meyer AJ, et al. Patterns of usage and preferences of users for tuberculosis-
8	693		related text messages and voice calls in Uganda. Int J Tuberc Lung Dis 2018;22:530-536.
9 10 11 12 13	694	21.	Oosterveen E, Tzelepis F, Ashton L, et al. A systematic review of eHealth behavioral
	695		interventions targeting smoking, nutrition, alcohol, physical activity and/or obesity for young
	696		adults. Prev Med 2017;99:197–206.
14 15	697	<u>22.</u>	Haug S, Paz Castro R, Kowatsch T, et al. Efficacy of a technology-based, integrated smoking
16 17	698		cessation and alcohol intervention for smoking cessation in adolescents: Results of a cluster-
18 19	699		randomised controlled trial. J Subst Abuse Treat 2017;82:55–66.
20	700	23.	Siddiqi K, Stubbs B, Lin Y, et al. TB multimorbidity: a global health challenge demanding
21 22	701		urgent attention. Int J Tuberc Lung Dis 2021;25:87–90.
23 24	702	<u>24.</u>	Moosa S, Derese A, Peersman W. Insights of health district managers on the implementation
25	703		of primary health care outreach teams in Johannesburg, South Africa: A descriptive study
26 27	704		with focus group discussions. Hum Resour Health 2017;15:1–9.
28 29	705	<u>25.</u>	Marcus TS, Hugo J, Jinabhai CC. Which primary care model? A qualitative analysis of ward-
30	706		based outreach teams in South Africa. African J Prim Heal Care Fam Med 2017;9:1-8.
31 32	707	<u>26.</u>	Seidman G, Atun R. Does task shifting yield cost savings and improve efficiency for health
33 34	708		systems? A systematic review of evidence from low-income and middle-income countries.
35	709		Hum Resour Health 2017;15:1–13.
36 37	710	<u>27.</u>	Heunis C, Wouters E, Kigozi G, et al. TB/HIV-related training, knowledge and attitudes of
38 39	711		community health workers in the Free State province, South Africa. African J AIDS Res
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	712		2013;12:113–9.
	713	<u>28.</u>	World Health Organization & Centers for Disease Control (U.S.). Tobacco questions for surveys: a
	714		subset of key questions from the Global Adult Tobacco Survey (GATS): global tobacco surveillance
	715		system. World Health Organization 2011. Available from:
	716		https://apps.who.int/iris/handle/10665/87331 [Accessed 16 Nov 2021]
	717	<u>29.</u>	Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT):
	718		validation of a screening instrument for use in medical settings. <i>J Stud Alcohol</i> 1995;56:423–
	719		<u>32.</u>
	720	<u>30.</u>	Moriarty AS, Louwagie GM, Mdege ND, et al. ImPROving TB outcomes by modifying LIFE-style
54			
55	721		behaviours through a brief motivational intervention followed by short text messages
55 56 57	721 722		(ProLife): Study protocol for a randomised controlled trial. Trials 2019;20:1–12.
55 56	721	<u>31.</u>	

1

1 2			
3 4	725		Transl Behav Med 2020; 10: 1491–1503.
5	726	<u>32.</u>	CommCare. Cambridge, MA: Dimagi; 2017. Available from:
6 7	727		https://play.google.com/store/apps/details?id=org.commcare.dalvik&hl=en_US≷=US.
8 9	728		[Accessed 15 June 2021].
10	729	<u>33.</u>	Siddiqi K, Khan A, Ahmad M, et al. Action to stop smoking in suspected tuberculosis (ASSIST)
11 12	730		in Pakistan: a cluster randomized, controlled trial. Ann Intern Med 2013;158:667–75.
13	731	<u>34.</u>	West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: proposal for a
14 15	732		common standard. Addiction 2005;100:299–303.
16 17	733	<u>35.</u>	van den Boogaard J, Lyimo RA, Boeree MJ, et al. Electronic monitoring of treatment
18	734		adherence and validation of alternative adherence measures in tuberculosis patients: A pilot
19 20	735		study. Bull World Health Organ 2011;89:632–9.
21 22	736	<u>36.</u>	OECD [Internet]. Available from: https://data.oecd.org/conversion/exchange-rates.htm
23 24	737		[Accessed 26 Oct 2021]
25	738	<u>37.</u>	Augustovski FA, Irazola VE, Velazquez AP, et al. Argentine valuation of the EQ-5D health
26 27	739		states. Value Heal 2009;12:587–96.
28 29	740	<u>38.</u>	StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.
30	741	<u>39.</u>	Team RC. R: A language and environment for statistical computing. Vienna, Austria: R
31 32	742		Foundation for Statistical Computing; 2017. Available from: https://www.r-project.org/
33 34	743		[Accessed 04 Aug 2021]
35	744	<u>40.</u>	Moyers TB, Rowell LN, Manuel JK, et al. The Motivational Interviewing Treatment Integrity
36 37	745		Code (MITI 4): Rationale, Preliminary Reliability and Validity. J Subst Abuse Treat 2016;65:36-
38 39	746		42. doi:10.1016/j.jsat.2016.01.001
40	747	<u>41.</u>	International Monetary Fund. IMF DataMapper - GDP per capita, current prices (Purchasing
41 42	748		power parity; international dollars per capita), 2018. Available from:
43 44	749		https://www.imf.org/external/datamapper/datasets [Accessed 04 Aug 2021]
45	750	<u>42.</u>	Richardson GMA. Calculation of quality adjusted life years in the published literature: a
46 47	751		review of methodology and transparency. <i>Health Econ</i> 2004;13:1203–10.
48 49	752	<u>43.</u>	Khachadourian V, Truzyan N, Harutyunyan A, et al. People-centred care versus clinic-based
50	753		DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. BMC Pulm
51 52	754		<u>Med 2020;20:105.</u>
53 54	755	<u>44.</u>	Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to
55	756		tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA
56 57	757		<u>2007;297:380–6.</u>
58 59	758	<u>45.</u>	Goel S, Kathiresan J, Singh P SR. Effect of a brief smoking cessation intervention on adult
60	I		

Page 143 of 155

1 2 BMJ Open

2			
3 4	759		tobacco smokers with pulmonary tuberculosis: A cluster randomized controlled trial from
5	760		North India. Indian J Public Heal 2017;61(Suppl 1):S47–53
6 7	761	46.	Manogaran C, Nagarajan K, Ovung S, et al. Alcohol intervention strategy among tuberculosis
8 9	762		patients: a pilot study from South India. Int J Tuberc Lung Dis 2017;21:947-52
10	763	<u>47.</u>	Siddiqi K, Keding A, Marshall AM, et al. Effect of quitting smoking on health outcomes during
11 12	764		treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial. Thorax 2021
13 14	765		Published Online First Jul 16:thoraxjnl-2020-215926. doi: 10.1136/thoraxjnl-2020-215926.
15	766	<u>48.</u>	Lindson N, Thompson TP, Ferrey A, et al. Motivational interviewing for smoking cessation.
16 17	767		Cochrane Database Syst Rev. 2019;2019(7).
18	768	<u>49.</u>	McCambridge J, Kypri K. Can simply answering research questions change behaviour?
19 20	769		Systematic review and meta analyses of brief alcohol intervention trials. PLoS One
21 22	770		<u>2011;6(10):e23748.</u>
23 24	771	<u>50.</u>	Peltzer K, Naidoo P, Louw J, et al. Screening and brief interventions for hazardous and
25	772		harmful alcohol use among patients with active tuberculosis attending primary public care
26 27	773		clinics in South Africa: results from a cluster randomized controlled trial. BMC Public Health
28 29	774		2013;13:699.
30	775	<u>51.</u>	Riper H, Andersson G, Hunter SB, et al. Treatment of comorbid alcohol use disorders and
31 32	776		depression with cognitive-behavioural therapy and motivational interviewing: a meta-
33 34	777		analysis. Addiction 2014;109:394–406.
35	778	<u>52.</u>	Moosa A, Gengiah TN, Lewis L, et al. Long-term adherence to antiretroviral therapy in a South
36 37	779		African adult patient cohort: a retrospective study. BMC Infect Dis 2019;19(1):775. doi:
38 39	780		<u>10.1186/s12879-019-4410-8.</u>
40	781	<u>53.</u>	Webb Mazinyo E, Kim L, Masuku S, et al. Adherence to Concurrent Tuberculosis Treatment
41 42	782		and Antiretroviral Treatment among Co-Infected Persons in South Africa, 2008–2010. PLoS
43 44	783		<u>One 2016;11(7): e0159317. https://doi.org/10.1371/journal.pone.0159317.</u>
45	784	<u>54.</u>	Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence
46 47	785		behavior: recommendations on optimal use. Transl Behav Med 2015;5:470-82.
48 49	786	<u>55.</u>	Wanyama JN, Nabaggala SM, Kiragga A, et al. High mobile phone ownership but low internet
50	787		access and use among young adults attending an urban HIV clinic in Uganda. Vulnerable Child
51 52	788		<u>Youth Stud 2018;13:3,207-20.</u>
53 54	789	<u>56</u> .	Meader N, King K, Wright K et al. Multiple risk behavior interventions: Meta-analyses of
55	790		RCTs. Am J Prev Med 2017;53:e19-e30.
56 57	791	<u>57.</u>	Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions.
58 59	792		Health Psychol 2008;27:379-87.
60	I		

3	793	58.	Frost H, Campbell P, Maxwell M, et al. Effectiveness of Motivational Interviewing on adult
4 5	794		behaviour change in health and social care settings: A systematic review of reviews. PLoS One
6 7	795		<u>2018;18:13(10):e0204890</u>
8	796	<u>59</u> .	Kahwati L, Viswanathan M, Golin CE, et al. Identifying configurations of behavior change
9 10	797		techniques in effective medication adherence interventions: a qualitative comparative
11 12	798		analysis. Syst Rev 2016;5(83).
13	799	60.	Telerivet. Message Statuses . User Guide, 2021. Available from:
14 15	800		https://guide.telerivet.com/hc/en-us/articles/360038959611-Message-Statuses. [Accessed
16 17	801		<u>21 June 2021]</u>
18	802	61.	Lustria MLA, Noar SM, Cortese J, et al. A meta-analysis of web-delivered tailored health
19 20	803		behavior change interventions. Journal of Health Communication 2013;18:1039–69.
21 22	804	62.	Gallacher K, May CR, Montori V, et al. Understanding Patients' Experiences of Treatment
23	805		
24 25	806		Burden in Chronic Heart Failure Using Normalization Process Theory. Ann Fam Med 2011;9:235-243.
26 27			
28			
29 30			
31 32			
33			
34 35			
36 37			
38			
39 40			
41 42			
43			
44 45			
46 47			
48			
49 50			
51 52			
53			
54 55			
56			
57 58			
59 60			

to peet terier only

5 6 7

8

9

10 11

12 13

14 15

16 17 18

19

20

25

26

27

28

29

30 31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

53

54

55 56

57


58

59

60

STUDY PROTOCOL

ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial



Abstract

Background: South Africa is among the seven highest tuberculosis (TB) burden countries. Harmful lifestyle behaviours, such as smoking and alcohol, and poor adherence to medication can affect clinical outcomes. Modification of these behaviours is likely to improve TB treatment outcomes and has proven possible using motivational interviewing (MI) techniques or use of short message service (SMS) text messaging. There have been no studies assessing the effect of combined MI and SMS interventions on multiple lifestyle factors and TB treatment outcomes.

Methods: This is a prospective, multicentre, two-arm individual randomised controlled trial looking at the effectiveness and cost-effectiveness of a complex behavioural intervention (the ProLife programme) on improving TB and lifestylerelated outcomes in three provinces of South Africa. The ProLife programme consists of an MI counselling strategy, delivered by lay health workers, augmented with subsequent SMS. We aim to recruit 696 adult participants (aged 18 years and over) with drug-sensitive pulmonary TB who are current smokers and/or report harmful or hazardous alcohol use. Patients will be consecutively enrolled at 27 clinics in three different health districts in South Africa. Participants randomised individually to the intervention arm will receive three MI counselling sessions one month apart. Each MI session will be followed by twice-weekly SMS messages targeting treatment adherence, alcohol use and tobacco smoking, as appropriate. We will assess the effect on TB treatment success, using standard World Health Organization (WHO) treatment outcome definitions (primary outcome), as well as on a range of secondary outcomes including smoking cessation, reduction in alcohol use, and TB medication and anti-retroviral therapy adherence. Secondary outcomes will be measured at the three-month and six-month follow-ups.

Discussion: This trial aligns with the WHO agenda of integrating TB care with the care for chronic diseases of lifestyle, such as provision of smoking cessation treatments, and with the use of digital technologies. If the ProLife programme is found to be effective and cost-effective, the programme could have significant implications for TB treatment globally and could be successfully implemented in a wide range of TB treatment settings.

Trial registration: ISRCTN Registry, ISRCTN62728852. Registered on 13 April 2018.

Keywords: Tuberculosis, Smoking, Alcohol, Motivational interviewing, Anti-retroviral therapy, Adherence

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Open Access

Trials



^{*} Correspondence: andrewmoriarty1@doctors.org.uk

¹Department of Health Sciences and the Hull York Medical School, University of York, York, UK

Full list of author information is available at the end of the article

South Africa has the second highest incidence of tuberculosis (TB) and the sixth highest TB burden of the 30 high TB burden countries. It also has a high prevalence of human immunodeficiency virus (HIV) co-infection in patients with TB and a high mortality in these coinfected patients relative to most other high-burden countries [1]. In addition to HIV co-infection, a range of social, psychological and economic factors influence treatment success in TB. Of these, tobacco smoking and hazardous or harmful alcohol use are specifically mentioned in the South Africa National TB Management Guidelines [2]. Tobacco use and problem drinking are prevalent in TB patients, often co-occur [3–5] and are known to increase the risk of death and poor treatment adherence and outcomes [6–9].

As well as increasing the risk of TB infection and progression of disease [10], smoking is also known to increase the risk of treatment failure [11], relapse [12, 13] and death [14], and is associated with resistance to isoniazid, one of the main antimicrobials used to treat TB [15]. There is evidence that patients who stop smoking have better TB treatment outcomes and, if co-infected, better HIV treatment outcomes than current smokers [16–18]. In addition, alcohol misuse is associated with poorer TB outcomes through a range of mechanisms including decreased effectiveness of medications used to treat TB (including drug resistance), increased recurrence and treatment default rates and social marginalisation [3]. It has been estimated that 10% of the global burden of TB is attributable to alcohol use [19, 20].

Poor adherence to TB medication and anti-retroviral therapy (ART) significantly increases the risk of adverse effects and death in TB patients. Strategies are needed to improve medication adherence in TB-HIV co-infected patients, in whom integration of TB and HIV care has been shown to decrease mortality [21].

A number of studies have attempted to evaluate the effectiveness of tobacco cessation, alcohol reduction or TB treatment adherence interventions in TB patients [21, 22], but few have assessed the effect on TB treatment outcomes [23, 24]. We know that brief smoking cessation interventions, ranging from opportunistic advice and proactive telephone support through to in-person behavioural support over multiple sessions, are effective and affordable in lowincome countries, in both TB patients and smokers in the general population [25, 26]. We also know that disease diagnosis could constitute a 'teachable moment, when people are more amenable to advice and motivated to modify harmful lifestyle behaviours [27]. For this reason, it is likely that patients receiving a TB diagnosis may be more successful in quitting smoking and moderating alcohol use if offered behavioural support, compared with smokers and problem drinkers in the general population.

Motivational interviewing (MI) is a counselling technique known to facilitate behaviour change [28], which has demonstrated effectiveness for the reduction of hazardous drinking, tobacco cessation, and TB treatment and/or ART adherence [19, 29, 30]. Our group has had previous success in achieving sustained smoking abstinence in TB patients through a brief MI intervention delivered by lay health workers (LHWs) [31]. There is also evidence to suggest that adherence to ART [32] and possibly TB medication [33], as well as tobacco cessation, can be enhanced with the use of short message service (SMS) text messages on mobile phone technology [34]. To our knowledge, no study has used MI in combination with SMS text messages to address multiple harmful behaviours that adversely impact TB outcomes.

The ProLife programme is a novel complex behavioural intervention targeting tobacco smoking, problem drinking, and TB and HIV medication adherence in patients with TB. This is the study protocol for the randomised controlled trial (RCT) aiming to assess the effectiveness and cost-effectiveness of the ProLife programme in improving TB treatment outcomes in primary healthcare clinics located in high TB-burden communities in three provinces in South Africa (Gauteng, Free State and North West). The protocol has been written in accordance with the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) guideline.

Methods/Design

Objectives

The primary objective is to assess the effectiveness and cost-effectiveness of the ProLife programme compared to usual care in improving pulmonary TB (PTB) treatment outcomes. We also aim to assess the effectiveness and cost-effectiveness of the programme in achieving abstinence from smoking, reducing harmful and hazardous drinking, and improving TB and ART medication adherence.

Trial design and setting

This is a pragmatic, prospective, multicentre, two-arm, parallel, individual RCT taking place in 27 purposively selected primary care clinics with the highest TB case-load in three districts in South Africa: Welkom in the Free State; Bojanala in the North West province; and Sedibeng in Gauteng province. To be eligible for inclusion in the trial, TB clinics had to be under the control of the provincial or local government (i.e. not a mining TB clinic). The intervention will be delivered by LHWs and three district coordinators who will each cover 1–2 clinics.

1

Participants will be randomly allocated to one of two arms:

Arm 1: Intervention arm – participants in the interventions arm will receive the ProLife programme; Arm 2: Control arm – participants will receive usual treatment and support provided to TB patients in TB treatment clinics in South Africa ('usual care').

Intervention

The ProLife programme is a complex behavioural intervention aimed at improving treatment outcomes in TB patients who smoke tobacco, drink alcohol at harmful or hazardous levels, or do both. The ProLife programme has been developed in line with the Medical Research Council (MRC) guidance on developing and evaluating complex interventions [35] and has undergone a period of development and feasibility testing in South Africa. The paper reporting the results of this evaluation has not yet been published. The conceptual framework used to develop the ProLife programme assumes that smoking cessation, reducing harmful alcohol use and improved adherence to TB and HIV treatment will result in improved TB treatment outcomes.

Participants randomised to the intervention arm will receive three brief MI counselling sessions, lasting 15-20 min, each one month apart, from a trained LHW at their TB clinic. In the initial MI session, occurring at the start of TB treatment, the counsellor will establish the participant's tobacco smoking habits and problem drinking; potential obstacles and facilitators for medication adherence or treatment initiation (both TB treatment and ART) will be determined. The participant will determine which factor should be prioritised (i.e. agenda setting), which could be a plan either to guit tobacco smoking, reduce or quit drinking or deal with barriers relating to ART or TB medication adherence. For participants who are HIV-infected and not yet on ART, beliefs and attitudes regarding HIV-testing or ART will be explored to facilitate ART initiation and adherence. The second session will build on the previous one and will focus on the previous agenda before moving on to the next behavioural problem (tobacco, alcohol or medication adherence) where applicable. The third session will deal with the last identified problem.

The individual counselling sessions will be re-enforced with SMS text messages regarding information, motivation and behaviours (IMB) supporting tobacco cessation, alcohol use and medication adherence. Text messages will be delivered twice a week over 12 weeks. All participants will first receive 10 TB-related messages. These messages will be followed by seven alcohol or smoking-related messages depending on whether the participant smokes or drinks. Co-joint users will receive all sets of messages (i.e. 24 in total).

Comparator

Participants in the second group are the controls and will receive usual TB treatment and support offered to TB patients. Control participants are seen by a TB nurse and receive the same biochemical investigations and medical treatments as the intervention arm. However, they will not receive the MI and SMS package of care as described above. Usual care also includes HIV testing with pre- and post-test HIV test counselling by a lay counsellor or a nurse (this varies by district).

In addition, health education is given on:

- nature of TB, treatment adherence, treatment sideeffects/complications, drug interactions, tobacco use, alcohol use and other substance abuse. This is mostly done by the TB nurses, is not intensive and is educational in nature rather than a form of counselling;
- healthy diet by a dietician where possible;
- social problems and family support for treatment by a social worker as needed and depending on the availability of social workers; and
- point of care blood glucose, haemoglobin and pregnancy tests are performed. If co-infected with HIV, a full blood count, liver function test and creatinine are also carried out.

Participants

The inclusion criteria for participants are:

- adult patients (aged ≥ 18 years) with drug-sensitive (bacteriologically or clinically confirmed) PTB;
- initiating TB treatment or on TB treatment for < 1 month (these include both 'new' and 'retreatment' patients);
- current smokers and/or hazardous/harmful drinkers who are not alcohol dependent (Alcohol Use Disorders Identification Test [AUDIT] score ≥ 8 for men or ≥ 7 for women but < 20);
- access to a functional mobile phone; and
- understands one of the four languages used for the trial (Sesotho, Setswana, Isizulu or English).

Exclusion criteria:

- alcohol-dependent participants (AUDIT score \geq 20);
- Extrapulmonary TB without PTB; or
- Resistance to one or more TB drugs at baseline (because drug-resistant TB needs further investigations which take several months and is treated through

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

a long, specialised treatment programme if present).

Recruitment process

Participants will be recruited consecutively from the starting date of the trial until the required sample size for each clinic has been achieved. The sample size per clinic will vary depending on the workload for each clinic. TB patients who initiate treatment (or who have been on treatment for < 1 month) will be asked if they would like to participate. If they agree, they will then be screened for eligibility by trained fieldworkers immediately after the TB nurse at the clinic has initiated TB treatment and started the routinely used TB treatment record. Eligibility screening will involve being assessed in line with the inclusion criteria listed above and being asked about their:

- smoking status: using the Global Adult Tobacco Survey [36] questionnaire, patients will be asked whether they currently smoke daily, less than daily or not at all, and in the past daily, less than daily or not at all. As TB patients in South Africa often smoke little or may not have smoked for a few days because of ill-health and the word 'current' is open to interpretation (particularly when translated); 'current' has been defined as smoking daily and nondaily in the last four weeks for the purpose of this study. Smoking habits will be further quantified at baseline interview;
- current alcohol usage: AUDIT, a validated tool for identifying problem alcohol behaviours [37], will be used to quantify alcohol intake. Those with an AUDIT score ≥ 8 for men or ≥ 7 for women but < 20 will be eligible for the trial.

If eligible, patients will be invited to join the trial. For those who wish to be enrolled into the trial, written informed consent will be obtained (Additional file 1).

Randomisation and allocation

Patients will be randomised using a randomised sequence generator performed by the trial statistician (MK) who will remain blind to the arm allocation. We will use block randomisation with varying block sizes stratified by the clinic to achieve equal numbers in intervention and control groups within each clinic (see the 'Sample size' section). Allocation concealment will be done with consecutively numbered, sealed, opaque envelopes.

Ethics and consent

Potential participants will be approached and given an introduction to the study and basic eligibility criteria


required for participation. Participants who meet the eligibility criteria for language, age, PTB, treatment duration and mobile phone access will be given a consent form (Additional file 1) to sign before screening for alcohol and tobacco use eligibility as the alcohol-related questions are sensitive and the fieldworkers must access the patient treatment record. If recruited to the trial, participants will be ask to consent to enter the trial, including consent for audio recording of the MI counselling sessions (Additional file 1). A witness signature will be required where the participant is unable to read or write.

The identity of participants will be protected by allocating each participant a unique trial number, which will be used on all research documents and will ensure anonymity for the data analysis. Participation will be voluntary; participants will be informed of their right to withdraw from the study at any time without giving a reason for their withdrawal. The project is unlikely to be directly harmful to TB patients with the exception of inconvenience in terms of time spent on the counselling sessions. Participants will receive ZAR 60 (US\$4.19) travel and other expenses reimbursement for each MI counselling session and follow-up visit related to the study.

Timeline and procedures

Figure 1 Additional file 4 outlines the overall participant flow through the trial. Eligible and consenting patients will be enrolled in the trial and the baseline intervieweradministered questionnaire and record review completed. Participants will receive a baseline interview on the same day as the recruitment or on the nearest available date suitable to both the participant and the LHW. The initial part of the questionnaire covers socioeconomic and demographic factors. We will also assess for depression using the CES-D10 [38], a validated tool, as depression may be a potentially moderating or mediating factor affecting treatment outcome. See Additional file 2 for the full case report form (CRF).

The next part will cover medical history, particularly TB and HIV history and current medications. Participants identified as current smokers at eligibility screening will be asked more in-depth about their smoking habits and quit history. All participants will be asked about their use of smokeless tobacco and exposure to second-hand smoke. Participants will also be asked about time and money spent on TB-related healthcare visits in the past three months and health-related quality of life (see the 'Economic evaluation' section). After administering the baseline interviews, fieldworkers will draw the allocation envelopes and organise the follow-up sessions for the participants. Each of the interviews on health status, tobacco and alcohol use at



baseline, three months and six months is not expected to last > 25 min.

Primary outcome

The primary outcome is TB treatment success at 6–9 months of follow-up, measured using the routinely collected programmatic TB treatment outcomes as defined by the World Health Organization (WHO) and adopted in South Africa. This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or 'default', or not outcome evaluated. Table 1 defines the different treatment outcomes according to the South African Department of Health National Tuberculosis Management Guidelines [2].

Individual TB treatment records will be used as the primary source of information. The TB treatment record is the routinely used clinical document initiated by the TB nurse when the patient first presents at the TB clinic and includes demographic information as well as a comprehensive overview of the patient's treatment over time. The TB treatment outcomes will be obtained 6–9 months after the TB treatment start dates. This is to allow for short periods of treatment interruption and time needed to confirm the TB treatment outcomes status. For example, the TB nurse may have to wait for end of treatment TB sputum or culture results or time may be required to determine whether a participant died. In some cases, TB patients may also undergo a longer TB treatment regimen.

Routinely reported outcomes will be verified for correctness by checking the actual individual diagnosis and treatment records. For example: if the outcome is classified as cured, then the criteria for diagnosis and outcome definitions should have been adhered to. Attempts will be made to verify the information of patients classified as 'defaulted' or who are lost to follow-up by contacting them telephonically or sending them a short text message. Sputum cultures and smears will be performed at baseline, two months, three months and six months per routine care.

Secondary outcomes

The following outcome measures will also be recorded at the six-month follow-up:

- sputum conversion at the end of treatment: this will be measured by negative culture or smears in the group of participants who had bacteriology confirmed PTB at baseline, i.e. cure rates in intervention group versus control group for participants who initially had sputum AFB-positive, culture-positive or GeneXpert-positive PTB;
- six-month continuous smoking abstinence: the Russell Standard defines continuous abstinence as a self-report of not smoking > 5 cigarettes from the

5

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

 Table 1
 Definitions for TB treatment outcomes according to the South African Department of Health National Tuberculosis

 Management Guidelines
 South African Department of Health National Tuberculosis

Treatment outcome	Definition
Cure	Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last month of treatment and on at least one previous occasion at least 30 days prior According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is considered 'Cured'.
Treatment completed	Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological findings who have shown clinical improvement and completed the prescribed course of treatment. <i>N.B. The smear examination may not have been done or the results may not be available at the end of treatment.</i>
Treatment failure	Patient whose baseline smear or culture was positive and remains or becomes positive again at 5 months or later during treatment. Patients who were negative at baseline but were later found to be positive. N.B. This definition excludes those patients who are diagnosed with RR-TB or MDR-TB during treatment.
Died	Patient who dies for any reason during the course of TB treatment.
Treatment default	Patient whose treatment was interrupted for two consecutive months or more during the treatment period.
Transfer out	Patient who was referred to a facility in another district to continue treatment and for whom the treatment outcome is not known.
Acquired resistance	Participants who are subsequently referred for MDR treatment.

start of the abstinence period (in this case, six months), supported by a negative biochemical test (exhaled carbon monoxide [CO] < 10 ppm) at final follow-up [39]. For the purpose of our study, we will, however, use a more stringent criterion of exhaled CO < 7 ppm, based on findings from our previous study that some participants who reported continued smoking had an exhaled CO < 10 ppm [26]. This analysis will be performed on the group of participants who were current tobacco smokers at baseline;

- reduction in harmful or hazardous drinking: alcohol use will be measured using the AUDIT questionnaire. The questionnaire will be administered at screening (which will take place on the same day or shortly after the baseline assessment) and again at three months and six months. Changes in the total AUDIT score will be used to compare change in drinking behaviour between control and intervention groups. This analysis will be performed on the group of participants who were harmful or hazardous drinkers at baseline.
- TB and ART medication adherence: adherence to both TB and ART medications will be measured using a modified version of the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire. The questionnaire is a validated tool for measuring adherence specifically to ART and we will use an adapted version to also measure TB medication adherence [40]. Field workers will administer the baseline part of this questionnaire as part of the

baseline CRF and adherence will be measured at both three months and six months.

Adherence will be measured using an adherence index calculated by the formula (using the four-day recall table):

[Total number of doses taken/Total number of doses prescribed] x 100

ART patients with at least 95% of adherence will be considered as having optimal adherence and those with < 95% will be considered as having low (or suboptimal) adherence. For the TB medication regimen, patients with at least 95% of adherence will be considered as having optimal adherence and those with < 95% will be considered as having low (or suboptimal) adherence:

• increase in proportion of HIV-positive participants on ART: HIV status will be recorded in the TB Treatment Record. HIV-positive participants will be asked about ART status at baseline, three months and six months using standardised questions on the CRF.

The following outcomes will be measured at three months:

- biochemically verified three-month sustained tobacco cessation;
- reduction in harmful or hazardous drinking;
- TB drug and ART adherence;

Page 152 of 155

• increase in proportion of HIV-positive participants on ART.

The schedule for enrolment, intervention and assessments is presented in Fig. 2. Table 2 summarises the methods of data collection and analysis for each of the primary and secondary outcomes.

Data collection and management

Data will be collected and recorded by field workers equipped with Android phones with a mobile data collection application installed. MI counselling and data collection will take place in a well-ventilated private area inside or outside the clinic (but within the grounds of the health facility); MI sessions will be audio-recorded where consent has been obtained. Fieldworkers and

		STUDY	PERI	IOD		
	Enrolment	Allocation	Pos	st-alloc	ation	Close- out
TIMEPOINT	-t	0	1m	2 m	3 m	6-9m
ENROLMENT:						
Eligibility screen (including smoking status and baseline AUDIT)	х					
Informed consent	Х					
Allocation		х				
Assigned trial ID and initial visit date		Х				
INTERVENTIONS:						
The ProLife Programme		ļ		+		
Usual care						
ASSESSMENTS:						
Clinical review of TB treatment record	Х	Х				Х
HIV Status		Х				
ART status (if HIV- positive)		Х			х	х
Smoking history	Х	х				
Socio-demographic history		Х				
Depression screen (CES-D10)		х			х	х
Record sputum culture, smear or Gene Xpert result		x		x	Х	х
Smoking abstinence (self-report)					Х	х
Smoking abstinence (Exhaled CO)					Х	Х
Repeat AUDIT					Х	Х
Modified ACTG					Х	Х
Economic evaluation		Х			Х	Х
Fig. 2 SPIRIT Figure outlining data collection throughout trial						

LHWs will be provided with high particulate respirator masks to minimise the risk of infection.

Fieldworkers will follow-up all participants in both arms at three and six months within a window period of two weeks before and two weeks after the ideal threemonth and six-month visit. Participants will receive SMS reminders three days before each planned visit. Participants will also be in a position to send 'please call me' messages to the district coordinators, who will then call the participant to solve problems that may have arisen with the appointment.

The electronic data captured will be stored on secured and password-protected storage servers and mobile phones which ensure data privacy through only allowing authorised research staff access to the data. The electronic data collection system used for the study requires an SMS gateway to send and receive messages to the research participants. Consenting participants' phone numbers, participant IDs and associated SMS messages will be stored on the SMS gateway's secured and password-protected server.

Data quality will be ensured by providing fieldworkers with standard operating procedures (SOPs), training and ongoing support on the importance of data quality, data collection and data collection problem solving. Training will consist of a four-day session before the commencement of the pilot and a one-day training session focusing on problems identified during the pilot preceded the trial. The data manager will continuously monitor the captured data for missing variables and inconsistencies in order to resolve any data problems.

The data manager will export the data from the secured server, conceal the participants study arm allocation and de-identify the data before sharing the data in STATA and R compatible formats. The exported deidentified data will be stored in Dropbox, a secure cloud storage platform, for sharing with the lead trial statistician at the University of York for analysis.

All research data and documents referring to the ProLife trial will be stored and maintained in a secured storage space at SMU for a minimum of 15 years from the end of the ProLife trial. Study materials will be destroyed 15 years after the study.

Blinding and limitation of risk of bias

This is a complex behavioural intervention and the team dynamics mean that all team members work very closely with one another. As such, LHWs and participants cannot be blinded to the intervention. The determination of the primary outcome will be done by the TB nurses who are blinded to the intervention status of the participants based on routinely collected data. Blinding of the field researchers collecting other questionnaire data (Additional file 2)

60

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

Table 2 Summary of methods of data collection and analy	ysis for primary and secondary outcomes
---	---

Variable	Method of data collection	Method of data analysis		
Primary outcome: TB treatment outcome as defined by WHO and the South Africa TB Management Guidelines (see Table 1)	CRF and TB treatment record Treatment outcome as recorded by TB nurses in TB cards using the standard WHO definitions of cure, completions, failure, death, TB treatment interruption, drug resistance developed in course of treatment (confirmed for correctness by checking sputum culture/smear at baseline, at 5 and 6 months)	Binary outcome: successful (cured of completed) vs not successful (died, failure, treatment interruption, drug-resistant TB) All participants, excluding those transferred ou		
Secondary outcome: sputum conversion	 Sputum culture/smear at baseline, 5 and 6 months to determine cure rates for PTB patients who had a positive smear or culture at baseline Sputum conversion at 2–3 months 	Binary cured vs not cured for the subgroups of participants who had a positive smear/culture at baseline Binary conversion vs not for the subgroups of participants who had a positive smear/culture at baseline		
Secondary outcome: change in smoking behaviour	 CRF – questions as per Russell's Standard – baseline smoking behaviours and then at 3 and 6 months Exhaled carbon monoxide reading at 3 and 6 months 	Binary outcome validated 3 and 6 months sustained smoking cessation for the subgroup of participants who were smoking at baseline		
Secondary outcome: percentage reduction in harmful or hazardous drinking (change in AUDIT score)	AUDIT score at baseline and at 3 and 6 months	Change in AUDIT score (continuous) for subgroups of participants who were hazardous or harmful drinkers at baseline		
Secondary outcome: HIV and TB medication adherence	CRF – questions modified from ACTG	Binary outcome (% adherent vs non-adherent)		
Secondary outcome: proportion of HIV- positive participants on ART	HIV status at baselineART status at baseline, 3 months and 6 months	Binary on ART vs not on ART for the subgroup of HIV-positive participants, taking into account baseline % on ART		

will not be possible. The statistician will be blinded to the intervention or control arm allocation of participants during the analysis stage.

There is a potential of biased outcome reporting on self-reported tobacco smoking or alcohol consumption favouring the intervention arm. This will be minimised by training the fieldworkers in open communication and standardised data collection. Tobacco cessation will also be verified by exhaled CO monitoring. Given the use of the TB treatment record as a primary source of information pertaining to TB outcomes, there is a risk of nondifferential misclassification. However, this risk is equal in both the treatment and control arms and therefore the decision has been taken that the TB treatment record can be used as a primary data source (i.e. bias would be towards the null).

Sample size

The sample size has been set at 696 participants (348 participants per arm). This sample size is sufficient to detect a 10% difference in TB treatment success rates (0.86 vs 0.76) in the ProLife group versus the control group with 80% power, a significance level of 0.05 and 25% attrition. The sample size per clinic was in the range of 14–74 participants per clinic with a median of 24. The assumed success rates in the control group are based on actual success rates in TB patients in the studied provinces.

Statistical analysis

We will summarise baseline data descriptively by trial arm; however, we will not undertake statistical comparisons. For continuous measures, we will report means and standard deviations (SD); for skewed data, we will also provide medians and interquartile ranges. For categorical data, we will report counts and percentages. For the primary outcome, we will conduct analysis on an intention-to-treat basis. We will use binary logistic regression to compare the main outcome between the intervention and the usual care arm.

We will carry out similar analyses for the secondary outcomes with appropriate regression techniques: logistic regression for categorical outcomes and linear regression for continuous outcomes. We will also adjust for baseline characteristics and other covariates (HIV status, sex, alcohol versus tobacco versus both, district) if these differ between trial arms at baseline.

In case of missing data, we will employ a number of methods including multiple imputations to assess the sensitivity of the results. We will conduct subgroup analyses to determine whether TB treatment outcomes differ between subgroups, as follows: HIV-positive versus HIV-negative participants; participants with an alcohol problem only versus smokers only versus participants who are conjoint smokers and drinkers; and participants who were GeneXpert positive versus participants who were GeneXpert negative at baseline. We will follow the CONSORT statement guidelines in reporting. We will use the statistical packages STATA and R to carry out the analyses and a P value < 0.05 will be considered as statistically significant. The statistical analysis pertaining to cost-effectiveness will be described in the section detailing the planned economic evaluation.

Monitoring

Each centre will be responsible for its own data entry and local trial management. Monitoring and site training will be carried out at each site within specified intervals. The project manager will visit each district every third month with the counselling supervisor. The district coordinators will visit each clinic bi-weekly; the site leads and data manager will visit the sites when required.

The monitoring will adhere to the principles of Good Clinical Practice and will follow an agreed monitoring plan. During their bi-weekly visits, the district coordinators will be guided by a checklist to confirm adherence to protocol, review eligibility verification and consent procedures, and provide additional training as needed. Any adverse events will be formally recorded and reported where appropriate.

The mobile data collection tool was improved based on findings from the pilot phase and feedback from the field staff capturing the data. Validation was added to the mobile questionnaires to ensure that all questions should be answered, participants only answer question relevant to them and that no unusual values (range checks) are entered. Coordinators can use the mobile data collection tool on their phones to monitor incomplete data activities, outstanding and upcoming appointments with participants and basic project performance indicators per clinic.

The data captured during the interviews with the participants are only captured on the electronic mobile data collection tool and can therefore not be verified by the site coordinators. However, the district coordinators will require access to all (enrolled TB) patient medical records including, but not limited to, laboratory test results and prescriptions. They will do spot checks by comparing the captured data with the medical records and look for missed outcomes reporting: verify completeness; consistency; and accuracy of data being entered on CRFs. The site leads (or delegated personnel) should work with the district coordinators to ensure that any problems detected are resolved.

The data will also be checked by the data manager for missing or unusual values (range checks) and checked for consistency within participants over time. If any such problems are identified, the individual centres will be contacted and asked to verify or correct the entry. Indicators related to enrolment, premature withdrawal, motivational interviewing completion, CRF completion and SMS delivery will be analysed and included in monthly reports.

As the ProLife programme is a low-risk intervention, the decision was taken not to appoint an external data monitoring committee.

Training and intervention fidelity monitoring

Eighteen LHWs, three district coordinators and one person who will be focusing on counselling supervision underwent MI training over five days, which covered: basic knowledge of TB; treatment adherence; tobacco and alcohol use; overview of the overall spirit of MI and communication style; core interviewing skills; evoking change talk, hope and confidence; developing a change plan; and strengthening commitment. The LHWs' knowledge in terms of TB, alcohol use, tobacco smoking, TB and ART treatment adherence, and motivational interviewing was assessed before and after the training

To ensure that all the essential steps, techniques and skills of an MI session are covered during each session, the LHWs will be provided with a checklist to use during each session (Additional file 3). At the end of each session, they will also complete a post-session semistructured form onto which they will indicate the extent to which they implemented each element of MI, as well as their general qualitative impressions of that particular session.

During the trial, the LHWs will receive regular supervisory support from the district and national study coordinators. In addition, an appointed supervisor with proficiency in MI will be providing monthly counselling supervision to the LHWs in each site, by travelling to each of the three sites and then providing support to the LHWs in a group, followed by individualised support to each LHW separately. All lay counsellors completed grade 12 and have at least one year of prior counselling experience in TB and/or HIV.

In order to assess the fidelity of the counsellors' delivery of motivational interviewing during the trial, the validated Motivational Interviewing Treatment Integrity Coding Manual 4.2.1 (MITI) tool will be used [41]. We will tape record each LHW's counselling sessions and then randomly select 5% of each counsellor's patients and then use the recordings of all three sessions with those patients for the MITI task. Those selected recordings will be transcribed and translated into English. Two independent raters who are Setswana/Sesotho speakers will listen to the recordings and code a randomly selected 20-min portion of the written transcript. In the case of shorter counselling sessions, the entire recording will be assessed. The coding will entail making 'Global Ratings' (on four dimensions: Cultivating change talk;

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

Softening sustain talk; Partnership; and Empathy) and 'Behaviour Counts' (with respect to the items: giving information; persuade; persuade with permission; question; simple reflection; complex reflection; affirm; seeking collaboration; emphasising autonomy; and confront). A score will be assigned to each of these items and the scores compared against the competency and proficiency thresholds that are specified in the MITI manual.

Economic evaluation

The economic evaluation will be a within-trial incremental cost-effectiveness analysis of the ProLife package over and above usual care conducted alongside the RCT. In each arm of the trial, we will estimate the costs of delivering the intervention to participants. Costs consist of the delivery of ProLife intervention (staff costs, overheads and consumables) in the intervention arm and the costs of behavioural support and support (staff time, overheads and consumables) in the control arm. Costs will be calculated based on the length of time of contacts and the unit cost of the healthcare worker delivering the intervention. These costs should demonstrate some within patient variability as cost will be partly dependent upon the length of the recorded appointments.

We will also record contacts with health services for TB by patients in each trial arm, using the questionnaires adapted from those used in a previous trial of TB [42]. Applying unit costs of healthcare to quantities recorded in the service use questionnaire will produce a healthcare cost profile for each patient at baseline, three-month and six-month follow-ups. Healthcare cost profiles based on TB contacts can then be used to investigate differences in total costs between the treatment and control groups. The base case analysis will use healthcare costs as the study perspective. This is justified by presenting the cost implications of delivering the ProLife intervention from a healthcare decision maker's perspective. However, we will also record participants' travel costs associated with making the journey to the intervention site. This will estimate the wider societal cost to patients associated with receiving treatment.

We will estimate the cost per additional successful TB outcome by computing an incremental cost-effectiveness ratio (ICER) combining treatment and wider healthcare costs with outcome data from the trial. The analysis will also use measures of health utility. We have registered on the EuroQol website to use the country specific version of EQ-5D-3L for South Africa to measure health-related quality of life at baseline, three-month and six-month follow-ups. We will use EQ-5D-3L to estimate changes in quality-adjusted life years (QALY) using the area under the curve by using the utility score at each time point to create a profile [41]. A cost utility analysis is then performed by combining incremental health outcomes using QALYs with the incremental cost. The cost utility analysis will estimate the cost per QALY that estimates the value for money afforded by administering the ProLife intervention over and above usual care. We will plot incremental cost against incremental outcome using a costeffectiveness plane. We will also conduct sensitivity analyses to assess the robustness of the ICER and use bootstrapping techniques to calculate cost-effectiveness acceptability curves. Supporting analysis will also present the costs to patients incurred by making visits to both trial arms to present the wider cost burden. However, these costs will not be included in the base case scenario as the objective is to present the value for money from the perspective of the purchaser or commissioner.

Discussion

BMJ Open

Ending the TB epidemic is one of the Sustainable Development Goals (SDG) established by the United Nations. The WHO calls for a 90% reduction in TB incidence by 2030 compared to 2015 and has highlighted the need for intensified research and innovation. The WHO has recently published guidance advocating the use of digital technologies, specifically mobile text messaging campaigns, in the treatment of TB as a means of improving the provision of patient-centred care and supporting medication adherence [43]. This publication highlights advances in mobile technologies and network coverage as opportunities to more effectively support patients during what can be a long period of treatment. This study is well-aligned with this guidance and, to our knowledge, this is the first trial looking at a complex behavioural intervention aiming to use MI techniques, alongside SMS, to modify a range of harmful lifestyle factors with the aim of improving TB treatment outcomes.

Work already undertaken in the formative phase suggests that the ProLife intervention is feasible and acceptable to patients. However, we anticipate some potential procedural challenges throughout the trial as we recognise that patients with TB may feel unwell and have taken steps to ensure that the MI and data collection are as brief and comfortable for patients as possible. The district coordinators will call participants to follow-up with those who missed appointments.

Implementing complex interventions in the real world can pose logistical challenges and careful process evaluation will be required to fully understand the challenges that may be presented. However, there is evidence to suggest that using MI techniques can be cost-effective when implemented in healthcare settings and the ProLife programme could represent a scalable and feasible approach to improving the care of patients with TB globally. Its scalability is particularly relevant in South

Africa as the government plans to formally introduce community health workers as part of its health workforce.

Trial status

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

Protocol Version 1.2, 5 January 2018. Recruitment ongoing; piloting started at 30 clinics: 7 May 2018 and was completed by 31 August. The actual trial enrolment started on 13 November 2018. We expect to enrol the target sample size by May 2019 and plan to continue with follow-up until December 2019. The trial was piloted internally from May 2018 until the end of August 2018; piloting results will be reported at a later stage, together with the trial results.

Additional files

Additional file 1 Participant consent form for screening and for trial. (DOCX 94 kb)

Additional file 2 Case report form. (DOCX 58 kb)

Additional file 3 Counselling Activities Reporting Form. (DOC 103 kb) Additional file 4 SPIRIT Checklist. (DOC 120 kb)

Abbreviations

ACTG: AIDS Clinical Trials Group; ART: Anti-retroviral therapy; AUDIT: Alcohol Use Disorders Identification Test; CO: Carbon monoxide; CRF: Case report form; EPTB: Extra-pulmonary TB; HIV: Human immunodeficiency virus; LHW: Lay health worker; MI: Motivational interviewing; PTB: Pulmonary TB; SADHS: South Africa Demographic and Health Survey; SMS: Short Message Service; TB: Tuberculosis

Acknowledgements

We are grateful to the following people: Ms. M Malefo for her work as research coordinator; Ms. D Bell for conducting the MI training; Mr. A van Zyl for research support; the district and clinic TB managers and TB nurses; and the fieldworkers and the lay counsellors.

Authors' contributions

ASM contributed to study design and preparation of the manuscript. GML led on study design and contributed to intervention development and preparation of the manuscript. NDM contributed to study design, particularly with respect to development. NM contributed to study design, particularly with respect to development of the MI intervention. JT is site lead for the Bojanala sub-district. OBO is site lead for the Sedibeng sub-district. MOB contributed to study design and led on the sample size determination and statistical analysis plan. AT contributed to the planned economic evaluation. SP contributed to study design and led on the planned economic evaluation. KS and OAA are co-principle investigators. All authors read and approved the final draft of the manuscript.

Funding

This project was funded by the SA-Medical Research/Newton Foundation Grant on TB control implementation science. UK/South Africa Newton Fund RFA: TB control implementation science (MRC-RFA-02: TB -05-2015). This UK funded award is part of the EDCTP2 programme supported by the European Union.The funder had no role in study design; collection, management, analysis and interpretation of data; writing of the report or the decision to submit the report for publication. The National Research Foundation of South Africa (Incentive Funding for Rated Researchers) paid for some of the travel and research costs of OAA and GML.Trial sponsor. Sefako Makgatho Health Sciences University, RSA. Contact: lekan.ayo-yusuf@smu.ac.za

Availability of data and materials

The data sharing plans for the current study are unknown and will be made available at a later date. Research results will be published in international indexed journals and disseminated to managers of the provincial and national Departments of Health. Furthermore, the provincial and national Departments of Health will be involved in the design and final evaluation of the project so as to assure their ownership, sustainability and scaling the programme beyond the life of the trial.

Ethics approval and consent to participate

The trial has received approval from the Research Ethics Committees of Sefako Makgatho Health Sciences University (SMU; Ref. SMUREC/D/234/2017: IR), the South African Medical Research Council (with the SMU Ethics Committee serving as the Research Ethics Committee Record), the University of Pretoria (Ref. 434/2017), the University of the Free State (Ref. HSREC 71/2016), the University of Witwatersrand (M160455) and the University of York (no reference number, approval date 15 January 2018). The protocol has gone through full external peer review throughout this process. In the case of any protocol amendments, these will be submitted to the SMU Ethics Committee for approval. Managerial approval has been obtained from the provincial adfrict (North West Province), Lejweleputswa district (Free State province) and Sedibeng district (Gauteng province). Informed consent will be obtained from all study participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Health Sciences and the Hull York Medical School, University of York, York, UK. ²School of Health Systems and Public Health, University of Pretoria and Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa. ³Department of Health Sciences, University of York, York, UK. ⁴Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa. ⁵Department of Family Medicine, Sefako Makgatho Health Sciences University of Witwatersrand, Johannesburg, South Africa. ⁷Norwich Medical School, University of East Anglia, Norwich, UK. ⁸School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. ⁹Africa Centre for Tobacco Industry Monitoring and Policy Research, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa.

Received: 18 March 2019 Accepted: 2 July 2019 Published online: 26 July 2019

References

- World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization. https://www.who.int/tb/publications/global_report/en/. Accessed 2 Dec 2017
- Department of Health, Republic of South Africa. National Tuberculosis Management Guidelines. 2014. http://www.tbonline.info/media/uploads/ documents/ntcp_adult_tb-guidelines-27.5.2014.pdf. Accessed 8 Jan 2018
- Peltzer K, Naidoo P, Louw J, Matseke G, Zuma K, McHunu G, et al. Screening and brief interventions for hazardous and harmful alcohol use among patients with active tuberculosis attending primary public care clinics in South Africa: results from a cluster randomized controlled trial. BMC Public Health. 2013;13:699. http://doi.org/https://doi.org/10.1186/1471-2458-13-699.
- Louwagie GM, Ayo-Yusuf OA. Tobacco use patterns in tuberculosis patients with high rates of human immunodeficiency virus co-infection in South Africa. BMC Public Health. 2013;13:1031. https://doi.org/10.11 86/1471-2458-13-1031.
- Peltzer K. Conjoint alcohol and tobacco use among tuberculosis patients in public primary healthcare in South Africa. S Afr J Psych. 2014;20(1):21–6 http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S2078-67862014 000100005&lng=en.
- Naidoo P, Peltzer K, Louw J, Matseke G, McHunu G, Tutshana B. Predictors of tuberculosis (TB) and antiretroviral (ARV) medication non-adherence in public primary care patients in South Africa: a cross sectional study. BMC Public Health. 2013;13:396. http://doi.org/https://doi.org/10.1186/14 71-2458-13-396.

5 4
4 5
6
7
, 8
9
10
11
12
12
17
12 13 14 15 16
15
10
17 18
19
20
21 22
22 23
25 24
24 25
26
20 27
28
28 29
30
31
32
33
34
35
36
37
38
39
40
40 41
42
42 43
44
45
46
47
48
49
50
50
52
53
55 54
55
56
57
57 58
58 59
<u> </u>

60

 Sendagire I, Cobelens F, Kambugu A, Konde-Lule J, van der Loeff MS. Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda. J Acquir Immune Defic Syndr. 2012;61(3):e33 –9. https://doi.org/10.1097/QAI.0b013e318265aad7.

- Finlay A, Lancaster J, Holtz TH, Weyer K, Miranda A, van der Walt M. Patient

 and provider-level risk factors associated with default from tuberculosis
 treatment, South Africa, 2002: a case-control study. BMC Public Health. 2012;
 12:56. https://doi.org/10.1186/1471-2458-12-56.
- Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;15(7): 871–85. https://doi.org/10.5588/ijtld.10.0352.
- 10. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007;4(1):e20 Review.
- Tachfouti N, Nejjari C, Benjelloun MC, Berraho M, Elfakir S, El Rhazi K, et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011;15(6):838–43. https://doi.org/10.5588/ijtld.10.0437.
- Yen YF, Yen MY, Lin YS, Lin YP, Shih HC, Li LH, et al. Smoking increases risk of recurrence after successful anti-tuberculosis treatment: a population -based study. Int J Tuberc Lung Dis. 2014;18(4):492–8. https://doi.org/10.55 88/ijtld.13.0694.
- Leung CC, Yew WW, Chan CK, Chang KC, Law WS, Lee SN, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J. 2015;45(3):738–45. https://doi.org/10.1183/09031936.00114214.
- Sitas F, Urban M, Bradshaw D, Kielkowski D, Bah S, Peto R. Tobacco attributable deaths in South Africa. Tob Control. 2004;13:396–9.
- Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. 2005; 60(2):130–5.
- Gegia M, Magee MJ, Kempker RR, Kalandadze I, Chakhaia T, Golub JE, et al. Tobacco smoking and tuberculosis treatment outcomes: a prospective cohort study in Georgia. Bull World Health Organ. 2015;93(6):390–9. https:// doi.org/10.2471/BLT.14.147439.
- 17. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–16.
- van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27–33. https://doi.org/10.11 83/09031936.00072909.
- Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lönnroth K, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450. https://doi.org/1 0.1186/1471-2458-9-450.
- Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.
- Suwankeeree W, Picheansathian W. Strategies to promote adherence to treatment by pulmonary tuberculosis patients: a systematic review. Int J Evid Based Healthc. 2014;12(1):3–16. https://doi.org/10.1097/01.XEB. 0000444614.17658.46.
- Shin S, Livchits V, Connery HS, Shields A, Yanov S, Yanova G, et al. Tomsk Tuberculosis Alcohol Working Group. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia. Addiction. 2013;108(8):1387–96. https://doi.org/10.1111/add.12148.
- Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource -poor setting: a cluster randomized controlled trial. JAMA. 2007;297(4):380–6.
- 24. Khachadourian V, Truzyan N, Harutyunyan A, Thompson ME, Harutyunyan T, Petrosyan V. People-centered tuberculosis care versus standard directly observed therapy: study protocol for a cluster randomized controlled trial. Trials. 2015;16:281 10.1186/s13063-015-0802-2.
- 25. West R, Raw M, McNeill A, Stead L, Aveyard P, Bitton J, et al. Health -care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015;110(9):1388–403. https://doi. org/10.1111/add.12998.
- Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al. Action to stop smoking in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. Ann Intern Med. 2013;158(9):667–75. https:// doi.org/10.7326/0003-4819-158-9-201305070-00006.

- McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: The case of smoking cessation. Health Educ Res. 2003;18:156–70.
- Rubak S, Sandbæk A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55(513):305–12.
- Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2010;1:CD006936. https://doi.org/1 0.1002/14651858.CD006936.pub2.
- Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42(1):42–51.
- Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomized controlled trial. Addiction. 2014;109:1942–52.
- Hirsch-Moverman Y, Daftary A, Yuengling KA, Saito S, Ntoane M, Frederix K, et al. Using mHealth for HIV/TB treatment support in Lesotho: Enhancing patient–provider communication in the START study. J Acquir Immune Defic Syndr. 2017;74:S37–43.
- Nglazi MD, Bekker LG, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis. 2013;13:566. https://doi.org/10.11 86/1471-2334-13-566.
- Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, et al. The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis. PLoS Med. 2013;10(1):e1001363. https://doi.org/10.1371/journal.pmed.1001363.
- Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655.
- 36. Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of key questions from the Global Adult Tobacco Survey (GATS). 2nd ed. Altanta: Centres for Disease Control and Prevention; 2011.
- Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423–32.
- Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for Depression in Well Older Adults: Evaluation of a short from of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10:77–84.
- West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005; 100(3):299–303.
- van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89:632–9.
- Moyers TB, Rowell LN, Manuel JK, Ernst D, Houck JM. The Motivational Interviewing Treatment Integrity Code (MITI 4): Rationale, Preliminary Reliability and Validity. J Subst Abuse Treat. 2016;65:36–42.
- Dogar OF, Barua D, Boeckmann M, Elsey H, Fatima R, Gabe R, et al. The safety, effectiveness and cost-effectiveness of cytisine in achieving six -month continuous smoking abstinence in tuberculosis patients
 protocol for a double-blind, placebo-controlled randomised trial. Addiction. 2018;20:1–24.
- World Health Organization/European Respiratory Society. Digital health for the End TB strategy: an agenda for action. Geneva: World Health Organization; 2015. http://www.who.int/tb/publications/digitalhealth-TB -agenda/en/. Accessed 2 Dec 2017

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.